


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update December 7 - December 13, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 50 2020 849 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[Retracted papers](#)

[AAN - Neurology resources](#)

[COVID-19 risk tools - Apps](#)

[COVID-19 resources \(Harvard\)](#)

[Web app for SARS-CoV2 mutations](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

[Covid-Plex trial - \(plasma exchange & convalescent plasma trial\)](#)

**Re: Plasma exchange and convalescent plasma in COVID-19 patients with
multi-organ failure –
The COVID-19 PLEX + Convalescent Plasma trial –
Enrollment initiated**

The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma.

If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark

Covid-Plex trial

Mainstream Media

New York Times - Corona update

Nurses Are Anxious and Angry in 2nd Wave: 'We're Not Prepared'

The New R.S.V.P.: A Signed Coronavirus 'Waiver'

'Nightmare' Australia Housing Lockdown Called Breach of Human Rights

How Effective Is the Mask You're Wearing? You May Know Soon

From Voter Fraud to Vaccine Lies: Misinformation Peddlers Shift Gears

'Like a Hand Grasping': Trump Appointees Describe the Crushing of the C.D.C.

When Can We Start Making Plans?

New At-Home Covid Test Gets Green Light From F.D.A.

With First Dibs on Vaccines, Rich Countries Have 'Cleared the Shelves'

Coronavirus Vaccine Tracker

Coronavirus Drug and Treatment Tracker

Washington Post - Corona update

The pandemic is traumatic for kids like mine. I have no idea how to help them.

Coronavirus vaccinations have started. But people in Africa face a much longer wait.

Record numbers of covid-19 patients push hospitals and staffs to the limit

his interactive tool tracks covid-19 travel restrictions by country.

British officials identify coronavirus mutations, but significance remains unclear

The vaccine scientists got the job done. Now the messengers need to do theirs.

Proof of vaccination will be very valuable — and easy to abuse

Scientists pinpoint genes common among people with severe coronavirus infections

Guardian - Corona update

How Covid-19 vaccines will get from the factory to millions of Americans

King of Sweden blasts 'failed' Covid strategy in rare royal rebuke

Pfizer vaccine: FDA says extra doses in vials can be used, potentially expanding US supply.

Recognise the risks teachers face in schools

Long Covid alarm as 21% report symptoms after five weeks

1. **Vascular Alterations Among Young Adults with SARS-CoV-2.** [Am. J. Physiol. Heart Circ. Physiol.](#) 2020; Ratchford SM, Stickford JL, Province VM et

al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306450>

Despite the general notion that COVID-19 infections are not posing a significant risk for children and adolescents, the impact on those that are suffering complications is quite severe. In this article, the authors point out the striking vascular changes observed in those who tested positive for the virus. Those with a positive PCR test had only mild or no symptoms but showed grim compromised flow-mediated dilatation compared to uninfected controls, $2.71 \pm 1.21\%$ vs. $8.81 \pm 2.96\%$ ($P < 0.01$). Femoral blood flow response showed similar outcomes, $-3 \pm 91\text{ml}$ vs. $+118 \pm 114\text{ml}$ ($P < 0.01$). These changes remained unchanged weeks after testing positive for the SARS-CoV2 virus.

2. Twelve tips for teaching medical students online under COVID-19. Med. Educ. Online 2021; 26:1854066 Jiang Z, Wu H, Cheng H *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280546>

Medical education in academic institutes and larger hospitals have been severely compromised because of the COVID-19 pandemic. Universally educators have been forced to embrace remote learning and online lectures to keep students on track with their training program. Chinese medical schools, forced by the early outbreaks in China, have expediently adapted their curriculum to online platforms. In this review, practices of 40 medical institutes are reviewed, and 12 essential strategies are shared on how to optimize teaching medical students online.

3. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 2020; Fozouni P, Son S, Díaz de León Derby M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306959>

Rapid testing for the SARS-CoV2 virus is considered pivotal to control the number of infections that are paralyzing economies and overburdening health care facilities on a global scale. Innovative technologies are emerging to provide simple, fast, and cheap testing solutions allowing for low-costs efficient testing. In this article, the authors report an amplification-free CRISPR-Cas13a assay for direct detection of SARS-CoV-2 RNA from nasal swabs, using a mobile phone attached microscope to read the test results. The assay was able to detect ± 100 copies/mL < 30 min. The authors suggest that this assay has the potential to swiftly escalate rapid, low costs point of care SARS-CoV-2 testing

4. Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy. Nutrition 2020;111055 Cereda E, Bogliolo L, Lobascio F *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288411>

5. Development and Validation of a Prognostic Risk Score System for COVID-19 Inpatients: A Multi-Center Retrospective Study in China.

Engineering (Beijing) 2020; Yuan Y, Sun C, Tang X *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282444>

6. A preliminary study of coronavirus disease 2019 in China: the impact of cardiovascular disease on death risk. Arch Med Sci Atheroscler Dis 2020;

5:e219-e223Rethemiotaki I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305058>

7. **Alteration of lipid profile and value of lipids in the prediction of the length of hospital stay in COVID-19 pneumonia patients.** Food Sci Nutr 2020; 8:6144-6152Qin C, Minghan H, Ziwen Z, Yukun L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282265>
8. **Impact of 2020 SARS-CoV-2 outbreak on telemedicine management of cardiovascular disease in Italy.** Intern Emerg Med 2020:1-6Molinari G, Brunetti ND, Nodari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294959>
9. **Coronavirus Disease 2019 and Cardiac Arrhythmias.** Eur Cardiol 2020; 15:e66Martínez-Rubio A, Ascoeta S, Taibi F, Soldevila JG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294034>
10. **Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks.** Front Med (Lausanne) 2020; 7:581521Mann R, Perisetti A, Gajendran M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282890>
11. **Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge.** J Korean Med Sci 2020; 35:e418Liang L, Yang B, Jiang N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289374>
12. **Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis.** Crit Care 2020; 24:676Kruse JM, Magomedov A, Kurreck A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287877>
13. **A Study of Policies and Guidelines for Collecting, Processing, and Storing Coronavirus Disease 2019 Patient Biospecimens for Biobanking and Research.** Biopreserv. Biobank. 2020; 18:511-516Gao F, Tao L, Ma X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290126>
14. **COVID-19, microthromboses, inflammation, and platelet activating factor.** Biofactors 2020; Demopoulos C, Antonopoulou S, Theoharides TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296106>
15. **SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.** Wellcome Open Res 2020; 5:181Andersson MI, Arancibia-Carcamo CV, Auckland K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283055>

1. **Identification of a SARS-like bat coronavirus that shares structural features with the spike glycoprotein receptor-binding domain of SARS-CoV-2.** Access Microbiol 2020; 2:acmi000166Fraguas Bringas C, Booth D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294769>
2. **Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges.** Am. J. Respir. Cell Mol. Biol. 2020; Jia H, Neptune E, Cui H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296619>
3. **Protracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure.** Ann Intensive Care 2020; 10:167Bitker L, Dhelft F, Chauvelot L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301059>
4. **Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications.** Antioxidants (Basel) 2020; 9Rahban M, Habibi-Rezaei M, Mazaheri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291560>
5. **The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.** Biochem. Biophys. Res. Commun. 2020; Santopolo S, Riccio A, Santoro MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303190>
6. **Exploring active ingredients and function mechanisms of Ephedra-bitter almond for prevention and treatment of Corona virus disease 2019 (COVID-19) based on network pharmacology.** BioData Min. 2020; 13:19Gao K, Song YP, Song A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292385>
7. **The Receptor for Advanced Glycation End Product (RAGE) Pathway in COVID-19.** Biomarkers 2020;1-17Yalcin Kehribar D, Cihangiroglu M, Sehmen E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284049>
8. **Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus.** Biomedicines 2020; 8Alavi M, Asare-Addo K, Nokhodchi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297444>
9. **An insight into the interaction between α -ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.** Biophys. Chem. 2020; 269:106510Banerjee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285430>
10. **The application of DNA polymerases and Cas9 as representative of DNA-modifying enzymes group in DNA sensor design (review).** Biosens. Bioelectron. 2020;112867Dronina J, Bubniene US, Ramanavicius A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303323>
11. **Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.** Cell Cycle 2020;1-7Theise ND, Arment AR, Chakravarty D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305659>
12. **D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.** Cell Host Microbe 2020; Weissman D, Alameh MG, de Silva T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306985>
13. **Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2.** Cells 2020; 9Hatmal MM, Alshaer W, Al-Hatamleh MAI *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33302501>
14. **ACE2, a multifunctional protein - from cardiovascular regulation to COVID-19.** Clin Sci (Lond) 2020; 134:3229-3232Bader M, Turner AJ, Alenina N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33305790>

15. **ACE2: from protection of liver disease to propagation of COVID-19.** Clin Sci (Lond) 2020; 134:3137-3158 Warner FJ, Rajapaksha H, Shackel N, Herath CB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284956>
16. **Next-generation computational tools and resources for coronavirus research: From detection to vaccine discovery.** Comput. Biol. Med. 2020; 128:104158 Kangabam R, Sahoo S, Ghosh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301953>
17. **A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2.** Comput. Biol. Med. 2020; 129:104137 Mhatre S, Naik S, Patravale V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302163>
18. **ACE2 partially dictates the host range and tropism of SARS-CoV-2.** Comput Struct Biotechnol J 2020; Gao S, Zhang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282147>
19. **Molecular descriptors of some chemicals that prevent COVID-19.** Curr Org Synth 2020; Mondal S, De N, Pal A, Gao W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292123>
20. **Silybin B and Cianidanol Inhibit M pro and Spike Protein of SARS-CoV-2: Evidence from in Silico Molecular Docking Studies.** Curr. Pharm. Des. 2020; Srivastava R, Tripathi S, Unni S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302853>
21. **Docking paradigm: Drug Design.** Curr. Top. Med. Chem. 2020; Sulimov VB, Kutov DC, Taschilova AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292135>
22. **An Organoid-derived Bronchioalveolar Model for SARS-CoV-2 Infection of Human Alveolar-type II-like Cells.** Embo j 2020:e105912 Lamers MM, van der Vaart J, Knoop K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283287>
23. **SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay.** Emerg Microbes Infect 2020:1-52 Elizondo V, Harkins GW, Mabvakure B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306459>
24. **Protease-activated receptor 1 as a potential therapeutic target for COVID-19.** Exp. Biol. Med. (Maywood) 2020:1535370220978372 Rovai ES, Alves T, Holzhausen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302737>
25. **Neuropathobiology of COVID-19: The Role for Glia.** Front. Cell. Neurosci. 2020; 14:592214 Tremblay ME, Madore C, Bordeleau M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304243>
26. **SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β -Cells and in the Human Pancreas Microvasculature.** Front. Endocrinol. (Lausanne) 2020; 11:596898 Fignani D, Licata G, Brusco N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281748>
27. **Comprehensive in silico identification of impacts of ACE2 SNPs on COVID-19 susceptibility in different populations.** Gene Rep 2020:100979 Paniri A, Hosseini MM, Eslam MM, Akhavan-Niaki H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294728>
28. **Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease.** Heliyon 2020; 6:e05641 Alnajjar R, Mostafa A, Kandeil A, Al-Karmalawy AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294721>
29. **Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19.** Immunity

- 2020; Bernardes JP, Mishra N, Tran F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296687>
30. **Coronavirus Disease 2019: Virology and Drug Targets.** Infect Disord Drug Targets 2020; Krishnamurthy PT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297920>
 31. **Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 through a Molecular Docking Study.** Infect Disord Drug Targets 2020; Mondal M, Sarkar C, Jamaddar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292147>
 32. **Interrelated Mechanism by Which the Methide Quinone Celastrol, Obtained from the Roots of *Tripterygium wilfordii*, Inhibits Main Protease 3CL(pro) of COVID-19 and Acts as Superoxide Radical Scavenger.** Int J Mol Sci 2020; 21Caruso F, Singh M, Belli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291769>
 33. **Micro-RNAs in the regulation of immune response against SARS COV-2 and other viral infections.** J Adv Res 2020; Abu-Izneid T, AlHajri N, Mohammed Ibrahim A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282419>
 34. **Depicting the inhibitory potential of polyphenols from *Isatis indigotica* root against the main protease of SARS CoV-2 using computational approaches.** J Biomol Struct Dyn 2020:1-12Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292085>
 35. **Biflavonoids from *Rhus succedanea* as probable natural inhibitors against SARS-CoV-2: a molecular docking and molecular dynamics approach.** J Biomol Struct Dyn 2020:1-13Lokhande K, Nawani N, S KV, Pawar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300454>
 36. **Immunohistochemical expression of angiotensin-converting enzyme 2 (ACE2) in minor salivary glands during SARS-CoV-2 infection.** J Med Virol 2020; Soares CD, Mosqueda-Taylor A, Hernandez-Guerrero JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300137>
 37. **SARS-CoV-2 Spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity.** J. Mol. Cell. Biol. 2020; Petruk G, Puthia M, Petrlova J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295606>
 38. **Modeling and simulations of CoViD-19 molecular mechanism induced by cytokines storm during SARS-CoV2 infection.** J. Mol. Liq. 2020:114863Yu Z, Ellahi R, Nutini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281252>
 39. **Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads.** J. Renin Angiotensin Aldosterone Syst. 2020; 21:1470320320979097Hoevenaars M, Goossens D, Roorda J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283602>
 40. **Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses.** J. Virol. Methods 2020:114032Chen Z, Boon SS, Wang MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290786>
 41. **Viruses' evolvement as a never stopping perpetuum mobile.** J. Virol. Methods 2020:114037Davidson I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290787>
 42. **Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2 induced systemic toxicity.** JCI Insight 2020; Li S, Ma F, Yokota T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284134>

43. **MINERVA: A Facile Strategy for SARS-CoV-2 Whole-Genome Deep Sequencing of Clinical Samples.** Mol. Cell 2020; Chen C, Li J, Di L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33290743>
44. **Antigenic variation of SARS-CoV-2 in response to immune pressure.** Mol. Ecol. 2020; Forni D, Cagliani R, Pontremoli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289207>
45. **In silico screening of potential anti-COVID-19 bioactive natural constituents from food sources by molecular docking.** Nutrition 2020; 82:111049 Xu J, Gao L, Liang H, Chen SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290972>
46. **Animal coronaviruses and coronavirus disease 2019: Lesson for One Health approach.** Open Vet J 2020; 10:239-251 Poudel U, Subedi D, Pantha S, Dhakal S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282694>
47. **Asymptomatic SARS-CoV-2 infection: Is it all about being refractile to innate immune sensing of viral spare-parts? - Clues from exotic animal reservoirs.** Pathog Dis 2020; Shankar EM, Che KF, Yong YK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289808>
48. **Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules.** Pharmaceuticals (Basel) 2020; 13 Al Adem K, Shanti A, Stefanini C, Lee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302344>
49. **A data-driven approach to identify risk profiles and protective drugs in COVID-19.** Proc Natl Acad Sci U S A 2020; Cippà PE, Cugnata F, Ferrari P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303654>
50. **A data-driven approach to identify risk profiles and protective drugs in COVID-19.** Proc Natl Acad Sci U S A 2021; 118 Cippà PE, Cugnata F, Ferrari P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303654>
51. **Exploring human-animal host interactions and emergence of COVID-19: evolutionary and ecological dynamics.** Saudi J. Biol. Sci. 2020; Perveen N, Bin Muzaffar S, Ali Al-Deeb M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281479>
52. **SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.** Wellcome Open Res 2020; 5:181 Andersson MI, Arancibia-Carcamo CV, Auckland K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283055>

Biomarkers - Genetics (102 articles)

1. **Inflammatory markers are poorly predictive of clinical outcomes among hospitalized patients with COVID-19.** Am J Emerg Med 2020; Barrett B, Pamphile S, Yang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280969>
2. **Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean.** Ann. Clin. Microbiol. Antimicrob. 2020; 19:58 Mattar S, Martinez-Bravo C, Rivero R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33287846>
3. **Protracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure.** Ann Intensive Care 2020; 10:167 Bitker L, Dhelft F, Chauvelot L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301059>
4. **IL-6 and other biomarkers as predictors of severity in COVID-19.** Ann. Med. 2020:1-5 Broman N, Rantasärkkä K, Feuth T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33305624>

5. **Myocardium injury biomarkers predict prognosis of critically ill coronavirus disease 2019 (COVID-19) patients.** Ann Palliat Med 2020; 9:4156-4165Cao L, Zhang S, Luo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302676>
6. **Elevated serum ferritin level effectively discriminates severity illness and liver injury of coronavirus disease 2019 pneumonia.** Biomarkers 2020:1-18Cao P, Wu Y, Wu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284041>
7. **A Study of Policies and Guidelines for Collecting, Processing, and Storing Coronavirus Disease 2019 Patient Biospecimens for Biobanking and Research.** Biopreserv. Biobank. 2020; 18:511-516Gao F, Tao L, Ma X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290126>
8. **Development of a SARS-CoV-2-specific biosensor for antigen detection using scFv-Fc fusion proteins.** Biosens. Bioelectron. 2020:112868Kim HY, Lee JH, Kim MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281048>
9. **Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study.** BMC Infect. Dis. 2020; 20:934Cattelan AM, Di Meco E, Trevenzoli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297986>
10. **The preliminary comparative results between Covid-19 and non-Covid-19 patients in Western China.** BMC Infect. Dis. 2020; 20:935Li Y, Li H, Han J, Yang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297990>
11. **Serum neopterin levels in relation to mild and severe COVID-19.** BMC Infect. Dis. 2020; 20:942Robertson J, Gostner JM, Nilsson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302893>
12. **Optimizing COVID-19 surveillance in long-term care facilities: a modelling study.** BMC Med 2020; 18:386Smith DRM, Duval A, Pouwels KB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287821>
13. **Biomarkers of acute respiratory distress syndrome in adults hospitalised for severe SARS-CoV-2 infection in Tenerife Island, Spain.** BMC Res. Notes 2020; 13:555Figueira Gonçalves JM, Hernández Pérez JM, Acosta Sorensen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298124>
14. **Challenges in COVID-19 diagnosis.** Bratisl. Lek. Listy 2020; 121:864Erenler AK, Baydin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300355>
15. **Exploratory drilling: how to set up, carry out, and evaluate a seroprevalence study.** Cas. Lek. Cesk. 2020; 159:217-225Krátka Z, Fürst T, Vencálek O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297697>
16. **Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy.** Cell 2020; Fozouni P, Son S, Díaz de León Derby M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306959>
17. **Lymphocyte cell population as a potential hematological index for early diagnosis of COVID-19.** Cell. Mol. Biol. (Noisy-le-grand) 2020; 66:202-206Zhu Y, Cao X, Lu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287943>
18. **The impact of biosafety enhancement on stat laboratory quality metrics: lessons from the COVID-19 pandemic.** Clin Chim Acta 2020; Frater JL, Anderson J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285119>
19. **The challenge of deciding between home-discharge versus hospitalization in COVID-19 patients: The role of initial imaging and clinicolaboratory data.** Clin Epidemiol Glob Health 2020; Mozafari A, Miladinia M, Sabri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289003>

20. **Peripheral arterial occlusion due to COVID-19: CT angiography findings of nine patients.** Clin Imaging 2020; 73:43-47 Ogawa M, Doo FX, Somwaru AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307372>
21. **Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey.** Clin Infect Dis 2020; Bajema KL, Dahlgren FS, Lim TW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300579>
22. **Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.** Clin Microbiol Infect 2020; Hingrat QL, Visseaux B, Laouenan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307227>
23. **Prevalence of SARS-CoV-2 IgG antibodies in a large prospective cohort study of elite football players in Germany (May-June 2020): implications for a testing protocol in asymptomatic individuals and estimation of the rate of undetected cases.** Clin Microbiol Infect 2020; Mack D, Gärtner BC, Rössler A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285279>
24. **Vitamin D and Covid-19: an update on evidence and potential therapeutic implications.** Clin. Mol. Allergy 2020; 18:23 Murdaca G, Pioggia G, Negrini S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292313>
25. **COVID-19 testing acceptability and uptake amongst the Rohingya and host community in Camp 21, Teknaf, Bangladesh.** Confl Health 2020; 14:74 McGowan CR, Hellman N, Chowdhury S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292358>
26. **Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis.** Crit Care 2020; 24:676 Kruse JM, Magomedov A, Kurreck A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287877>
27. **The role of Interleukin-6 in the pathogenesis, prognosis and treatment of severe COVID-19.** Curr Med Chem 2020; Giannakodimos I, Gkountana GV, Lykouras D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297909>
28. **Rising to the challenge: Overcoming Shared Resource Laboratory biosafety challenges during a pandemic.** Cytometry A 2020; Aspland AM, Douagi I, Filby A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289290>
29. **Evidence of SARS-CoV-2 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019.** Emerg Infect Dis 2020; 27:Amendola A, Bianchi S, Gori M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292923>
30. **SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay.** Emerg Microbes Infect 2020; 1-52 Elizondo V, Harkins GW, Mabvakure B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306459>
31. **D-dimer level elevation can aid in detection of asymptomatic COVID-19 presenting with acute cerebral infarction.** eNeurologicalSci 2021; 22:100294 Umemura T, Kondo H, Ohta H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283061>
32. **Alteration of lipid profile and value of lipids in the prediction of the length of hospital stay in COVID-19 pneumonia patients.** Food Sci Nutr 2020; 8:6144-6152 Qin C, Minghan H, Ziwen Z, Yukun L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282265>

33. **SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β -Cells and in the Human Pancreas Microvasculature.** *Front. Endocrinol. (Lausanne)* 2020; 11:596898 Fignani D, Licata G, Brusco N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281748>
34. **Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload.** *Front Med (Lausanne)* 2020; 7:586307 Goudot G, Chocron R, Augy JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282891>
35. **Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review.** *Front Med (Lausanne)* 2020; 7:572115 Váncsa S, Hegyi PJ, Zádori N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282888>
36. **Searching for COVID-19 Antibodies in Czech Children-A Needle in the Haystack.** *Front Pediatr* 2020; 8:597736 Bloomfield M, Pospisilova I, Cabelova T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304869>
37. **A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level.** *Front Public Health* 2020; 8:584552 Hambali NL, Mohd Noh M, Paramasivam S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304877>
38. **Steering the Private Sector in COVID-19 Diagnostic Test Kit Development in South Korea.** *Front Public Health* 2020; 8:563525 Lee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282810>
39. **Enhancement of the IFN- β -induced host signature informs repurposed drugs for COVID-19.** *Heliyon* 2020; 6:e05646 Huang CT, Chao TL, Kao HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289002>
40. **Haematological abnormalities and risk of COVID-19 infection in adult patients attending primary healthcare settings.** *Hematol Rep.* 2020; 12:8829 Hamed E, Syed MA, Alnuaimi AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282166>
41. **An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.** *Immun. Ageing* 2020; 17:34 Saavedra D, Añé-Kourí AL, Sánchez N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292350>
42. **Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19.** *Immunity* 2020; Bernardes JP, Mishra N, Tran F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296687>
43. **ABO Blood groups in COVID-19 patients; cross-sectional study.** *Int J Clin Pract* 2020; e13927 Solmaz İ, Araç S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296536>
44. **Cerebrospinal fluid findings and hyponatremia in COVID-19 patients with altered mental status.** *Int. J. Emerg. Med.* 2020; 13:63 Toklu H, Ganti L, Crimi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297938>
45. **Contact Screening for Healthcare Workers Exposed to Patients with COVID-19.** *Int J Environ Res Public Health* 2020; 17: Coppel L, Somma G, Ippoliti L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291364>
46. **Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis.** *Int. J. Lab. Hematol.* 2020; Kumano O, Ieko M, Komiyama Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301236>
47. **Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection.** *Int. J. Lab. Hematol.* 2020; Soni M.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289964>
48. **Outlier-SMOTE: A refined oversampling technique for improved detection of COVID-19.** Intell Based Med 2020;100023Kumar Turlapati VP, Prusty MR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289013>
 49. **Endotoxemia and circulating bacteriome in severe COVID-19 patients.** Intensive Care Med Exp 2020; 8:72Sirivongrangson P, Kulvichit W, Payungporn S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284413>
 50. **Thermal inactivation of COVID-19 specimens improves RNA quality and quantity.** J. Cell. Physiol. 2020; Hemati M, Soosanabadi M, Ghorashi T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33305832>
 51. **Hyperglycemia associated with lymphopenia and disease severity of COVID-19 in type 2 diabetes mellitus.** J. Diabetes Complications 2020;107809Cheng Y, Yue L, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288414>
 52. **A Case of Covid-19 Diagnosed at Home With Portable Ultrasound and Confirmed With Home Serology Test.** J. Emerg. Med. 2020; Aminlari A, Quenzer F, Hayden S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288350>
 53. **Occurrence, fate and removal of SARS-CoV-2 in wastewater: Current knowledge and future perspectives.** J Environ Chem Eng 2021; 9:104870Saawarn B, Hait S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282675>
 54. **Prevalence and prognostic value of elevated troponins in patients hospitalised for coronavirus disease 2019: a systematic review and meta-analysis.** J Intensive Care 2020; 8:88Zhao BC, Liu WF, Lei SH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292649>
 55. **Neutrophils mediate Th17 promotion in COVID-19 patients.** J. Leukoc. Biol. 2020; Parackova Z, Bloomfield M, Klocperk A, Sediva A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289169>
 56. **Saliva for diagnosis of SARS-CoV-2: first report from India.** J Med Virol 2020; Bhattacharya D, Parai D, Rout UK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295640>
 57. **Development and Validation of a Nomogram Using on Admission Routine Laboratory Parameters to Predict In-hospital Survival of Patients With COVID-19.** J Med Virol 2020; Chen H, Chen R, Yang H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289142>
 58. **Understanding the Pathophysiological Changes Via Untargeted Metabolomics in COVID-19 Patients.** J Med Virol 2020; Doğan HO, Şenol O, Bolat S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33300133>
 59. **Over 90% of clinical swabs used for SARS-CoV-2 diagnostics contain sufficient nucleic acid concentrations.** J Med Virol 2020; Klingen RL, Katschinski B, Anastasiou OE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289117>
 60. **SARS-CoV-2 positive tests efficiently predict pressure on healthcare system.** J Med Virol 2020; Lippi G, Mattiuzzi C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295648>
 61. **COVID-19 Transient Snoring (CVTS): Clinical and Laboratory Description.** J Med Virol 2020; Riad A, Kassem I, Badrah M, Klugar M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289127>
 62. **Immunohistochemical expression of angiotensin-converting enzyme 2 (ACE2) in minor salivary glands during SARS-CoV-2 infection.** J Med Virol 2020; Soares CD, Mosqueda-Taylor A, Hernandez-Guerrero JC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33300137>

63. **Whom Should We Test for COVID-19? Performance of a Symptom and Risk Factor Questionnaire on COVID-19 Test Results and Patient Outcomes in an Immediate Care Setting.** J. Prim. Care Community Health 2020; 11:2150132720981297 Oshman L, Caplan A, Ali R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33300408>
64. **Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads.** J. Renin Angiotensin Aldosterone Syst. 2020; 21:1470320320979097 Hoevenaar M, Goossens D, Roorda J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283602>
65. **Comparison of clinical characteristics between patients with coronavirus disease 2019 (COVID-19) who retested RT-PCR positive versus negative: a retrospective study of data from Nanjing.** J Thorac Dis 2020; 12:6435-6445 Liu Y, Ding N, Zhou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282346>
66. **Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait.** J Travel Med 2020; Alali WQ, Bastaki H, Longenecker JC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283232>
67. **Immunochromatographic test for differentiation detection of IgM and IgG to SARS-CoV-2.** Klin. Lab. Diagn. 2020; 65:688-692 Akinshina YA, Mardarly SS, Kiseleva VA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301658>
68. **Hematological indicators for lung damage caused by COVID-19 infection.** Klin. Lab. Diagn. 2020; 65:676-682 Borodulina EA, Vasneva ZP, Borodulin BE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301656>
69. **Development of an enzyme-linked immunosorbent assay for the detection of IgG-antibodies to the causative agent of COVID-19 in human serum (plasma).** Klin. Lab. Diagn. 2020; 65:683-687 Mardarly SG, Avdonina AS, Mamedova SG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301657>
70. **Potential Use of Antigen-Based Rapid Test for SARS-CoV-2 in Respiratory Specimens in Low-Resource Settings in Egypt for Symptomatic Patients and High-Risk Contacts.** Lab Med 2020; Abdelrazik AM, Elshafie SM, Abdelaziz HM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283230>
71. **Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients.** Mech. Ageing Dev. 2020; 193:111413 Sabbatinelli J, Giuliani A, Maccacchione G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307107>
72. **Decreased serum levels of the inflammaging marker miR-146a are associated with non-clinical response to tocilizumab in COVID-19 patients.** Mech. Ageing Dev. 2020; 193:111413 Sabbatinelli J, Giuliani A, Maccacchione G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307107>
73. **Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.** Mech. Ageing Dev. 2020; 193:111413 Sabbatinelli J, Giuliani A, Maccacchione G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307107>
74. **COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics?** Med. Hypotheses 2020:110431 Van Damme W, Dahake R, van de Pas R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288314>
75. **High serum nitrates levels in non-survivor COVID-19 patients.** Med. Intensiva 2020; Lorente L, Gómez-Bernal F, Martín MM *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293102>
76. **Eosinopenia in COVID-19 Patients: A Retrospective Analysis.** Microorganisms 2020; 8Ndieugnou Djangang N, Peluso L, Talamonti M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291791>
 77. **MINERVA: A Facile Strategy for SARS-CoV-2 Whole-Genome Deep Sequencing of Clinical Samples.** Mol. Cell 2020; Chen C, Li J, Di L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33290743>
 78. **The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients.** Molecules 2020; 25Fois AG, Paliogiannis P, Scano V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291581>
 79. **Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.** Mult Scler Relat Disord 2020; 46:102592Masuccio FG, Lo Re M, Bertolotto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296987>
 80. **Testing the waters: COVID-19 first wave and shielding among BAME patients with rheumatological conditions in the United Kingdom.** Musculoskeletal Care 2020; Dubey S, Kumar K, Bunting H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306871>
 81. **The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease.** Neurosci Insights 2020; 15:2633105520975743Haghighi MM, Kakhki EG, Sato C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283188>
 82. **Evaluation of electrolyte status of sodium, potassium and magnesium, and fasting blood sugar at the initial admission of individuals with COVID-19 without underlying disease in Golestan Hospital, Kermanshah.** New Microbes New Infect 2020; 38:100807Sarvazad H, Cahngaripour SH, Eskandari Roozbahani N, Izadi B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294198>
 83. **Implementation of a modified drive-through sampling strategy for SARS-CoV-2-the Nigerian experience.** Pan Afr. Med. J. 2020; 35:107Amoo OS, Ohihoin AG, Musa AZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282062>
 84. **Three COVID-19 cases with a long-term viral shedding period in Tunisia.** Pan Afr. Med. J. 2020; 35:117Bennasrallah C, Bannour R, Jlassi O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282072>
 85. **Cochrane corner: rapid point-of-care antigen and molecular-based tests for the diagnosis of COVID-19 infection.** Pan Afr. Med. J. 2020; 37:10Ndwandwe D, Mathebula L, Kamadjeu R, Wiysonge CS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294111>
 86. **Antibody tests for diagnosing COVID-19: how relevant are they?** Pan Afr. Med. J. 2020; 37:4Shey MS, Schmidt BM, Wiysonge CS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294105>
 87. **Real-time RT-PCR for COVID-19 diagnosis: challenges and prospects.** Pan Afr. Med. J. 2020; 35:121Sule WF, Oluwayelu DO.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282076>
 88. **Circulating markers of angiogenesis and endotheliopathy in COVID-19.** Pulm Circ 2020; 10:2045894020966547Pine AB, Meizlish ML, Goshua G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282193>
 89. **Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age.** Reprod. Biomed. Online 2020; Li K, Chen G, Hou H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288478>
 90. **A Systematic Review on the Investigation of SARS-CoV-2 in Semen.** Res Rep Urol 2020; 12:615-621Gonzalez DC, Khodamoradi K, Pai R *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294423>
91. **Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care.** SAGE Open Med 2020; 8:2050312120974174Valk T, McMorro C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282306>
 92. **Evaluation of viral concentration methods for SARS-CoV-2 recovery from wastewaters.** Sci Total Environ 2020; 756:144105Barril PA, Pianciola LA, Mazzeo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302076>
 93. **Biosensors for the Detection of Bacterial and Viral Clinical Pathogens.** Sensors (Basel) 2020; 20Castillo-Henríquez L, Brenes-Acuña M, Castro-Rojas A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291722>
 94. **A simultaneous exploratory and quantitative amino acid and biogenic amine metabolic profiling platform for rapid disease phenotyping via UPLC-QToF-MS.** Talanta 2021; 223:121872Gray N, Lawler NG, Yang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298292>
 95. **Rapid diagnostics of coronavirus disease 2019 in early stages using nanobiosensors: Challenges and opportunities.** Talanta 2021; 223:121704Sharifi M, Hasan A, Haghighat S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303154>
 96. **Differences in RAAS/vitamin D linked to genetics and socioeconomic factors could explain the higher mortality rate in African Americans with COVID-19.** Ther. Adv. Cardiovasc. Dis. 2020; 14:1753944720977715Martín Giménez VM, Ferder L, Inserra F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283618>
 97. **Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy.** Thromb Res 2020; 198:79-82Lawlor M, Gupta A, Ranard LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302210>
 98. **Blood Cell Anomalies in COVID-19.** Turk J Haematol 2020; Ahnach M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283491>
 99. **A SENSITIVE INDICATOR FOR THE SEVERITY OF COVID-19: THIOL.** Turk J Med Sci 2020; Erel Ö, Neşelioğlu S, Ergin Tunçay M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306332>
 100. **Persistent Detection and Infectious Potential of SARS-CoV-2 Virus in Clinical Specimens from COVID-19 Patients.** Viruses 2020; 12Zapor M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287245>
 101. **Guidelines for Preoperative Testing for Neurosurgery in Coronavirus Disease 2019 (COVID-19) Era: Indian Viewpoint Amidst Global Practice.** World Neurosurg 2020; 146:103-112Agarwal N, Raheja A, Suri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283759>
 102. **[Prediction of severe outcomes of patients with COVID-19].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1595-1600Peng ZH, Chen XF, Hu QY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297614>

Children (19 articles)

1. **Vascular Alterations Among Young Adults with SARS-CoV-2.** Am. J. Physiol. Heart Circ. Physiol. 2020; Ratchford SM, Stickford JL, Province VM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306450>
2. **Awake proning of a 2-year-old extubated child with severe COVID-19 pneumonitis.** Anaesth Rep 2020; 8:180-183Alseoudy MM, Abo Elfetoh MA,

- Alrefaey AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283190>
3. **Kawasaki or Kawasaki-like disease? A debate on COVID-19 infection in children.** Clin Immunol 2020;108646Hosseini MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301883>
 4. **COVID-19 related acute decline in paediatric admissions in Malta, a population-based study.** Early Hum. Dev. 2020;105251Degiorgio S, Grech N, Dimech YM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293107>
 5. **Searching for COVID-19 Antibodies in Czech Children-A Needle in the Haystack.** Front Pediatr 2020; 8:597736Bloomfield M, Pospisilova I, Cabelova T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304869>
 6. **Managing Children's Anxiety During COVID-19 Pandemic: Strategies for Providers and Caregivers.** Front Psychiatry 2020; 11:552823Kang YQ, Lim TSH, Ragen ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281637>
 7. **Subtle olfactory dysfunction after SARS-CoV-2 virus infection in children.** Int J Pediatr Otorhinolaryngol 2020; 140:110539Concheiro-Guisan A, Fiel-Ozores A, Novoa-Carballal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307419>
 8. **Criteria for referral of pediatric SARS-CoV-2 infection: a real-life experience in the pandemic era.** Ital. J. Pediatr. 2020; 46:181Montagnani C, Venturini E, L'Erario M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287859>
 9. **"I Hate This": A Qualitative Analysis of Adolescents' Self-Reported Challenges During the COVID-19 Pandemic.** J. Adolesc. Health 2020; Scott SR, Rivera KM, Rushing E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288454>
 10. **Two sides of a coin: differential response to COVID-19 distancing measures in children with narcolepsy.** J. Clin. Sleep Med. 2020; Quaedackers L, Overeem S, Pillen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295278>
 11. **Disordered eating behaviors in youths with type 1 diabetes during COVID-19 lockdown: an exploratory study.** J Eat Disord 2020; 8:76Troncone A, Chianese A, Zanfardino A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292623>
 12. **Epidemiological characteristics and transmission dynamics of paediatric cases with coronavirus disease 2019 in Hubei province, China.** J. Paediatr. Child Health 2020; Wang M, Nie X, Huang S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289923>
 13. **Spectrum of cardiovascular diseases in children during high peak COVID-19 period infection in Northern Italy: is there a link?** J Pediatric Infect Dis Soc 2020; Fabi M, Filice E, Andreozzi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283237>
 14. **Youth OUD treatment during and after COVID: Increasing family involvement across the services continuum.** J. Subst. Abuse Treat. 2021; 120:108159Hogue A, Becker SJ, Fishman M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298299>
 15. **SARS-CoV-2 Associated Coagulopathy And Thromboembolism Prophylaxis In Children: A Single Centre Observational Study.** J Thromb Haemost 2020; Del Borrello G, Giraudo I, Bondone C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305475>
 16. **Foreign-body Ingestions in Children During COVID-19 Pandemic in a Pediatric Referral Center.** JPGN Rep 2020; 1:e018Pizzol A, Rigazio C, Calvo PL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294883>
 17. **Dynamic and evolving response of pediatric medical emergencies in Rabat during the COVID-19 pandemic.** Pan Afr. Med. J. 2020; 35:116Mekaoui N, Jeddi Y,

- Khachani K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282071>
18. **Innovating and Adapting in Pediatric Pulmonology and Sleep Medicine During the COVID-19 Pandemic: ATS Pediatric Assembly Web Committee Consensus Statement for Initial COVID-19 Virtual Response.** *Pediatr Pulmonol* 2020; Taylor JB, Oermann CM, Deterding RR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300286>
 19. **Comparative analysis of clinical features of SARS-CoV-2 and adenovirus infection among children.** *Virol J* 2020; 17:193Li K, Li L, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302983>

Clinical Features (27 articles)

1. **Cutaneous Manifestations in Confirmed COVID-19 Patients: A Systematic Review.** *Biology (Basel)* 2020; 9Conforti C, Dianzani C, Agozzino M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291502>
2. **Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study.** *BMC Infect. Dis.* 2020; 20:934Cattelan AM, Di Meco E, Trevenzoli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297986>
3. **The preliminary comparative results between Covid-19 and non-Covid-19 patients in Western China.** *BMC Infect. Dis.* 2020; 20:935Li Y, Li H, Han J, Yang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297990>
4. **COVID-19 Pneumonia: ST-segment Elevation Myocardial Infarction (STEMI) and Myocarditis.** *Cureus* 2020; 12:e11901Ali A, Khattak MF, Khan MW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304708>
5. **Anosmia: A Clinical Indicator of COVID-19 Reinfection.** *Ear Nose Throat J* 2020;145561320978169Jain A, Kaur J, Rai AK, Pandey AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295221>
6. **Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks.** *Front Med (Lausanne)* 2020; 7:581521Mann R, Perisetti A, Gajendran M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282890>
7. **Identification of COVID-19 Clinical Phenotypes by Principal Component Analysis-Based Cluster Analysis.** *Front Med (Lausanne)* 2020; 7:570614Ye W, Lu W, Tang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282887>
8. **Clinical features and outcomes of COVID-19 in Patients with Solid Tumors: Turkish National Registry Data.** *Int. J. Cancer* 2020; Özdemir N, Dizdar Ö, Yazıcı O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284987>
9. **Subtle olfactory dysfunction after SARS-CoV-2 virus infection in children.** *Int J Pediatr Otorhinolaryngol* 2020; 140:110539Concheiro-Guisan A, Fiel-Ozores A, Novoa-Carballal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307419>
10. **COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation.** *J Am Soc Nephrol* 2020; Friedman DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288631>
11. **Fever and Other Clinical Indicators May Fail to Detect COVID-19-Infected Individuals.** *J. Evid. Based Dent. Pract.* 2020; 20:101499Markowitz K, Strickland M, Huang A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303095>
12. **Clinical Characteristics of 33 Asymptomatic COVID-19 Infections in Wuhan, China.** *J Infect Dev Ctries* 2020; 14:1252-1255Chen Y, Chen X, Wang L, Zheng R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296337>

13. **COVID-19 Transient Snoring (CVTS): Clinical and Laboratory Description.** J Med Virol 2020; Riad A, Kassem I, Badrah M, Klugar M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289127>
14. **Comparison of clinical characteristics between patients with coronavirus disease 2019 (COVID-19) who retested RT-PCR positive versus negative: a retrospective study of data from Nanjing.** J Thorac Dis 2020; 12:6435-6445Liu Y, Ding N, Zhou S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282346>
15. **Clinical Characteristics and Outcomes of Patients With Diabetes Admitted for COVID-19 Treatment in Dubai: Single-Centre Cross-Sectional Study.** JMIR Public Health Surveill 2020; 6:e22471Bhatti R, Khamis AH, Khatib S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284130>
16. **COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics?** Med. Hypotheses 2020:110431Van Damme W, Dahake R, van de Pas R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288314>
17. **Symptomatic Retinal Microangiopathy in a Patient with Coronavirus Disease 2019 (COVID-19): Single Case Report.** Ocul Immunol Inflamm 2020:1-3Gonzalez-Lopez JJ, Felix Espinar B, Ye-Zhu C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284032>
18. **Analysis of Symptoms of COVID-19 Positive Patients and Potential Effects on Initial Assessment.** Open Access Emerg. Med. 2020; 12:451-457Korell F, Giannitsis E, Merle U, Kihm LP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299361>
19. **Can SARS-CoV-2 infect the eye? An overview of the receptor status in ocular tissue.** Ophthalmologe 2020:1-4Schnichels S, Rohrbach JM, Bayyoud T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289868>
20. **Three COVID-19 cases with a long-term viral shedding period in Tunisia.** Pan Afr. Med. J. 2020; 35:117Bennasrallah C, Bannour R, Jlassi O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282072>
21. **Epidemiological characteristics and treatment outcomes of hospitalized patients with COVID-19 in Ethiopia.** Pan Afr. Med. J. 2020; 37:7Gebremariam BM, Shienka KL, Kebede BA, Abiche MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294108>
22. **Delayed hypersensitivity as a pathophysiological mechanism in cutaneous lesions due to SARS-CoV-2.** Pan Afr. Med. J. 2020; 35:115Rafai M, Elbenaye J, Sabry S, Janah H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282070>
23. **Asymptomatic SARS-CoV-2 infection: Is it all about being refractile to innate immune sensing of viral spare-parts? - Clues from exotic animal reservoirs.** Pathog Dis 2020; Shankar EM, Che KF, Yong YK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289808>
24. **Cases and etiologies of suspected COVID-19 reactivation.** Qatar Med J 2020; 2020:26Ghali A, Rico-Mesa JS, Nashawi M, Cadena J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282710>
25. **Comparative analysis of clinical features of SARS-CoV-2 and adenovirus infection among children.** Virol J 2020; 17:193Li K, Li L, Wang X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33302983>
26. **[Prediction of severe outcomes of patients with COVID-19].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1595-1600Peng ZH, Chen XF, Hu QY *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33297614>

27. **[Epidemiological characteristics of imported COVID-19 cases in Guangzhou].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:1786-1790 Zhen RN, Huang Y, Li YL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297639>

CNS (18 articles)

1. **Spinal Cord Injury From an Epidural Abscess as a Serious Complication of COVID-19 Infection.** *Cureus* 2020; 12:e11327 Soh P, Doan N, Manning B, Doan H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282600>
2. **Thromboembolic Complications in COVID-19.** *Deutsche Medizinische Wochenschrift* 2020; 145:1728-1734 Müller S, Beyer-Westendorf J.
3. **Anosmia: A Clinical Indicator of COVID-19 Reinfection.** *Ear Nose Throat J* 2020; 145:561320978169 Jain A, Kaur J, Rai AK, Pandey AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295221>
4. **Neuropathobiology of COVID-19: The Role for Glia.** *Front. Cell. Neurosci.* 2020; 14:592214 Tremblay ME, Madore C, Bordeleau M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304243>
5. **Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Nervous System: Implications of COVID-19 in Neurodegeneration.** *Front. Neurol.* 2020; 11:583459 Rodriguez M, Soler Y, Perry M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304309>
6. **How Does SARS-CoV-2 Affect the Central Nervous System? A Working Hypothesis.** *Front Psychiatry* 2020; 11:582345 Panariello F, Cellini L, Speciani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304284>
7. **Pathophysiological Mechanisms and Neurological Manifestations in COVID-19.** *Indian J. Crit. Care Med.* 2020; 24:975-980 Zirpe KG, Dixit S, Kulkarni AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281325>
8. **Covid-19 Infection Induced Neuromyelitis Optica - A Case Report.** *Int. J. Neurosci.* 2020; 1-7 Batur M, Kisabay Ak A, Mavioğlu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280477>
9. **Subtle olfactory dysfunction after SARS-CoV-2 virus infection in children.** *Int J Pediatr Otorhinolaryngol* 2020; 140:110539 Concheiro-Guisan A, Fiel-Ozores A, Novoa-Carballal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307419>
10. **Guillain-Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series.** *J. Clin. Neurosci.* 2020; Abolmaali M, Heidari M, Zeinali M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281050>
11. **Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID-19.** *J Med Virol* 2020; Bodnar B, Patel K, Ho W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300152>
12. **Comparing COVID-19-linked neurological complications with other viral infections.** *J Transl Med* 2020; 18:465 Deng X, Lo YL, Tan E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298079>
13. **"Neurological manifestations of COVID-19" - guideline of the German society of neurology.** *Neurol Res Pract* 2020; 2:51 Berlit P, Bösel J, Gahn G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283160>
14. **The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease.** *Neurosci Insights* 2020; 15:2633105520975743 Haghighi MM, Kakhki EG, Sato C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283188>

15. **COVID-19 pandemic and management of patients with chronic neurological conditions in low-middle income countries: the added burden.** Pan Afr. Med. J. 2020; 35:104Hazim A, Yacoubi H, Guennouni H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282059>
16. **Guillain-Barré syndrome associated with COVID-19 infection.** Pan Afr. Med. J. 2020; 35:118Manji HK, George U, Mkopi NP, Manji KP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282073>
17. **Severe cortical damage associated with COVID-19 case report.** Seizure 2020; 84:66-68Zombori L, Bacon M, Wood H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285362>
18. **Guidelines for Preoperative Testing for Neurosurgery in Coronavirus Disease 2019 (COVID-19) Era: Indian Viewpoint Amidst Global Practice.** World Neurosurg 2020; 146:103-112Agarwal N, Raheja A, Suri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283759>

Coagulation (17 articles)

1. **Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19.** Am J Clin Pathol 2020; Moosavi M, Wooten M, Goodman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300981>
2. **Extensive Peripheral Arterial Thrombosis in a Patient with SARS-CoV-2 Infection.** Am J Med Case Rep 2020; 8:486-490Chowdhury YS, Mitre CA, Rotella VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294588>
3. **COVID-19, microthromboses, inflammation, and platelet activating factor.** Biofactors 2020; Demopoulos C, Antonopoulou S, Theoharides TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296106>
4. **Before attributing COVID_19-related ischemic stroke to hypercoagulability alternative causes should be excluded.** Brain Behav Immun Health 2021; 11:100179Elkhider H, Ibrahim F, Onteddu S, Nalleballe K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289012>
5. **High Prevalence of Deep Venous Thrombosis in Non-Severe COVID-19 Patients Hospitalized for a Neurovascular Disease.** Cerebrovasc Dis Extra 2020; 10:174-180Rouyer O, Pierre-Paul IN, Balde AT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285543>
6. **Peripheral arterial occlusion due to COVID-19: CT angiography findings of nine patients.** Clin Imaging 2020; 73:43-47Ogawa M, Doo FX, Somwaru AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307372>
7. **Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis.** Crit Care 2020; 24:676Kruse JM, Magomedov A, Kurreck A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287877>
8. **Coronavirus-Associated Coagulopathy: Lessons From SARS-CoV1 and MERS-CoV for the Current SARS-CoV2 Pandemic.** Cureus 2020; 12:e11310Singh S, Zuwasti U, Haas C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282586>
9. **Thromboembolic Complications in COVID-19.** Deutsche Medizinische Wochenschrift 2020; 145:1728-1734Müller S, Beyer-Westendorf J.
10. **Cardiac rehabilitation in a 42-year-old after peripheral pulmonary artery embolism as part of a SARS-CoV-2 infection.** Diabetes, Stoffwechsel und Herz

- 2020; 29:376-379 Ossenberg M, Stoevesandt D, Schwarz S, Schlitt A.
11. **Impact of the shift to a fibrinolysis-first strategy on care and outcomes of patients with ST-segment-elevation myocardial infarction during the COVID-19 pandemic-The experience from the largest cardiovascular-specific centre in China.** *Int J Cardiol* 2020; Leng WX, Yang JG, Li XD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307137>
 12. **Pulmonary Embolism in COVID-19 Pneumonia: An Overlapping Diagnosis or a Misdiagnosis?** *J Cardiovasc Echogr* 2020; 30:110-112 Secco E, Pasqualetto MC, Rigo F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282650>
 13. **SARS-CoV-2 Associated Coagulopathy And Thromboembolism Prophylaxis In Children: A Single Centre Observational Study.** *J Thromb Haemost* 2020; Del Borrello G, Giraudo I, Bondone C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305475>
 14. **Revisiting One of the Dreaded Outcomes of the Current Pandemic: Pulmonary Embolism in COVID-19.** *Medicina (Kaunas)* 2020; 56 Sharma M, Surani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287199>
 15. **Adequate anticoagulation and ECMO therapy in COVID-19 patients with severe pulmonary embolism.** *Perfusion* 2020; 267659120979887 Gaisendrees C, Walter SG, Elderia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280533>
 16. **Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis.** *Thromb J* 2020; 18:34 Boonyawat K, Chantrathammachart P, Numthavej P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292258>
 17. **Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy.** *Thromb Res* 2020; 198:79-82 Lawlor M, Gupta A, Ranard LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302210>

Complications (60 articles)

1. **Evolution of COVID-19 in patients with autoimmune rheumatic diseases.** *Aging (Albany NY)* 2020; 12 Pang R, Zhao J, Gan Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289698>
2. **Extensive Peripheral Arterial Thrombosis in a Patient with SARS-CoV-2 Infection.** *Am J Med Case Rep* 2020; 8:486-490 Chowdhury YS, Mitre CA, Rotella VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294588>
3. **Trends in Intensive Care for Patients with COVID-19 in England, Wales and Northern Ireland.** *Am J Respir Crit Care Med* 2020; Doidge JC, Gould DW, Ferrando-Vivas P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306946>
4. **Awake proning of a 2-year-old extubated child with severe COVID-19 pneumonitis.** *Anaesth Rep* 2020; 8:180-183 Alseoudy MM, Abo Elfetoh MA, Alrefaey AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283190>
5. **Reliability and limits of transport-ventilators to safely ventilate severe patients in special surge situations.** *Ann Intensive Care* 2020; 10:166 Savary D, Lesimple A, Beloncle F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296045>
6. **COVID-19 Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs) Compared to the General Population: A US Multi-Center Comparative Cohort Study.** *Arthritis Rheumatol* 2020; D'Silva KM, Jorge A, Cohen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305544>
7. **Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: a single-centre, retrospective study.** *BMC Infect. Dis.* 2020;

- 20:943Yi P, Yang X, Ding C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302889>
8. **Before attributing COVID_19-related ischemic stroke to hypercoagulability alternative causes should be excluded.** Brain Behav Immun Health 2021; 11:100179Elkhider H, Ibrahim F, Onteddu S, Nalleballe K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289012>
 9. **Diffuse skin rash in tropical areas: Dengue fever or COVID-19?** An. Bras. Dermatol. 2020; Pastor Bandeira I, Sordi Chara B, Meneguzzi de Carvalho G, Magno Gonçalves MV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281008>
 10. **A case of severe course of COVID-19 treated with experimental therapy.** Cas. Lek. Cesk. 2020; 159:181-184Zlámál M, Štěchovská K, Holub M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297704>
 11. **High Prevalence of Deep Venous Thrombosis in Non-Severe COVID-19 Patients Hospitalized for a Neurovascular Disease.** Cerebrovasc Dis Extra 2020; 10:174-180Rouyer O, Pierre-Paul IN, Balde AT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285543>
 12. **Peripheral arterial occlusion due to COVID-19: CT angiography findings of nine patients.** Clin Imaging 2020; 73:43-47Ogawa M, Doo FX, Somwaru AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307372>
 13. **Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis.** Crit Care 2020; 24:676Kruse JM, Magomedov A, Kurreck A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287877>
 14. **COVID-19 Pneumonia: ST-segment Elevation Myocardial Infarction (STEMI) and Myocarditis.** Cureus 2020; 12:e11901Ali A, Khattak MF, Khan MW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304708>
 15. **Sudden Cardiac Arrest at the Triage of Emergency Medicine Department in a Patient With COVID-19.** Cureus 2020; 12:e11795Altuwaijri F, Alotaibi O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304706>
 16. **An Interesting Case of COVID-19 Induced Reversed Takotsubo Cardiomyopathy and Insight on Cardiac Biomarkers.** Cureus 2020; 12:e11296Panchal A, Kyvernitakis A, Biederman R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282573>
 17. **Thyrototoxic Crisis and COVID-19 Infection: An Extraordinary Case and Literature Review.** Cureus 2020; 12:e11305Pastor S, Molina Á, Sr., De Celis E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282582>
 18. **Spinal Cord Injury From an Epidural Abscess as a Serious Complication of COVID-19 Infection.** Cureus 2020; 12:e11327Soh P, Doan N, Manning B, Doan H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282600>
 19. **Expression and clinical significance of SARS-CoV-2 human targets in neoplastic and non-neoplastic lung tissues.** Curr Cancer Drug Targets 2020; Subbarayan K, Ulagappan K, Wickenhauser C, Seliger B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292131>
 20. **Thromboembolic Complications in COVID-19.** Deutsche Medizinische Wochenschrift 2020; 145:1728-1734Müller S, Beyer-Westendorf J.
 21. **Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.** Diabetes Metab Syndr 2020; 15:33-38Nafakhi H, Alareedh M, Al-Buthabhak K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296788>

22. **Cardiac rehabilitation in a 42-year-old after peripheral pulmonary artery embolism as part of a SARS-CoV-2 infection.** Diabetes, Stoffwechsel und Herz 2020; 29:376-379 Ossenberrg M, Stoevesandt D, Schwarz S, Schlitt A.
23. **Covid-19 and impairment of spermatogenesis: What if fever was the only cause?** EClinicalMedicine 2020; 29:100670 Bendayan M, Boitrelle F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283179>
24. **COVID-19-Associated Fusobacterium nucleatum Bacteremia, Belgium.** Emerg Infect Dis 2020; 27:Wolff L, Martiny D, Deyi VYM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292922>
25. **Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea.** Endocrinol Metab (Seoul) 2020; You JH, Lee SA, Chun SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297603>
26. **Case Report: Renal potassium wasting in SARS-CoV-2 infection.** F1000Res 2020; 9:659 Mabillard H, Tedd H, Speight A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33299549>
27. **Random effects meta-analysis of COVID-19/S. aureus partnership in co-infection.** GMS Hyg Infect Control 2020; 15:Doc29 Adeiza SS, Shuaibu AB, Shuaibu GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299742>
28. **Mechanisms of Hypoxia in COVID-19 Patients: A Pathophysiologic Reflection.** Indian J. Crit. Care Med. 2020; 24:967-970 Nitsure M, Sarangi B, Shankar GH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281323>
29. **Awake Prone Positioning in COVID-19 Patients.** Indian J. Crit. Care Med. 2020; 24:914-918 Singh P, Jain P, Deewan H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281314>
30. **Noninvasive Oxygen Strategies to Manage Confirmed COVID-19 Patients in Indian Intensive Care Units: A Survey.** Indian J. Crit. Care Med. 2020; 24:926-931 Subramaniam A, Haji JY, Kumar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281316>
31. **Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report.** Infect Disord Drug Targets 2020; SeyedAlinaghi S, Ghadimi M, Gharabaghi MA, Ghiasvand F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297919>
32. **Covid-19 Infection Induced Neuromyelitis Optica - A Case Report.** Int. J. Neurosci. 2020:1-7 Batum M, Kisabay Ak A, Mavioğlu H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280477>
33. **Endotoxemia and circulating bacteriome in severe COVID-19 patients.** Intensive Care Med Exp 2020; 8:72 Sirivongrangson P, Kulvichit W, Payungporn S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284413>
34. **Criteria for referral of pediatric SARS-CoV-2 infection: a real-life experience in the pandemic era.** Ital. J. Pediatr. 2020; 46:181 Montagnani C, Venturini E, L'Erario M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287859>
35. **Pulmonary Embolism in COVID-19 Pneumonia: An Overlapping Diagnosis or a Misdiagnosis?** J Cardiovasc Echogr 2020; 30:110-112 Secco E, Pasqualetto MC, Rigo F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282650>
36. **Guillain-Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series.** J. Clin. Neurosci. 2020; Abolmaali M, Heidari M, Zeinali M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281050>
37. **Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19.** J Cyst Fibros 2020; McElvaney OJ, O'Connor E, McEvoy NL *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288475>

38. **Increased DKA at presentation among newly diagnosed type 1 diabetes patients with or without COVID-19; Data from a multi-site surveillance registry.** J. Diabetes 2020; Beliard K, Ebekozen O, Demeterco-Berggren C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283979>
39. **Atypical course of COVID-19 in patient with Bruton agammaglobulinemia.** J Infect Dev Ctries 2020; 14:1248-1251 Milošević I, Jovanović J, Stevanovic O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296336>
40. **SARS-CoV-2 Associated Coagulopathy And Thromboembolism Prophylaxis In Children: A Single Centre Observational Study.** J Thromb Haemost 2020; Del Borrello G, Giraudo I, Bondone C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305475>
41. **[Endoscopy-assisted dilatational tracheostomy in patients with COVID-19].** Khirurgija (Mosk.) 2020; 16-21 Starkov YG, Lukich KV, Dzhantukhanova SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301248>
42. **Triage bei COVID-19: Ist Krebs ein Kriterium?** Klinikerzt 2020; 49:445 Wiedemann GJ.
43. **Patient barrier acceptance during airway management among anesthesiologists: A simulation pilot study.** Korean J Anesthesiol 2020; Querney J, Cubillos J, Ding Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285048>
44. **The flexible endoscopic nasopharyngoscopy in infectious patients.** Laryngo-Rhino- Otologie 2020; 99:770-771.
45. **Takotsubo Syndrome: Cardiotoxic Stress in the COVID Era.** Mayo Clin Proc Innov Qual Outcomes 2020; O'Keefe EL, Torres-Acosta N, O'Keefe JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283161>
46. **Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group.** Med. J. Aust. 2020; Brewster DJ, Groombridge CJ, Gatward JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295002>
47. **Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group.** Med. J. Aust. 2020; Triplett KE, Collett LW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295047>
48. **Revisiting One of the Dreaded Outcomes of the Current Pandemic: Pulmonary Embolism in COVID-19.** Medicina (Kaunas) 2020; 56 Sharma M, Surani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287199>
49. **COVID-19: general overview, pharmacological options and ventilatory support strategies.** Multidiscip Respir Med 2020; 15:708 Menzella F, Matucci A, Vultaggio A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282284>
50. **Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis.** Oncoimmunology 2020; 9:1824646 Wang B, Huang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294299>
51. **Malaria and COVID-19: commonalities, intersections and implications for sustaining malaria control.** Pan Afr. Med. J. 2020; 37:1 Ajayi IO, Ajumobi OO, Falade C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294102>
52. **Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with**

- chloroquine and rifampin.** *Pan Afr. Med. J.* 2020; 35:110Bouaré F, Laghmari M, Etouche FN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282065>
53. **Preventing Acute Respiratory Distress Syndrome (ARDS) and to avoiding intubation in patients with COVID-19: an experience from a reanimation service in Morocco.** *Pan Afr. Med. J.* 2020; 37:6Kaissi JE, Jebbar N, Diai A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294107>
 54. **Guillain-Barré syndrome associated with COVID-19 infection.** *Pan Afr. Med. J.* 2020; 35:118Manji HK, George U, Mkopi NP, Manji KP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282073>
 55. **Fatal pulmonary fibrosis complicating COVID-19 infection in preexistent emphysema.** *Radiol Case Rep* 2021; 16:361-363Mazzolini M, Monari M, Angeletti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288987>
 56. **Tension pneumothorax in patient with COVID-19 infection.** *Radiol Case Rep* 2021; 16:358-360Vahidirad A, Jangjoo A, Ghelichli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288986>
 57. **Rapidly developing large pneumatocele and spontaneous pneumothorax in SARS-CoV-2 infection.** *Respir Med Case Rep* 2020; 31:101303Sanivarapu RR, Farraj K, Sayedy N, Anjum F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294361>
 58. **Improvement of COVID-19 with renal failure and paralytic ileus by using steroids.** *Respirol Case Rep* 2021; 9:e00689Kitamura A, So C, Jinta T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282314>
 59. **Severe cortical damage associated with COVID-19 case report.** *Seizure* 2020; 84:66-68Zombori L, Bacon M, Wood H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285362>
 60. **Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis.** *Thromb J* 2020; 18:34Boonyawat K, Chantrathamchart P, Numthavej P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292258>

Cured – Recovered (9 articles)

1. **Protocol for a systematic review and meta-analysis of respiratory rehabilitation following intensive care unit discharge for COVID-19 survivors.** *BMJ Open* 2020; 10:e041184Wang D, Li J, Zhu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293395>
2. **Fatal SARS-CoV-2 infection in a male patient with Good's syndrome.** *Clin Immunol* 2020; 223:108644Pozzi MR, Baronio M, Janetti MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301884>
3. **A case of COVID-19 reinfection in the UK.** *Clin Med (Lond)* 2020; West J, Everden S, Nikitas N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303623>
4. **Anosmia: A Clinical Indicator of COVID-19 Reinfection.** *Ear Nose Throat J* 2020; 145561320978169Jain A, Kaur J, Rai AK, Pandey AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295221>
5. **Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge.** *J Korean Med Sci* 2020; 35:e418Liang L, Yang B, Jiang N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289374>
6. **COVID-19 related fatigue: which role for rehabilitation in post-COVID-19 patients? A case series.** *J Med Virol* 2020; Ferraro F, Calafiore D, Dambruoso F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295637>

7. **Psychiatric morbidity and protracted symptoms after COVID-19.** Psychiatry Res 2020; 295:113604 Poyraz B, Poyraz CA, Olgun Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296818>
8. **Cases and etiologies of suspected COVID-19 reactivation.** Qatar Med J 2020; 2020:26 Ghali A, Rico-Mesa JS, Nashawi M, Cadena J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282710>
9. **COVID-19 reinfection? A suspected case in a Peruvian patient.** Travel Med Infect Dis 2020:101947 Arteaga-Livias K, Panduro-Correa V, Pinzas-Acosta K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307196>

Cardiovascular disease (49 articles)

1. **Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction Before and During COVID in New York.** Am. J. Cardiol. 2020; Hannan EL, Wu Y, Cozzens K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301770>
2. **Extensive Peripheral Arterial Thrombosis in a Patient with SARS-CoV-2 Infection.** Am J Med Case Rep 2020; 8:486-490 Chowdhury YS, Mitre CA, Rotella VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294588>
3. **Vascular Alterations Among Young Adults with SARS-CoV-2.** Am. J. Physiol. Heart Circ. Physiol. 2020; Ratchford SM, Stickford JL, Province VM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306450>
4. **Myocardium injury biomarkers predict prognosis of critically ill coronavirus disease 2019 (COVID-19) patients.** Ann Palliat Med 2020; 9:4156-4165 Cao L, Zhang S, Luo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302676>
5. **Vitamin C and Cardiovascular Disease: An Update.** Antioxidants (Basel) 2020; 9:Morelli MB, Gambardella J, Castellanos V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33287462>
6. **A preliminary study of coronavirus disease 2019 in China: the impact of cardiovascular disease on death risk.** Arch Med Sci Atheroscler Dis 2020; 5:e219-e223 Rethemiotaki I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305058>
7. **Before attributing COVID_19-related ischemic stroke to hypercoagulability alternative causes should be excluded.** Brain Behav Immun Health 2021; 11:100179 Elkhider H, Ibrahim F, Onteddu S, Nalleballe K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289012>
8. **Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey.** Cardiooncology 2020; 6:28 Sadler D, DeCara JM, Herrmann J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292763>
9. **High Prevalence of Deep Venous Thrombosis in Non-Severe COVID-19 Patients Hospitalized for a Neurovascular Disease.** Cerebrovasc Dis Extra 2020; 10:174-180 Rouyer O, Pierre-Paul IN, Balde AT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285543>
10. **Acute myocardial infarction secondary to COVID-19 infection: A case report and review of the literature.** Clin Imaging 2020; 72:178-182 Capaccione KM, Leb JS, D'Souza B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296828>
11. **Peripheral arterial occlusion due to COVID-19: CT angiography findings of nine patients.** Clin Imaging 2020; 73:43-47 Ogawa M, Doo FX, Somwaru AS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307372>

12. **Kawasaki or Kawasaki-like disease? A debate on COVID-19 infection in children.** Clin Immunol 2020;108646Hosseini MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301883>
13. **Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis.** Crit Care 2020; 24:676Kruse JM, Magomedov A, Kurreck A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287877>
14. **COVID-19 Pneumonia: ST-segment Elevation Myocardial Infarction (STEMI) and Myocarditis.** Cureus 2020; 12:e11901Ali A, Khattak MF, Khan MW.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304708>
15. **Sudden Cardiac Arrest at the Triage of Emergency Medicine Department in a Patient With COVID-19.** Cureus 2020; 12:e11795Altuwaijri F, Alotaibi O.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304706>
16. **An Interesting Case of COVID-19 Induced Reversed Takotsubo Cardiomyopathy and Insight on Cardiac Biomarkers.** Cureus 2020; 12:e11296Panchal A, Kyvernitakis A, Biederman R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282573>
17. **Coronavirus-Associated Coagulopathy: Lessons From SARS-CoV1 and MERS-CoV for the Current SARS-CoV2 Pandemic.** Cureus 2020; 12:e11310Singh S, Zuwasti U, Haas C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282586>
18. **COVID-19 Severity: Lung-Heart Interplay.** Curr. Cardiol. Rev. 2020; Puri G, Pal Singh V, Naura AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305712>
19. **Thromboembolic Complications in COVID-19.** Deutsche Medizinische Wochenschrift 2020; 145:1728-1734Müller S, Beyer-Westendorf J.
20. **Cardiac rehabilitation in a 42-year-old after peripheral pulmonary artery embolism as part of a SARS-CoV-2 infection.** Diabetes, Stoffwechsel und Herz 2020; 29:376-379Ossenberg M, Stoevesandt D, Schwarz S, Schlitt A.
21. **D-dimer level elevation can aid in detection of asymptomatic COVID-19 presenting with acute cerebral infarction.** eNeurologicalSci 2021; 22:100294Umemura T, Kondo H, Ohta H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283061>
22. **Distribution, infrastructure, and expertise of heart failure and cardio-oncology clinics in a developing network: temporal evolution and challenges during the coronavirus disease 2019 pandemic.** ESC Heart Fail 2020.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284510>
23. **Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID-19 pandemic.** ESC Heart Fail 2020; Primessnig U, Pieske BM, Sherif M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283476>
24. **Coronavirus Disease 2019 and Cardiac Arrhythmias.** Eur Cardiol 2020; 15:e66Martínez-Rubio A, Ascoeta S, Taibi F, Soldevila JG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294034>
25. **Greater decline of acute stroke admissions compared with acute coronary syndromes during COVID-19 outbreak in Greece: Cerebro/Cardiovascular implications amidst a second wave surge.** Eur. J. Neurol. 2020; Katsouras C, Karapanayiotides T, Papafaklis M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290619>
26. **Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload.** Front

- Med (Lausanne) 2020; 7:586307 Goudot G, Chocron R, Augy JL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282891>
27. **Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report.** Infect Disord Drug Targets 2020; SeyedAlinaghi S, Ghadimi M, Gharabaghi MA, Ghiasvand F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297919>
 28. **Impact of the shift to a fibrinolysis-first strategy on care and outcomes of patients with ST-segment-elevation myocardial infarction during the COVID-19 pandemic-The experience from the largest cardiovascular-specific centre in China.** Int J Cardiol 2020; Leng WX, Yang JG, Li XD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307137>
 29. **Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis.** Int. J. Lab. Hematol. 2020; Kumano O, Ieko M, Komiyama Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301236>
 30. **Impact of 2020 SARS-CoV-2 outbreak on telemedicine management of cardiovascular disease in Italy.** Intern Emerg Med 2020:1-6 Molinari G, Brunetti ND, Nodari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294959>
 31. **Pulmonary Embolism in COVID-19 Pneumonia: An Overlapping Diagnosis or a Misdiagnosis?** J Cardiovasc Echogr 2020; 30:110-112 Secco E, Pasqualetto MC, Rigo F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282650>
 32. **Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.** J. Electrocardiol. 2020; 64:30-35 Echarte-Morales J, Minguito-Carazo C, Del Castillo-García S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307378>
 33. **Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist.** J. Neurointerv. Surg. 2020; Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33298508>
 34. **Spectrum of cardiovascular diseases in children during high peak COVID-19 period infection in Northern Italy: is there a link?** J Pediatric Infect Dis Soc 2020; Fabi M, Filice E, Andreozzi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283237>
 35. **Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads.** J. Renin Angiotensin Aldosterone Syst. 2020; 21:1470320320979097 Hoevenaars M, Goossens D, Roorda J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283602>
 36. **Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability.** J Saudi Heart Assoc 2020; 32:350-357 El Ouarradi A, Abdeladim S, Oualim S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299775>
 37. **Effect of COVID-19 Pandemic on the Cardiac Outpatients' Perception of Seeking Medical Advice.** J Saudi Heart Assoc 2020; 32:377-382 Samargandy SA, Al Garni TA, Almoghairi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299779>
 38. **Managements of 13 emergency cardiac surgeries under COVID-19 pandemic in a Sentinel Hospital.** J Thorac Dis 2020; 12:6663-6669 Hu X, Wang Y, Xia J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282367>

39. **Screening of Potential Cardiac Involvement in Competitive Athletes Recovering From COVID-19: An Expert Consensus Statement.** JACC Cardiovasc. Imaging 2020; 13:2635-2652 Phelan D, Kim JH, Elliott MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303102>
40. **Takotsubo Syndrome: Cardiotoxic Stress in the COVID Era.** Mayo Clin Proc Innov Qual Outcomes 2020; O'Keefe EL, Torres-Acosta N, O'Keefe JH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283161>
41. **Revisiting One of the Dreaded Outcomes of the Current Pandemic: Pulmonary Embolism in COVID-19.** Medicina (Kaunas) 2020; 56 Sharma M, Surani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287199>
42. **Electrocardiogrammes d'un patient COVID-19 traité par l'association hydroxychloroquine et azithromycine.** Pan Afr. Med. J. 2020; 35:112 Benouna ME, Ech-Chenbouli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282067>
43. **Coronavirus Disease 2019 (COVID-19) set to increase burden of atherosclerotic cardiovascular disease in Kenya.** Pan Afr. Med. J. 2020; 35:120 O'geng'o J, Karau PB, Misiani M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282075>
44. **Adequate anticoagulation and ECMO therapy in COVID-19 patients with severe pulmonary embolism.** Perfusion 2020; 267659120979887 Gaisendrees C, Walter SG, Elderia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280533>
45. **Gas exchange and hypertension in COVID-19.** Pneumologie 2020; 74:719 Krome S.
46. **Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails.** Stem Cell Reports 2020; Yiangou L, Davis RP, Mummery CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306986>
47. **Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis.** Thromb J 2020; 18:34 Boonyawat K, Chantrathammachart P, Numthavej P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292258>
48. **Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy.** Thromb Res 2020; 198:79-82 Lawlor M, Gupta A, Ranard LS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302210>
49. **The cardiac complications of COVID-19: many publications, multiple uncertainties.** Vasc Biol 2020; 2:R105-r114 Al-Mohammad A, Partridge DG, Fent G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283157>

Diagnosis (10 articles)

1. **Before attributing COVID_19-related ischemic stroke to hypercoagulability alternative causes should be excluded.** Brain Behav Immun Health 2021; 11:100179 Elkhider H, Ibrahim F, Onteddu S, Nalleballe K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289012>
2. **Challenges in COVID-19 diagnosis.** Bratisl. Lek. Listy 2020; 121:864 Erenler AK, Baydin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300355>
3. **Lymphocyte cell population as a potential hematological index for early diagnosis of COVID-19.** Cell. Mol. Biol. (Noisy-le-grand) 2020; 66:202-206 Zhu Y, Cao X, Lu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287943>
4. **COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review.** Curr. Pharm. Des. 2020; Aziz A, Asif M, Ashraf G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280586>

5. **Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19.** Diagnosics (Basel) 2020; 10:Kassirian S, Taneja R, Mehta S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291238>
6. **Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks.** Front Med (Lausanne) 2020; 7:581521Mann R, Perisetti A, Gajendran M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282890>
7. **Identification of COVID-19 Clinical Phenotypes by Principal Component Analysis-Based Cluster Analysis.** Front Med (Lausanne) 2020; 7:570614Ye W, Lu W, Tang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282887>
8. **Computing SARS-CoV-2 Infection Risk From Symptoms, Imaging, and Test Data: Diagnostic Model Development.** J Med Internet Res 2020; 22:e24478D'Ambrosia C, Christensen H, Aronoff-Spencer E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301417>
9. **Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails.** Stem Cell Reports 2020; Yiangou L, Davis RP, Mummery CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306986>
10. **Rapid diagnostics of coronavirus disease 2019 in early stages using nanobiosensors: Challenges and opportunities.** Talanta 2021; 223:121704Sharifi M, Hasan A, Haghighat S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303154>

DM-MS-Obesity (12 articles)

1. **COVID-19 and diabetes: A bidirectional relationship.** Clin Investig Arterioscler 2020; Lima-Martínez MM, Carrera Boada C, Madera-Silva MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303218>
2. **Costs of COVID-19 pandemic associated with diabetes in Europe: a health care cost model.** Curr. Med. Res. Opin. 2020;1Bain SC, Czernichow S, Bøgelund M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306421>
3. **Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.** Diabetes Metab Syndr 2020; 15:33-38Nafakhi H, Alareedh M, Al-Buthabhak K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296788>
4. **COVID-19 Associated with Diabetes and Other Noncommunicable Diseases Led to a Global Health Crisis.** Diabetes Res Clin Pract 2020;108587Thomaz Ugliara Barone M, Ngongo B, Bega Harnik S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307134>
5. **Patients with diabetes have a higher risk of severe COVID-19 progression - Which protective measures are possible?** Diabetes, Stoffwechsel und Herz 2020; 29:367-371Pfützner A, Frankenberger R.
6. **Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea.** Endocrinol Metab (Seoul) 2020; You JH, Lee SA, Chun SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297603>
7. **Hyperglycemia associated with lymphopenia and disease severity of COVID-19 in type 2 diabetes mellitus.** J. Diabetes Complications 2020;107809Cheng Y, Yue L, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288414>
8. **Disordered eating behaviors in youths with type 1 diabetes during COVID-19 lockdown: an exploratory study.** J Eat Disord 2020; 8:76Troncone A, Chianese A, Zanfardino A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292623>

9. **Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China.** J Med Virol 2020; Dai W, Wu J, Li T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289151>
10. **Clinical Characteristics and Outcomes of Patients With Diabetes Admitted for COVID-19 Treatment in Dubai: Single-Centre Cross-Sectional Study.** JMIR Public Health Surveill 2020; 6:e22471 Bhatti R, Khamis AH, Khatib S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284130>
11. **Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care.** SAGE Open Med 2020; 8:2050312120974174 Valk T, McMorrow C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282306>
12. **Combination of obesity and co-morbidities leads to unfavorable outcomes in COVID-19 patients.** Saudi J. Biol. Sci. 2020; Al Heialy S, Yaseen Hachim M, Yaseen Hachim I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293887>

Education and training and science (47 articles)

1. **From the pandemic's front lines: A social responsibility initiative to develop an international free online emergency medicine course for medical students.** Afr J Emerg Med 2021; 11:1-2 Cevik AA, Cakal ED, Kwan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304802>
2. **Virtual microscopy and other technologies for teaching histology during Covid-19.** Anat Sci Educ 2020; Caruso MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283455>
3. **A journey like no other: Anatomy 2020!** Anat Sci Educ 2020; Smith CF, Pawlina W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306260>
4. **A Study of Policies and Guidelines for Collecting, Processing, and Storing Coronavirus Disease 2019-Patient Biospecimens for Biobanking and Research.** Biopreserv. Biobank. 2020; Gao F, Tao L, Ma X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290126>
5. **A Study of Policies and Guidelines for Collecting, Processing, and Storing Coronavirus Disease 2019 Patient Biospecimens for Biobanking and Research.** Biopreserv. Biobank. 2020; 18:511-516 Gao F, Tao L, Ma X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290126>
6. **Introduction to the quality of medical journalism and initial assessments of COVID-19 media coverage.** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2020; Daube D, Ruhrmann G.
7. **Challenges for science journalism in the Corona pandemic-some observations about a mediated world event.** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2020; Stollorz V.
8. **Exploratory drilling: how to set up, carry out, and evaluate a seroprevalence study.** Cas. Lek. Cesk. 2020; 159:217-225 Krátká Z, Fürst T, Vencálek O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297697>
9. **Conducting Examinations in India: Emergency, Contention and Challenges of Students amidst Covid-19 Pandemic.** Child Youth Serv Rev 2020:105768 Roy B, Roy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281253>
10. **Conducting examinations in India: Emergency, contention and challenges of students amidst covid-19 pandemic.** Child Youth Serv Rev 2021; 120:105768 Roy B, Roy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281253>

11. **Compiling Observational Research During a Pandemic: A Necessary Bridge.** Clin Infect Dis 2020; Moehring RW, Holland TL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306094>
12. **Risk and mitigation actions for clinical trials during COVID-19 pandemic (RiMiCOPa).** Contemp Clin Trials Commun 2020:100682Bacchieri A, Rossi A, Morelli P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283069>
13. **A comprehensive dataset for bibliometric analysis of SARS and coronavirus impact on social sciences.** Data Brief 2020; 33:106520Shaukat K, Alam TM, Hameed IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294517>
14. **Reimagining medical education for primary care in the time of COVID-19: a world view.** Educ. Prim. Care 2020:1-4Ramsay R, Nashat NH, Thuraisingham C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295252>
15. **Instructional interface's blueprint for guiding instructional-technological interactions' research: the Big Bang shift in K-12.** Educ Technol Res Dev 2020:1-5Assaf N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281425>
16. **Communication strategies and media discourses in the age of COVID-19: an urgent need for action.** Health Promot. Int. 2020; Génèreux M, David MD, O'Sullivan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294917>
17. **Knowledge and perception on the transmission and control of SARS-COV-2 infection among allied radiation medicine professionals in Ghana.** Health Technol (Berl) 2020:1-8Hasford F, Sosu EK, Awua AK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282626>
18. **Quality and Safety in Healthcare for Medical Students: Challenges and the Road Ahead.** Healthcare (Basel) 2020; 8López-Hernández LB, Díaz BG, González EOZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291837>
19. **The clinical and translational research activities at the INT - IRCCS "Fondazione Pascale" cancer center (Naples, Italy) during the COVID-19 pandemic.** Infect. Agent. Cancer 2020; 15:69Buonaguro FM, Botti G, Ascierto PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292365>
20. **Knowledge, Attitude, and Precautionary Measures Towards COVID-19 Among Medical Visitors at the University of Gondar Comprehensive Specialized Hospital Northwest Ethiopia.** Infect Drug Resist 2020; 13:4355-4366Abate H, Mekonnen CK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299333>
21. **COVID-19 in Switzerland and Liechtenstein: A Cross-Sectional Survey among Dentists' Awareness, Protective Measures and Economic Effects.** Int J Environ Res Public Health 2020; 17Wolf TG, Zeyer O, Campus G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291659>
22. **Protocol for a Systematic Review Assessing Surgery versus Primary Endocrine Therapy in Operable Breast Cancer. Prep for Pandemic.** Int J Surg Protoc 2020; 24:36-38Roberts S, Rojas A, Gachabayov M, Castaldi M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294752>
23. **Education in uncertainty: Academic life as Indigenous health scholars during COVID-19.** Int Rev Educ 2020:1-16Galloway T, Bowra A, Butsang T, Mashford-Pringle A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281222>
24. **Academic conferencing in the age of COVID-19 and climate crisis: The case of the Comparative and International Education Society (CIES).** Int Rev Educ 2020:1-20Goebel J, Manion C, Millei Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281221>

25. **Participation in an existing massive open online course in dentistry during the COVID-19 pandemic.** *J. Dent. Educ.* 2020; France K, Hangorsky U, Wu CW *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283273>
26. **Psychological well-being during COVID-19 lockdown: Insights from a Saudi State University's Academic Community.** *J King Saud Univ Sci* 2021; 33:101262Alfawaz HA, Wani K, Aljumah AA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288977>
27. **More than Just Soup: Use of a Student-Led COVID-19 Social Pediatrics Initiative to Propose the Integration of Social Medicine Electives in Undergraduate Medical Education.** *J Med Educ Curric Dev* 2020; 7:2382120520973210Daccache J, Khoury M, Habibi C, Bennett S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283048>
28. **Medical Education and E-Learning During COVID-19 Pandemic: Awareness, Attitudes, Preferences, and Barriers Among Undergraduate Medicine and Nursing Students at Makerere University, Uganda.** *J Med Educ Curric Dev* 2020; 7:2382120520973212Olum R, Atulinda L, Kigozi E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283049>
29. **Impacts on Surgery Resident Education at a First Wave COVID-19 Epicenter.** *J Med Educ Curric Dev* 2020; 7:2382120520975022Ostapenko A, McPeck S, Liechty S, Kleiner D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283051>
30. **Artificial Intelligence in the Fight Against COVID-19: Scoping Review.** *J Med Internet Res* 2020; 22:e20756Abd-Alrazaq A, Alajlani M, Alhuwail D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284779>
31. **An Educational Network for Surgical Education Supported by Gamification Elements: Protocol for a Randomized Controlled Trial.** *JMIR Res Protoc* 2020; 9:e21273Guérard-Poirier N, Beniey M, Meloche-Dumas L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284780>
32. **Twelve tips for teaching medical students online under COVID-19.** *Med. Educ. Online* 2021; 26:1854066Jiang Z, Wu H, Cheng H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280546>
33. **Ethical considerations and interdisciplinary approach to research on COVID-19 pandemic: The response of Iran University of Medical Sciences.** *Med. J. Islam. Repub. Iran* 2020; 34:87Hashemi A, Bahmani F, Saeedi Tehrani S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306052>
34. **Rapid transfer of knowledge for multiple sclerosis clinical care during COVID-19: ECHO MS.** *Mult Scler Relat Disord* 2020; 46:102600Alschuler KN, von Geldern G, Ball D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296992>
35. **COVID-19: ensuring safe clinical teaching at university optometry schools.** *Ophthalmic Physiol. Opt.* 2020; Jonuscheit S, Lam AKC, Schmid KL *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33300622>
36. **Effects of COVID-19 lockdowns on PhD candidates.** *Pan Afr. Med. J.* 2020; 35:123Hlongwa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282078>
37. **Medicine Residency Training Program during COVID-19: Qatari Experience.** *Pan Afr. Med. J.* 2020; 35:126Nasrallah MS, Tawfik HA, Aseel MT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282081>
38. **The relationship between nursing students' technology addiction levels and attitudes toward e-learning during the COVID-19 pandemic: A cross-sectional study.** *Perspect. Psychiatr. Care* 2020; Guven Ozdemir N, Sonmez M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33305866>

39. **Training and Incorporating Students in SARS-CoV-2 Case Investigations and Contact Tracing.** Public Health Rep. 2020:33354920974664Pogreba Brown K, Austhof E, Rosa Hernández AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301694>
40. **Family perspectives of COVID-19 research.** Res Involv Engagem 2020; 6:69Vanderhout SM, Birken CS, Wong P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292759>
41. **COVID-19 in Ethiopia: Assessment of How the Ethiopian Government has Executed Administrative Actions and Managed Risk Communications and Community Engagement.** Risk Manag. Healthc. Policy 2020; 13:2803-2810Zikargae MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299368>
42. **The new norm: Computer Science conferences respond to COVID-19.** Scientometrics 2020:1-15Mubin O, Alnajjar F, Shamail A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281245>
43. **Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails.** Stem Cell Reports 2020; Yiangou L, Davis RP, Mummery CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306986>
44. **Joining European Scientific Forces to Face Pandemics.** Trends Microbiol. 2020; Vasconcelos MH, Alcaro S, Arechavala-Gomez V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288385>
45. **Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future?** Tumori 2020:300891620977916Cagnazzo C, Besse MG, Manfellotto D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297885>
46. **COVID 19 SCIENTIFIC PUBLICATIONS FROM TURKEY.** Turk J Med Sci 2020; Çiftçiler R, Haznedaroğlu İ C, Tufan A, Öztürk MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306333>
47. **Is the Coronavirus crisis a Teacher for the Future? Italian experiences in the frame of worldwide discourses.** Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2020; Aliberti SM, De Caro F, Boccia G, Capunzo M.

Elderly (15 articles)

1. **Challenging behavior of nursing home residents during COVID-19 measures in the Netherlands.** Aging Ment. Health 2020:1-6Leontjevas R, Knippenberg IAH, Smalbrugge M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291991>
2. **COVID-19 among nursing home residents: results of an urgent pre-hospital intervention by a multidisciplinary task force.** Braz. J. Infect. Dis. 2020; Dolveck F, Strazzulla A, Noel C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290728>
3. **COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review.** Curr. Pharm. Des. 2020; Aziz A, Asif M, Ashraf G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280586>
4. **Lockdown During COVID-19 and the Increase of Frailty in People With Neurological Conditions.** Front. Neurol. 2020; 11:604299Pelicioni PHS, Schulz-Moore JS, Hale L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304316>
5. **A Polish and German Population Study of Quality of Life, Well-Being, and Life Satisfaction in Older Adults During the COVID-19 Pandemic.** Front Psychiatry 2020; 11:585813Bidzan-Bluma I, Bidzan M, Jurek P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281646>

6. **The Effects of COVID-19 Among the Elderly Population: A Case for Closing the Digital Divide.** Front Psychiatry 2020; 11:577427Martins Van Jaarsveld G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304283>
7. **A Survey for Examining the Effects of COVID-19 and Infection Control Measures in Older Persons With Mild Cognitive Impairment and Dementia and Their Caregivers.** Front Psychiatry 2020; 11:599851Porcari DE, Palmer K, Spalletta G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304288>
8. **Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study.** Gastroenterology 2020; Belli LS, Fondevila C, Cortesi PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307029>
9. **Thirty-Day Mortality in COVID-19 Positive Patients With Hip Fractures: A Case-Series and Literature Review.** Geriatr Orthop Surg Rehabil 2020; 11:2151459320972681Al Farii H, Al Rawahi S, Samaila E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282447>
10. **Changes in Advance Care Planning for Nursing Home Residents During the COVID-19 Pandemic.** J. Am. Med. Dir. Assoc. 2020; Ye P, Fry L, Champion JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290730>
11. **Prognostic Factors of COVID-19 Infection in Elderly Patients: A Multicenter Study.** J Clin Med 2020; 9Hwang J, Ryu HS, Kim HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291617>
12. **Risk factors for severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective study.** J Transl Med 2020; 18:461Wang P, Sha J, Meng M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287826>
13. **Impact of a Serious Game on the Intention to Change Infection Prevention and Control Practices in Nursing Homes During the COVID-19 Pandemic: Protocol for a Web-Based Randomized Controlled Trial.** JMIR Res Protoc 2020; 9:e25595Suppan L, Abbas M, Catho G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296329>
14. **COVID-19 and residential aged care: priorities for optimising preparation and management of outbreaks.** Med. J. Aust. 2020; Aitken GE, Holmes AL, Ibrahim JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296510>
15. **Health service inequalities during the COVID-19 pandemic among elderly people living in large urban and non-urban areas in Florida, USA.** SAGE Open Med 2020; 8:2050312120974168Yu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282304>

Epidemiology (105 articles)

1. **A fractional order approach to modeling and simulations of the novel COVID-19.** Adv Differ Equ 2020; 2020:683Owusu-Mensah I, Akinyemi L, Oduro B, Iyiola OS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288983>
2. **Crowding effects on the dynamics of COVID-19 mathematical model.** Adv Differ Equ 2020; 2020:675Zhang Z, Zeb A, Alzahrani E, Iqbal S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281894>
3. **Transmission dynamics of COVID-19 in Algeria: The impact of physical distancing and face masks.** AIMS Public Health 2020; 7:816-827Moussaoui A, Zerga EH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294484>

4. **Generalized Richards model for predicting COVID-19 dynamics in Saudi Arabia based on particle swarm optimization Algorithm.** AIMS Public Health 2020; 7:828-843Zreiq R, Kamel S, Boubaker S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294485>
5. **Prevalence and Neighborhood Geomapping of COVID-19 in an Underserved Chicago Pregnant Population.** AJP Rep 2020; 10:e413-e416Buhimschi CS, Elam GL, Locher SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294287>
6. **Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean.** Ann. Clin. Microbiol. Antimicrob. 2020; 19:58Mattar S, Martinez-Bravo C, Rivero R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287846>
7. **All-cause mortality supports the COVID-19 mortality in Belgium and comparison with major fatal events of the last century.** Arch Public Health 2020; 78:117Bustos Sierra N, Bossuyt N, Braeye T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292536>
8. **Rapid establishment of a national surveillance of COVID-19 hospitalizations in Belgium.** Arch Public Health 2020; 78:121Van Goethem N, Vilain A, Wyndham-Thomas C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292566>
9. **Demographic Profile of COVID-19 Cases: An Early Analysis of the Local Outbreak in a "Hotspot District" of Western Rajasthan in India.** Asia Pac. J. Public Health 2020:1010539520975288Samantaray S, Nag VL, Rawat P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289399>
10. **Public behaviour in response to the COVID-19 pandemic: understanding the role of group processes.** BJPsych Open 2020; 7:e11Drury J, Carter H, Ntontis E, Guven ST. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283693>
11. **Epidemiology and Outcomes of Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome: A Multicenter Retrospective Study.** Blood Purif. 2020:1-7Wang F, Ran L, Qian C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291098>
12. **Hindsight is 2020 vision: a characterisation of the global response to the COVID-19 pandemic.** BMC Public Health 2020; 20:1868Warne DJ, Ebert A, Drovandi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287789>
13. **Sequential Data Assimilation of the Stochastic SEIR Epidemic Model for Regional COVID-19 Dynamics.** Bull Math Biol 2020; 83:1Engbert R, Rabe MM, Kliegl R, Reich S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289877>
14. **Lessons learned from the MERS-CoV outbreak.** Cardiovasc. Revasc. Med. 2020; Sutton NR, Kawamoto KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303374>
15. **Prediction of COVID-19 Confirmed Cases Combining Deep Learning Methods and Bayesian Optimization.** Chaos Solitons Fractals 2020:110511Abbasimehr H, Paki R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281305>
16. **Data Analysis of Covid-19 Pandemic and Short-Term Cumulative Case Forecasting Using Machine Learning Time Series Models.** Chaos Solitons Fractals 2020:110512Ballı S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281306>
17. **Data analysis of Covid-19 pandemic and short-term cumulative case forecasting using machine learning time series methods.** Chaos Solitons Fractals 2021; 142:110512Ballı S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281306>
18. **Conducting examinations in India: Emergency, contention and challenges of students amidst covid-19 pandemic.** Child Youth Serv Rev 2021; 120:105768Roy

- B, Roy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281253>
19. **Prevalence of SARS-CoV-2 IgG antibodies in a large prospective cohort study of elite football players in Germany (May-June 2020): implications for a testing protocol in asymptomatic individuals and estimation of the rate of undetected cases.** *Clin Microbiol Infect* 2020; Mack D, Gärtner BC, Rössler A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285279>
 20. **COVID-19 testing acceptability and uptake amongst the Rohingya and host community in Camp 21, Teknaf, Bangladesh.** *Confl Health* 2020; 14:74 McGowan CR, Hellman N, Chowdhury S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292358>
 21. **The early phase of the COVID-19 pandemic in Bavaria, Germany.** *Deutsche medizinische Wochenschrift* (1946) 2020; Wjst M.
 22. **The Unlikely Saviour: Portugal's National Health System and the Initial Impact of the COVID-19 Pandemic?** *Development (Rome)* 2020;1-7 Varanda J, Gonçalves L, Craveiro I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288975>
 23. **A New Discrete Analog of the Continuous Lindley Distribution, with Reliability Applications.** *Entropy (Basel)* 2020; 22 Al-Babtain AA, Ahmed AHN, Afify AZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33286375>
 24. **Entropy Ratio and Entropy Concentration Coefficient, with Application to the COVID-19 Pandemic.** *Entropy (Basel)* 2020; 22 Bandt C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287080>
 25. **Some Dissimilarity Measures of Branching Processes and Optimal Decision Making in the Presence of Potential Pandemics.** *Entropy (Basel)* 2020; 22 Kammerer NB, Stummer W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33286645>
 26. **Susceptible-Infected-Susceptible Epidemic Discrete Dynamic System Based on Tsallis Entropy.** *Entropy (Basel)* 2020; 22 Momani S, Ibrahim RW, Hadid SB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33286541>
 27. **Ordinal Decision-Tree-Based Ensemble Approaches: The Case of Controlling the Daily Local Growth Rate of the COVID-19 Epidemic.** *Entropy (Basel)* 2020; 22 Singer G, Marudi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33286642>
 28. **The impact of lockdown strategies targeting age groups on the burden of COVID-19 in France.** *Epidemics* 2020; 33:100424 Roche B, Garchitorena A, Roiz D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285420>
 29. **Secondary transmission of COVID-19 in preschool and school settings in northern Italy after their reopening in September 2020: a population-based study.** *Euro Surveill* 2020; 25 Larosa E, Djuric O, Cassinadri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303065>
 30. **Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020.** *Euro Surveill* 2020; 25 Riccardo F, Ajelli M, Andrianou XD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303064>
 31. **An Update on COVID-19 Pandemic: The Epidemiology, Pathogenesis, Prevention and Treatment Strategies.** *Expert Rev. Anti Infect. Ther.* 2020; Tsang HF, Chan LWC, Cho WCS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306423>
 32. **Lockdown During COVID-19 and the Increase of Frailty in People With Neurological Conditions.** *Front. Neurol.* 2020; 11:604299 Pelicioni PHS, Schulz-Moore JS, Hale L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304316>

33. **COVID-SGIS: A Smart Tool for Dynamic Monitoring and Temporal Forecasting of Covid-19.** Front Public Health 2020; 8:580815de Lima CL, da Silva CC, da Silva ACG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282815>
34. **Individual Behaviors and COVID-19 Lockdown Exit Strategy: A Mid-Term Multidimensional Bio-economic Modeling Approach.** Front Public Health 2020; 8:606371Ferchiou A, Bornet R, Lhermie G, Raboisson D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282820>
35. **Adherence to Social Distancing Measures for Controlling COVID-19 Pandemic: Successful Lesson From Vietnam.** Front Public Health 2020; 8:589900Vo HL, Nguyen HAS, Nguyen KN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304878>
36. **Global health governance for travel health: Lessons learned from the coronavirus disease 2019 (COVID-19) outbreaks in large cruise ships.** Glob Health J 2020; Zhou S, Han L, Liu P, Zheng Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294249>
37. **A collaborative effort of China in combating COVID-19.** Glob Health Res Policy 2020; 5:47Bangura MS, Gonzalez MJ, Ali NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292746>
38. **Application of artificial neural networks to predict the COVID-19 outbreak.** Glob Health Res Policy 2020; 5:50Niazkar HR, Niazkar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292780>
39. **COVID-19 cases and testing in 53 prison systems.** Health Justice 2020; 8:24Lemasters K, McCauley E, Nowotny K, Brinkley-Rubinstein L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306151>
40. **Communication strategies and media discourses in the age of COVID-19: an urgent need for action.** Health Promot. Int. 2020; Génèreux M, David MD, O'Sullivan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294917>
41. **A rapid pre-implementation evaluation to inform a family engagement navigator program during COVID-19.** Implement Sci Commun 2020; 1:110Taylor SP, Short RT, 3rd, Asher AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298192>
42. **The association between COVID-19 cases and deaths and web-based public inquiries.** Infect Dis (Lond) 2020;1-8Schnoell J, Besser G, Jank BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287607>
43. **Air travel in a COVID-19 world: Commercial airline passengers' health concerns and attitudes towards infection prevention and disease control measures.** Infect Dis Health 2020; Sotomayor-Castillo C, Radford K, Li C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303405>
44. **Breaking the chain of transmission within a tertiary health service: An approach to contact tracing during the COVID-19 pandemic.** Infect Dis Health 2020; Stuart RL, Zhu W, Morand EF, Stripp A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281108>
45. **Modeling and forecasting of COVID-19 using a hybrid dynamic model based on SEIRD with ARIMA corrections.** Infect Dis Model 2020; 6:98-111Ala'raj M, Majdalawieh M, Nizamuddin N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294749>
46. **Modeling and forecasting of COVID-19 using a hybrid dynamic model based on SEIRD with ARIMA corrections.** Infect Dis Model 2021; 6:98-111Ala'raj M,

- Majdalawieh M, Nizamuddin N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294749>
47. **Correlation of subway turnstile entries and COVID-19 prevalence and deaths in New York City.** *Infect Dis Model* 2020; Fathi-Kazerooni S, Rojas-Cessa R, Dong Z, Umpaichitra V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294750>
 48. **Host range projection of SARS-CoV-2: South Asia perspective.** *Infect Genet Evol* 2020;104670Ahmed R, Hasan R, Siddiki A, Islam MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301987>
 49. **Scrutinizing the spread of COVID-19 in Madagascar.** *Infect Genet Evol* 2020;104668Narison S, Maltezos S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290827>
 50. **Early Phase Management of the SARS-CoV-2 Pandemic in the Geographic Area of the Veneto Region, in One of the World's Oldest Populations.** *Int J Environ Res Public Health* 2020; 17Camerotto A, Sartorio A, Mazzetto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291638>
 51. **Aerosol Release by Healthy People during Speaking: Possible Contribution to the Transmission of SARS-CoV-2.** *Int J Environ Res Public Health* 2020; 17Eiche T, Kuster M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291404>
 52. **Influence of Officially Ordered Restrictions During the First Wave of COVID-19 Pandemic on Physical Activity and Quality of Life in Patients after Kidney Transplantation in a Telemedicine Based Aftercare Program-A KTx360° Sub Study.** *Int J Environ Res Public Health* 2020; 17Hanke AA, Sundermeier T, Boeck HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297529>
 53. **How to Form Behavioral Intentions in the Field of Drone Food Delivery Services: The Moderating Role of the COVID-19 Outbreak.** *Int J Environ Res Public Health* 2020; 17Hwang J, Kim D, Kim JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291294>
 54. **Prevention of SARS-CoV-2 Infection Among Police Officers in Poland- Implications for Public Health Policies.** *Int J Environ Res Public Health* 2020; 17Raciborski F, Jankowski M, Gujski M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291761>
 55. **An overview of the effect of bioaerosol size in coronavirus disease 2019 transmission.** *Int. J. Health Plann. Manage.* 2020; Guzman MI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295073>
 56. **A neonatal cluster of novel coronavirus disease 2019: clinical management and considerations.** *Ital. J. Pediatr.* 2020; 46:180Olivini N, Calò Carducci FI, Santilli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287880>
 57. **A Novel Diffusion-Based Model for Estimating Cases, and Fatalities in Epidemics: The Case of COVID-19.** *J Bus Res* 2020; Eryarsoy E, Delen D, Davazdahemami B, Topuz K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281248>
 58. **A novel diffusion-based model for estimating cases, and fatalities in epidemics: The case of COVID-19.** *J Bus Res* 2021; 124:163-178Eryarsoy E, Delen D, Davazdahemami B, Topuz K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281248>
 59. **Modeling the COVID-19 Pandemic: A Comprehensive Guide of Infectious Disease and Decision-Analytic Models.** *J. Clin. Epidemiol.* 2020; Mac S, Mishra S, Ximenes R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301904>
 60. **A review of the prevalence of COVID-19 in the Arab world.** *J Infect Dev Ctries* 2020; 14:1238-1245Alwahaibi N, Al-Maskari M, Al-Dhahli B *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296334>
61. **What influences the infection of COVID-19 in healthcare workers?** J Infect Dev Ctries 2020; 14:1231-1237Lai X, Zhou Q, Zhang X, Tan L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296333>
 62. **Linear behavior in Covid19 epidemic as an effect of lockdown.** J Math Ind 2020; 10:27Bambusi D, Ponno A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282624>
 63. **Quantifying the shift in social contact patterns in response to non-pharmaceutical interventions.** J Math Ind 2020; 10:28McCarthy Z, Xiao Y, Scarabel F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282625>
 64. **Pandemics Past and Present: A Guided Inquiry Approach.** J Med Educ Curric Dev 2020; 7:2382120520976957Willey JM, Olvet DM, Bird JB, Brenner JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294621>
 65. **Computing SARS-CoV-2 Infection Risk From Symptoms, Imaging, and Test Data: Diagnostic Model Development.** J Med Internet Res 2020; 22:e24478D'Ambrosia C, Christensen H, Aronoff-Spencer E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301417>
 66. **COVID-19 and Tuberculosis Overlapping epidemics: A holistic review from Pakistan.** J Med Virol 2020; Awan UA, Khattak AA, Afzal MS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33295641>
 67. **SARS-CoV-2 positive tests efficiently predict pressure on healthcare system.** J Med Virol 2020; Lippi G, Mattiuzzi C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295648>
 68. **Immunohistochemical expression of angiotensin-converting enzyme 2 (ACE2) in minor salivary glands during SARS-CoV-2 infection.** J Med Virol 2020; Soares CD, Mosqueda-Taylor A, Hernandez-Guerrero JC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33300137>
 69. **Epidemiological characteristics and transmission dynamics of paediatric cases with coronavirus disease 2019 in Hubei province, China.** J. Paediatr. Child Health 2020; Wang M, Nie X, Huang S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289923>
 70. **The Effectiveness of Community-based Social Distancing for Mitigating the Spread of the COVID-19 Pandemic in Turkey.** J Prev Med Public Health 2020; 53:397-404Durmuş H, Gökler ME, Metintaş S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296579>
 71. **Whom Should We Test for COVID-19? Performance of a Symptom and Risk Factor Questionnaire on COVID-19 Test Results and Patient Outcomes in an Immediate Care Setting.** J. Prim. Care Community Health 2020; 11:2150132720981297Oshman L, Caplan A, Ali R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33300408>
 72. **Demographic variables associated with Covid-19 mortality.** J Public Health Res 2020; 9:1827Madrado Cabo JM, Monter Valera NA, Hernández Sánchez EJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282790>
 73. **Epidemiology of imported infectious diseases, China, 2014-18.** J Travel Med 2020; Wu Y, Liu MY, Wang JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283238>
 74. **SARS-CoV-2 and aerosols-Arguing over the evidence.** J. Virol. Methods 2020:114033Tang JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285192>
 75. **Time for a clear national COVID-19 strategy.** Med. J. Aust. 2020; Trauer JM, Marais BJ, Ragonnet R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295024>

76. **Resilient urban form to pandemics: Lessons from COVID-19.** Med. J. Islam. Repub. Iran 2020; 34:71Lak A, Shakouri Asl S, Maher A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306051>
77. **All-cause excess mortality and COVID-19-related deaths in Iran.** Med. J. Islam. Repub. Iran 2020; 34:80Tadbiri H, Moradi-Lakeh M, Naghavi M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306040>
78. **Non-physician practice assistants can take a refresher course a few months later due to the corona pandemic.** MMW-Fortschritte der Medizin 2020; 162:33Zimmermann GW.
79. **Testing the waters: COVID-19 first wave and shielding among BAME patients with rheumatological conditions in the United Kingdom.** Musculoskeletal Care 2020; Dubey S, Kumar K, Bunting H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306871>
80. **Nonlinear model predictive control with logic constraints for COVID-19 management.** Nonlinear Dyn 2020:1-22Péni T, Csutak B, Szederkényi G, Röst G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281298>
81. **Epidemiological characteristics and treatment outcomes of hospitalized patients with COVID-19 in Ethiopia.** Pan Afr. Med. J. 2020; 37:7Gebremariam BM, Shienka KL, Kebede BA, Abiche MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294108>
82. **Overcoming COVID-19 in West African countries: is herd immunity an option?** Pan Afr. Med. J. 2020; 35:103Ilesanmi OS, Akande A, Afolabi AA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282058>
83. **Why policy action should focus on the vulnerable commercial sex workers in Uganda during COVID-19 fight.** Pan Afr. Med. J. 2020; 35:102Kawala BA, Kirui BK, Cumber SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282057>
84. **COVID-19 changing pandemic pattern: why sub-Saharan Africa should reassess the current response approach.** Pan Afr. Med. J. 2020; 35:111Ogundele OA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282066>
85. **COVID-19 pandemic: implementing control measures in Africa using the 'SHEF2' model.** Pan Afr. Med. J. 2020; 37:3Wirsiy FS, Nkfusai CN, Ako-Arrey DE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294104>
86. **Contact Tracing: A Memory Task With Consequences for Public Health.** Perspect. Psychol. Sci. 2020:1745691620978205Garry M, Hope L, Zajac R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301692>
87. **Real time monitoring of the evolution of an epidemic regarded as a physical relaxation process.** Phys Lett A 2021; 388:127074Trujillo J, Raicu V.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33299265>
88. **International comparisons of coronavirus deaths and infections should be avoided if not adjusted per capita.** Public Health 2020; Kremer HJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303206>
89. **Training and Incorporating Students in SARS-CoV-2 Case Investigations and Contact Tracing.** Public Health Rep. 2020:33354920974664Pogreba Brown K, Austhof E, Rosa Hernández AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301694>
90. **Challenges in Translating National and State Reopening Plans Into Local Reopening Policies During the COVID-19 Pandemic.** Public Health Rep. 2020:33354920971721Vest JR, Blackburn J, Yeager VA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33290170>

91. **Beyond Predicting the Number of Infections: Predicting Who is Likely to Be COVID Negative or Positive.** *Risk Manag. Healthc. Policy* 2020; 13:2811-2818Zhang SX, Sun S, Afshar Jahanshahi A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33299369>
92. **COVID-19 in Ethiopia: Assessment of How the Ethiopian Government has Executed Administrative Actions and Managed Risk Communications and Community Engagement.** *Risk Manag. Healthc. Policy* 2020; 13:2803-2810Zikargae MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299368>
93. **Knowledge, attitude and practice regarding COVID-19 among Sudanese population during the early days of the pandemic: Online cross-sectional survey.** *Sci Afr* 2020; 10:e00652Sayedahmed AMS, Abdalla AAA, Khalid MHM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283079>
94. **Sociodemographic determinants of COVID-19 incidence rates in Oman: Geospatial modelling using multiscale geographically weighted regression (MGWR).** *Sustain Cities Soc* 2020; 65:102627Mansour S, Al Kindi A, Al-Said A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288993>
95. **Sociodemographic determinants of COVID-19 incidence rates in Oman: Geospatial modelling using multiscale geographically weighted regression (MGWR).** *Sustain Cities Soc* 2021; 65:102627Mansour S, Al Kindi A, Al-Said A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288993>
96. **Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. Primary and Community Healthcare.** *Toxicol Rep* 2020; Farsalinos K, Poulas K, Kouretas D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294384>
97. **Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare.** *Toxicol Rep* 2021; 8:1-9Farsalinos K, Poulas K, Kouretas D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294384>
98. **Features of family clusters of COVID-19 patients: A retrospective study.** *Travel Med Infect Dis* 2020;101950Diao KY, Zhang XC, Huang S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307197>
99. **"Staying at home" to tackle COVID-19 pandemic: rhetoric or reality? Cross-cutting analysis of nine population groups vulnerable to homelessness in Japan.** *Trop Med Health* 2020; 48:92Fujita M, Matsuoka S, Kiyohara H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292830>
100. **Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review.** *Trop Med Health* 2020; 48:91Girum T, Lentiro K, Geremew M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292755>
101. **[The role of time-series propagation map and activity path of confirmed cases in the analysis and determination of COVID-19 epidemic].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:1782-1785Cao L, Zhou YJ, Zhang F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33297638>
102. **[Epidemiological characteristics of COVID-19 in Wuchang district of Wuhan].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:1616-1622Chen YL, Wang H, Zhou YN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297617>
103. **[Preliminary analysis on COVID-19 case spectrum and spread intensity in different provinces in China except Hubei province].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:1601-1605Cheng C, Chen SY, Geng J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33297615>

104. **[Epidemic dynamic model based evaluation of effectiveness of prevention and control strategies for COVID-19 in Ningbo].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1606-1610 Hong H, Shi HB, Jiang HB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33297616>
105. **[Epidemiological characteristics of imported COVID-19 cases in Guangzhou].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1786-1790 Zhen RN, Huang Y, Li YL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297639>

Gastro-enterology (7 articles)

1. **Elevated serum ferritin level effectively discriminates severity illness and liver injury of coronavirus disease 2019 pneumonia.** Biomarkers 2020;1-18 Cao P, Wu Y, Wu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284041>
2. **ACE2: from protection of liver disease to propagation of COVID-19.** Clin Sci (Lond) 2020; 134:3137-3158 Warner FJ, Rajapaksha H, Shackel N, Herath CB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284956>
3. **Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review.** Front Med (Lausanne) 2020; 7:572115 Váncsa S, Hegyi PJ, Zádori N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282888>
4. **Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study.** Gastroenterology 2020; Belli LS, Fondevila C, Cortesi PA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307029>
5. **The gastrointestinal tract is an alternative route for SARS-CoV-2 infection in a nonhuman primate model.** Gastroenterology 2020; Jiao L, Li H, Xu J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307034>
6. **Alimentary System is Directly Attacked by SARS-COV-2 and Further Prevents Immune Dysregulation Caused by COVID-19.** Int J Clin Pract 2020:e13893 Chen S, Zhou J, Ou X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289233>
7. **The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?** Therap. Adv. Gastroenterol. 2020; 13:1756284820974914 Segal JP, Mak JWY, Mullish BH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281941>

Guidelines (7 articles)

1. **Comparative analysis of COVID-19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti.** BMC Public Health 2020; 20:1853 Yoo JY, Dutra SVO, Fanfan D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33272250>
2. **Traditional Chinese Medicine guidelines for coronavirus disease 2019.** J. Tradit. Chin. Med. 2020; 40:891-896 Liang N, Ma Y, Wang J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33258339>
3. **German recommendations on lung and thoracic ultrasonography in patients with COVID-19.** Medizinische Klinik - Intensivmedizin und Notfallmedizin 2020; 115:654-667 Kiefl D, Eisenmann S, Michels G *et al.*
4. **Pediatric neurosurgery during the COVID-19 pandemic: update and recommendations from the Brazilian Society of Pediatric Neurosurgery.** Neurosurg. Focus 2020; 49:E2 Ballesterio MFM, Furlanetti L, de Oliveira RS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33260125>

5. **Reconversion of neurosurgical practice in times of the SARS-CoV-2 pandemic: a narrative review of the literature and guideline implementation in a Mexican neurosurgical referral center.** *Neurosurg. Focus* 2020; 49:E4Díaz-Bello S, Hernández-Hernández A, Guinto-Nishimura GY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33260129>
6. **Preparedness and guidelines for neurosurgery in the COVID-19 era: Indian perspective from a tertiary care referral hospital.** *Neurosurg. Focus* 2020; 49:E3Raheja A, Agarwal N, Mohapatra S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33260133>
7. **A review of COVID-19-related thrombosis and anticoagulation strategies specific to the Asian population.** *Singapore Med J* 2020; Poh KC, Tay VYJ, Lin SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33264831>

Imaging (19 articles)

1. **Exploration of CT manifestations of different clinical types of novel coronavirus pneumonia.** *Ann Palliat Med* 2020; Li XY, Zhou Y, Kong ZX *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302632>
2. **Lung ultrasound in the emergency department - a valuable tool in the management of patients presenting with respiratory symptoms during the SARS-CoV-2 pandemic.** *BMC Emerg. Med.* 2020; 20:96Schmid B, Feuerstein D, Lang CN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287732>
3. **The preliminary comparative results between Covid-19 and non-Covid-19 patients in Western China.** *BMC Infect. Dis.* 2020; 20:935Li Y, Li H, Han J, Yang L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297990>
4. **Early Extrapulmonary Prognostic Features in Chest Computed tomography in COVID-19 Pneumonia: Bone Mineral Density is a Relevant Predictor for the Clinical Outcome - a Multicenter Feasibility Study.** *Bone* 2020;115790Kottlors J, Große Hokamp N, Fervers P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301962>
5. **Challenges in COVID-19 diagnosis.** *Bratisl. Lek. Listy* 2020; 121:864Erenler AK, Baydin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300355>
6. **The challenge of deciding between home-discharge versus hospitalization in COVID-19 patients: The role of initial imaging and clinicolaboratory data.** *Clin Epidemiol Glob Health* 2020; Mozafari A, Miladinia M, Sabri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289003>
7. **Interstitial lung opacities in patients with severe COVID-19 pneumonia by bedside high-resolution ultrasound in association to CO2 retention.** *Clin. Hemorheol. Microcirc.* 2020; Peschel G, Jung EM, Fisser C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285628>
8. **Radiology indispensable for tracking COVID-19.** *Diagn Interv Imaging* 2020; Li J, Long X, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281082>
9. **Chest CT scan features from 302 patients with COVID-19 in Jordan.** *Eur J Radiol Open* 2020; 7:100295Albtoush OM, Al-Shdefat RB, Al-Akaileh A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288999>
10. **Chest CT imaging features of COVID-19 pneumonia: First radiological insights from Porto, Portugal.** *Eur J Radiol Open* 2020; 7:100294Carvalho A, Cunha R, Lima BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283031>

11. **Echocardiography Abnormal Findings and Laboratory Operations during the COVID-19 Pandemic at a High Volume Center in New York City.** Healthcare (Basel) 2020; 8Pang L, Stahl EP, Fujikura K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33287257>
12. **On Cancer, COVID-19, and CT Scans: A Monocentric Retrospective Study.** J Clin Med 2020; 9Martini F, D'Alessio A, Bracchi F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291710>
13. **A Case of Covid-19 Diagnosed at Home With Portable Ultrasound and Confirmed With Home Serology Test.** J. Emerg. Med. 2020; Aminlari A, Quenzer F, Hayden S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288350>
14. **Screening of Potential Cardiac Involvement in Competitive Athletes Recovering From COVID-19: An Expert Consensus Statement.** JACC Cardiovasc. Imaging 2020; 13:2635-2652Phelan D, Kim JH, Elliott MD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303102>
15. **Hypergraph learning for identification of COVID-19 with CT imaging.** Med. Image Anal. 2020; 68:101910Di D, Shi F, Yan F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285483>
16. **COVID-AL: The diagnosis of COVID-19 with deep active learning.** Med. Image Anal. 2020; 68:101913Wu X, Chen C, Zhong M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285482>
17. **Hybrid-COVID: a novel hybrid 2D/3D CNN based on cross-domain adaptation approach for COVID-19 screening from chest X-ray images.** Phys Eng Sci Med 2020:1-17Bayoudh K, Hamdaoui F, Mtibaa A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301073>
18. **Predictive value of chest CT scoring in COVID-19 patients in Wuhan, China: A retrospective cohort study.** Respir. Med. 2020; 176:106271Li S, Liu S, Wang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296777>
19. **Lung Ultrasound in the Emergency Department for Early Identification of COVID-19 Pneumonia.** Respiration 2020:1-9Zanforlin A, Strapazzon G, Falk M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285550>

Immune response (17 articles)

1. **Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.** Biochem. Biophys. Res. Commun. 2020; Bacca E, Digaetano M, Meschiari M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303188>
2. **Cancer patient management strategy in a Cancer Center of Zhejiang, China during the COVID-19 pandemic.** BMC Cancer 2020; 20:1194Xu S, Cheng X, Pan Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287747>
3. **Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.** Cell 2020; Rodda LB, Netland J, Shehata L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296701>
4. **Maturation of T and B Lymphocytes in the Assessment of the Immune Status in COVID-19 Patients.** Cells 2020; 9Kwiecień I, Rutkowska E, Kłos K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291439>
5. **Prevalence of SARS-CoV-2 IgG antibodies in a large prospective cohort study of elite football players in Germany (May-June 2020): implications for a testing protocol in asymptomatic individuals and estimation of the rate of undetected**

- cases.** *Clin Microbiol Infect* 2020; Mack D, Gärtner BC, Rössler A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285279>
6. **A Prospective Study on Rapidly Declining SARS-CoV-2 IgG Antibodies Within One to Three Months of Testing IgG Positive: Can It Lead to Potential Reinfections?** *Cureus* 2020; 12:e11845Nag DS, Chaudhry R, Mishra M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282604>
 7. **Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals.** *Diagn. Microbiol. Infect. Dis.* 2020; 99:115273Alserahi HA, Alqunaibet AM, Al-Tawfiq JA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296851>
 8. **Searching for COVID-19 Antibodies in Czech Children-A Needle in the Haystack.** *Front Pediatr* 2020; 8:597736Bloomfield M, Pospisilova I, Cabelova T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304869>
 9. **Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19.** *Immunity* 2020; Bacher P, Rosati E, Esser D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296686>
 10. **Welcome to the 13th Volume of Immunotherapy.** *Immunotherapy* 2020; Torrington E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280421>
 11. **The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease.** *Int Immunopharmacol* 2020; 90:107225Pasrija R, Naime M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302033>
 12. **Micro-RNAs in the regulation of immune response against SARS COV-2 and other viral infections.** *J Adv Res* 2020; Abu-Izneid T, AlHajri N, Mohammed Ibrahim A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282419>
 13. **Modeling and simulations of CoViD-19 molecular mechanism induced by cytokines storm during SARS-CoV2 infection.** *J. Mol. Liq.* 2020:114863Yu Z, Ellahi R, Nutini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281252>
 14. **Immunochromatographic test for differentiation detection of IgM and IgG to SARS-CoV-2.** *Klin. Lab. Diagn.* 2020; 65:688-692Akinshina YA, Mardanly SS, Kiseleva VA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301658>
 15. **Antigenic variation of SARS-CoV-2 in response to immune pressure.** *Mol. Ecol.* 2020; Forni D, Cagliani R, Pontremoli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289207>
 16. **Asymptomatic SARS-CoV-2 infection: Is it all about being refractile to innate immune sensing of viral spare-parts? - Clues from exotic animal reservoirs.** *Pathog Dis* 2020; Shankar EM, Che KF, Yong YK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289808>
 17. **Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2.** *Pathogens* 2020; 9Taefehshokr N, Taefehshokr S, Heit B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33302366>

Management miscellaneous diseases (79 articles)

1. **Development and implementation of an end-of-shift clinical debriefing method for emergency departments during COVID-19.** *Adv Simul (Lond)* 2020; 5:32Servotte JC, Welch-Horan TB, Mullan P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292850>
2. **Challenging behavior of nursing home residents during COVID-19 measures in the Netherlands.** *Aging Ment. Health* 2020:1-6Leontjevas R, Knippenberg IAH,

- Smalbrugge M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291991>
3. **The global impact of the COVID-19 pandemic on the management and course of chronic urticaria.** *Allergy* 2020; Kocatürk E, Salman A, Cherrez-Ojeda I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284457>
 4. **Non-COVID-19 admissions to the emergency department during the pandemic second wave in Italy: What is changed from the first wave?** *Am J Emerg Med* 2020; Mantica G, Riccardi N, Terrone C, Gratarola A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303298>
 5. **Protective Measures For Burn Care Professionals During The Coronavirus Disease 2019 Pandemic: Systematic Review.** *Ann Burns Fire Disasters* 2020; 33:182-190 Al-Benna S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304207>
 6. **Availability Of Covid-19 Information From National And International Burn Society Websites.** *Ann Burns Fire Disasters* 2020; 33:177-181 Al-Benna S, Gohritz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304206>
 7. **The number of obstructive colorectal cancers in Japan has increased during the COVID-19 pandemic: A retrospective single-center cohort study.** *Ann Med Surg (Lond)* 2020; 60:675-679 Mizuno R, Ganeko R, Takeuchi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282280>
 8. **Infection-prevention measures against COVID-19 during anesthesia: a narrative review of current clinical literature.** *Ann Palliat Med* 2020; 9:4300-4307 Chen Y, Guo X, Zhang X, Lv H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302684>
 9. **Factors for peripherally inserted central catheters care delay in cancer patients during the COVID-19 pandemic.** *Ann Palliat Med* 2020; 9:3818-3829 Hu L, Tao H, Xu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302650>
 10. **Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients.** *Anticancer Res.* 2020; 40:7119-7125 Vanni G, Tazzioli G, Pellicciaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288611>
 11. **High acceptability of PrEP teleconsultation and HIV self-test among PrEP users during the COVID-19 pandemic in Brazil.** *Braz. J. Infect. Dis.* 2020; Hoagland B, Torres TS, Bezerra DRB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285137>
 12. **High acceptability of PrEP teleconsultation and HIV self-testing among PrEP users during the COVID-19 pandemic in Brazil.** *Braz. J. Infect. Dis.* 2020; Hoagland B, Torres TS, Bezerra DRB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285137>
 13. **A prospective cohort study of the safety of breast cancer surgery during COVID-19 pandemic in the West of Scotland.** *Breast* 2020; 55:1-6 Romics L, Doughty J, Stallard S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285400>
 14. **Radiotherapy management of rectal cancer in the backdrop of the COVID pandemic.** *Cancer Rep (Hoboken)* 2020:e1320 Lewis S, Talapatra K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295140>
 15. **Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey.** *Cardiooncology* 2020; 6:28 Sadler D, DeCara JM, Herrmann J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292763>
 16. **Impact of the COVID-19 pandemic on radiology physician work RVUs at a large subspecialized radiology practice.** *Clin Imaging* 2020; 73:38-42 Poyiadji N,

- Klochko C, Palazzolo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302235>
17. **The Impact of the COVID-19 Pandemic on Ophthalmic Care at an Eye-Specific Emergency Department in an Outbreak Hotspot.** Clin. Ophthalmol. 2020; 14:4155-4163 Moon JY, Miller JB, Katz R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293788>
 18. **Do COVID-19 restrictions lead to a decrease in severely injured patients at a level 1 trauma center in Germany?** Der Unfallchirurg 2020; Fuchs KF, Eden L, Gilbert F *et al.*
 19. **The impact of COVID-19 pandemic on the management of patients with chronic urticaria: an observational two-center study from Turkey.** Dermatol Ther 2020; Erdem Y, Polat Ekinici A, Altunay IK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301190>
 20. **Can Rituximab Be Used In The Treatment Of Pemphigus Vulgaris During The COVID-19 Pandemic?** Dermatol Ther 2020:e14647 Uzuncakmak TK, Özkoca D, Askin O, Kutlubay Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296557>
 21. **Reconfigure rehabilitation services during the Covid-19 pandemic: best practices from Southwest China.** Disabil. Rehabil. 2020:1-7 Zhu S, Zhang L, Xie S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280457>
 22. **Impact of the COVID-19 Pandemic on Patients With Idiopathic Subglottic Stenosis.** Ear Nose Throat J 2020:145561320977467 Anderson C, Sandhu G, Yaghchi CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302743>
 23. **The Impact of the COVID-19 Pandemic on Follow-Ups for Vertigo/Dizziness Outpatients.** Ear Nose Throat J 2020:145561320980186 Ueda K, Ota I, Yamanaka T, Kitahara T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295213>
 24. **COVID-19 related acute decline in paediatric admissions in Malta, a population-based study.** Early Hum. Dev. 2020:105251 Degiorgio S, Grech N, Dimech YM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293107>
 25. **Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic.** Endocrine 2020; Palladino R, Migliatino I, Sgariglia R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284396>
 26. **Distribution, infrastructure, and expertise of heart failure and cardio-oncology clinics in a developing network: temporal evolution and challenges during the coronavirus disease 2019 pandemic.** ESC Heart Fail 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284510>
 27. **Living with cancer in the COVID-19 pandemic: An Italian survey on self-isolation at home.** Eur. J. Cancer Care (Engl.) 2020:e13385 Biagioli V, Albanesi B, Belloni S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289205>
 28. **Implementing continued radiation therapy for cancer management in low resource countries during and after the COVID-19 crisis.** Expert Rev. Anticancer Ther. 2020; Upadhyay R, Shankar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287614>
 29. **Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid.** Expert Rev. Hematol. 2020; Lázaro Del Campo P, Ramírez López A, de la Cruz Benito B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280467>
 30. **Change in Patient Flow in the Epilepsy Care Network Due to Novel Coronavirus Infection: An Opportunity to Strengthen Local Interdisciplinary**

- Epilepsy Care With General Physicians.** *Front. Neurol.* 2020; 11:591423Fujimoto A, Sato K, Enoki H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304311>
31. **A Survey for Examining the Effects of COVID-19 and Infection Control Measures in Older Persons With Mild Cognitive Impairment and Dementia and Their Caregivers.** *Front Psychiatry* 2020; 11:599851Porcari DE, Palmer K, Spalletta G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304288>
 32. **Evidence-based National Consensus: Recommendations for Physiotherapy Management in COVID-19 in Acute Care Indian Setup.** *Indian J. Crit. Care Med.* 2020; 24:905-913Jiandani MP, Agarwal B, Baxi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281313>
 33. **Trends of interventional radiology procedures during the COVID-19 pandemic: the first 27 weeks in the eye of the storm.** *Insights Imaging* 2020; 11:131How GY, Pua U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296046>
 34. **Hospital emergency management plan during 2019 novel coronavirus (SARS-CoV-2) pandemic in non-epidemic areas.** *Int. J. Clin. Exp. Pathol.* 2020; 13:2753-2757Xu L, Xia D, Hu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284879>
 35. **Dental Challenges and the Needs of the Population during the Covid-19 Pandemic Period. Real-Time Surveillance Using Google Trends.** *Int J Environ Res Public Health* 2020; 17Sycinska-Dziarnowska M, Paradowska-Stankiewicz I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287130>
 36. **Emergency Orthopaedic surgery in the pandemic era: A case series at a national tertiary hospital in Jakarta, Indonesia.** *Int. J. Surg. Case Rep.* 2020; 77:870-874Kamal AF, Widodo W, Kuncor MW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288992>
 37. **Emergency orthopaedic surgery in the pandemic era: A case series at Cipto Mangunkusumo national tertiary hospital in Jakarta, Indonesia.** *Int. J. Surg. Case Rep.* 2020; 77:870-874Kamal AF, Widodo W, Kuncoro MW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288992>
 38. **Protocol for a Systematic Review Assessing Surgery versus Primary Endocrine Therapy in Operable Breast Cancer. Prep for Pandemic.** *Int J Surg Protoc* 2020; 24:36-38Roberts S, Rojas A, Gachabayov M, Castaldi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294752>
 39. **Community Supports and COVID-19: Self-Determination in a Pandemic.** *Intellect Dev Disabil* 2020; 58:453-457Ervin DA, Hobson-Garcia D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290529>
 40. **Dermatological surgery during the COVID-19 pandemic: experience of a large academic center.** *J Am Acad Dermatol* 2020; Tee MW, Stewart C, Aliessa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290801>
 41. **Crisis Standards of Care for the COVID-19 Pandemic: An Essential Resource for the PALTC Community.** *J. Am. Med. Dir. Assoc.* 2020; Wright J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306997>
 42. **Changes in Advance Care Planning for Nursing Home Residents During the COVID-19 Pandemic.** *J. Am. Med. Dir. Assoc.* 2020; Ye P, Fry L, Champion JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290730>
 43. **"The Tip of the Iceberg": Commentary on Sports, Health Inequity, and Trauma Exacerbated by COVID-19.** *J Athl Train* 2020; Noel-London KC, Grimsley C, Porter J, Breitbach AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290542>
 44. **Brachytherapy practice during the COVID-19 pandemic: a review on the practice changes.** *J Contemp Brachytherapy* 2020; 12:393-396Barthwal M, Pareek

- V, Mallick S, Sharma DN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293979>
45. **Pandemic Considerations on Essential Oral Health Care.** J Dent Res 2020;22034520979830Benzian H, Beltrán-Aguilar E, Mathur MR, Niederman R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295831>
 46. **Increased DKA at presentation among newly diagnosed type 1 diabetes patients with or without COVID-19; Data from a multi-site surveillance registry.** J. Diabetes 2020; Beliard K, Ebekozién O, Demeterco-Berggren C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283979>
 47. **Older survivors of cancer in the COVID-19 pandemic: Reflections and recommendations for future care.** J. Geriatr. Oncol. 2020; Haase KR, Kain D, Merchant S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303410>
 48. **A point prevalence survey to assess antibiotic prescribing in patients hospitalized with confirmed and suspected coronavirus disease 2019 (COVID-19).** J Glob Antimicrob Resist 2020; Tan SH, Ng TM, Tay HL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307276>
 49. **Comparative study of orthopaedic trauma pattern in covid lockdown versus non-covid period in a tertiary care centre.** J Orthop 2020; Bhat AK, Kamath KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281370>
 50. **Living With a Trifecta of Pain and Cancer With Personal Reflections of COVID-19.** J Patient Exp 2020; 7:645-647Hovey RB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294592>
 51. **Awareness of Human Factors in the operating theatres during the COVID-19 pandemic.** J Perioper Pract 2020;1750458920978858Britton CR, Hayman G, Stroud N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292057>
 52. **Pharmacy response to COVID-19: lessons learnt from Canada.** J Pharm Policy Pract 2020; 13:76Elbeddini A, Botross A, Gerochi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298184>
 53. **Pharmacy services during COVID-19 pandemic: experience from a tertiary care teaching hospital in Pakistan.** J Pharm Policy Pract 2020; 13:74Hussain K, Ambreen G, Muzammil M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292772>
 54. **Teledentistry applications for mitigating risk and balancing the clinical schedule.** J. Public Health Dent. 2020; 80 Suppl 2:S126-s131Suter N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306848>
 55. **Rehabilitation setting during and after Covid-19: An overview on recommendations.** J Rehabil Med 2020; Agostini F, Mangone M, Ruiu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284353>
 56. **COVID-19 and treating incarcerated populations for opioid use disorder.** J. Subst. Abuse Treat. 2020;108216Donelan CJ, Hayes E, Potee RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288348>
 57. **A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose.** J. Subst. Abuse Treat. 2021; 120:108158Linás BP, Savinkina A, Barbosa C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298298>
 58. **Managements of 13 emergency cardiac surgeries under COVID-19 pandemic in a Sentinel Hospital.** J Thorac Dis 2020; 12:6663-6669Hu X, Wang Y, Xia J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282367>
 59. **Foreign-body Ingestions in Children During COVID-19 Pandemic in a Pediatric Referral Center.** JPGN Rep 2020; 1:e018Pizzol A, Rigazio C, Calvo PL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294883>

60. **[Surgical management of cancer patients within the COVID-19 pandemic].** *Khirurgiia (Mosk.)* 2020;5-15Kaprin AD, Fedenko AA, Polyakov AA, Polyakov AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301247>
61. **Remote monitoring using donor-derived, cell-free DNA after kidney transplantation during the coronavirus disease 2019 pandemic.** *Kidney Res Clin Pract* 2020; Potter SR, Hinojosa R, Miles CD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303727>
62. **Clinical prioritisation of revision knee surgical procedures: BASK working group consensus document.** *Knee* 2020; 28:57-63Kalson NS, Mathews JA, Toms AD, Murray JRD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307320>
63. **Antibiotic Prescribing for Acute Rhinosinusitis: In-Person Versus Virtual Visits During Covid-19.** *Laryngoscope* 2020; Miller LE, Bhattacharyya N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296088>
64. **Rapid transfer of knowledge for multiple sclerosis clinical care during COVID-19: ECHO MS.** *Mult Scler Relat Disord* 2020; 46:102600Alschuler KN, von Geldern G, Ball D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296992>
65. **Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis.** *Oncoimmunology* 2020; 9:1824646Wang B, Huang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294299>
66. **Managing cancer care during the COVID-19 pandemic: brief report from a North African single center.** *Pan Afr. Med. J.* 2020; 35:127Benhima N, Kaakoua M, Rachidi SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282082>
67. **COVID-19 pandemic and management of patients with chronic neurological conditions in low-middle income countries: the added burden.** *Pan Afr. Med. J.* 2020; 35:104Hazim A, Yacoubi H, Guennouni H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282059>
68. **Dynamic and evolving response of pediatric medical emergencies in Rabat during the COVID-19 pandemic.** *Pan Afr. Med. J.* 2020; 35:116Mekaoui N, Jeddi Y, Khachani K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282071>
69. **COVID-19: challenges and the impact on care in clinical settings in Cameroon.** *Pan Afr. Med. J.* 2020; 35:122Ngeh EN, Kuaban C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282077>
70. **A critical appraisal of COVID-19 as a nosocomial infection: an African perspective.** *Pan Afr. Med. J.* 2020; 36:310Oladipo EK, Ariyo OE, Ibukun FI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282093>
71. **Spécificités de la réorganisation de la prise en charge des patients cancéreux au cours de la pandémie COVID-19 dans un centre régional d'oncologie au Maroc.** *Pan Afr. Med. J.* 2020; 35:114Rais G, Amaoui B, Lahlou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282069>
72. **Innovating and Adapting in Pediatric Pulmonology and Sleep Medicine During the COVID-19 Pandemic: ATS Pediatric Assembly Web Committee Consensus Statement for Initial COVID-19 Virtual Response.** *Pediatr Pulmonol* 2020; Taylor JB, Oermann CM, Deterding RR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300286>
73. **A local dental network approach to COVID-19 pandemic: innovation through collaboration.** *Prim Dent J* 2020:2050168420980979Hearnshaw S, Serban S, Suida I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302790>

74. **Provision of clinical pharmacy services during the COVID-19 pandemic: Experiences of pharmacists from 16 European countries.** Res Social Adm Pharm 2020; Paudyal V, Cadogan C, Fialová D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288420>
75. **Rapid response to COVID-19, escalation and de-escalation strategies to match surge capacity of Intensive Care beds to a large scale epidemic.** Rev. Esp. Anesthesiol. Reanim. 2020; Bardi T, Gómez-Rojo M, Candela-Toha AM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33293100>
76. **Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care.** SAGE Open Med 2020; 8:2050312120974174Valk T, McMorro C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282306>
77. **Impact of home confinement during COVID-19 pandemic on sleep parameters in Parkinson's disease.** Sleep Med. 2020; 77:15-22Kumar N, Gupta R, Kumar H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302094>
78. **A model for the incremental burden of invasive Haemophilus influenzae type b due to a decline of childhood vaccination during the COVID-19 outbreak: A dynamic transmission model in Japan.** Vaccine 2020; Kitano T, Aoki H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280853>
79. **Impact of the SARS-CoV-2 pandemic on emergency surgery services-a multi-national survey among WSES members.** World J Emerg Surg 2020; 15:64Reichert M, Sartelli M, Weigand MA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33298131>

Management (57 articles)

1. **Impact of non-pharmaceutical interventions for the COVID-19 pandemic on emergency department patient trends in Japan: a retrospective analysis.** Acute Med Surg 2020; 7:e603Sekine I, Uojima H, Koyama H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282316>
2. **Trends in Intensive Care for Patients with COVID-19 in England, Wales and Northern Ireland.** Am J Respir Crit Care Med 2020; Doidge JC, Gould DW, Ferrando-Vivas P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306946>
3. **Reliability and limits of transport-ventilators to safely ventilate severe patients in special surge situations.** Ann Intensive Care 2020; 10:166Savary D, Lesimple A, Beloncle F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296045>
4. **A Rapidly Deployable Test Suite for Respiratory Protective Devices in the COVID-19 Pandemic.** Appl. Biosaf. 2020; 25:161-168Blad T, Nijssen J, Broeren F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281505>
5. **Life in 90 words: opportunities for person-centred care amidst COVID-19.** Australas Psychiatry 2020;1039856220975280Theodoros T, Wyder M, Lombardo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297747>
6. **Hospice care self-efficacy among clinical medical staff working in the coronavirus disease 2019 (COVID-19) isolation wards of designated hospitals: a cross-sectional study.** BMC Palliat. Care 2020; 19:188Zheng ZH, Luo ZC, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302944>
7. **How primary healthcare in Iceland swiftly changed its strategy in response to the COVID-19 pandemic.** BMJ Open 2020; 10:e043151Sigurdsson EL, Blondal AB, Jonsson JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293329>

8. **The challenge of deciding between home-discharge versus hospitalization in COVID-19 patients: The role of initial imaging and clinicolaboratory data.** Clin Epidemiol Glob Health 2020; Mozafari A, Miladinia M, Sabri A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289003>
9. **Vitamin D and Covid-19: an update on evidence and potential therapeutic implications.** Clin. Mol. Allergy 2020; 18:23Murdaca G, Pioggia G, Negrini S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292313>
10. **Electrical impedance tomography to titrate positive end-expiratory pressure in COVID-19 acute respiratory distress syndrome.** Crit Care 2020; 24:678Perier F, Tuffet S, Maraffi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287864>
11. **Preparing for the Behavioral Health Impact of COVID-19 in Michigan.** Curr Psychiatry Rep 2020; 22:88Edwards E, Janney CA, Mancuso A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33289041>
12. **Patients with diabetes have a higher risk of severe COVID-19 progression - Which protective measures are possible?** Diabetes, Stoffwechsel und Herz 2020; 29:367-371Pfützner A, Frankenberger R.
13. **Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19.** Diagnostics (Basel) 2020; 10Kassirian S, Taneja R, Mehta S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291238>
14. **Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid.** Expert Rev. Hematol. 2020; Lázaro Del Campo P, Ramírez López A, de la Cruz Benito B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280467>
15. **Multi-dimensional COVID-19 short- and long-term outcome prediction algorithm.** Expert Rev Precis Med Drug Dev 2020; 5:239-242Deng MC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283045>
16. **Update on the Use of Transcranial Electrical Brain Stimulation to Manage Acute and Chronic COVID-19 Symptoms.** Front. Hum. Neurosci. 2020; 14:595567Pilloni G, Bikson M, Badran BW *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281589>
17. **GlasVent-The Rapidly Deployable Emergency Ventilator.** Glob Chall 2020; 4:2000046Christou A, Ntagios M, Hart A, Dahiya R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304608>
18. **Hospitals' responsibility in response to the threat of infectious disease outbreak in the context of the COVID-19 pandemic: Implications for low- and middle-income countries.** Glob Health J 2020; Zhang J, Lu X, Jin Y, Zheng Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294250>
19. **A collaborative effort of China in combating COVID-19.** Glob Health Res Policy 2020; 5:47Bangura MS, Gonzalez MJ, Ali NM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292746>
20. **Role of Noninvasive Oxygen Therapy Strategies in COVID-19 Patients: Where are We Going?** Indian J. Crit. Care Med. 2020; 24:897-898Dixit SB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281309>
21. **Mechanisms of Hypoxia in COVID-19 Patients: A Pathophysiologic Reflection.** Indian J. Crit. Care Med. 2020; 24:967-970Nitsure M, Sarangi B, Shankar GH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281323>
22. **Awake Prone Positioning in COVID-19 Patients.** Indian J. Crit. Care Med. 2020; 24:914-918Singh P, Jain P, Deewan H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281314>

23. **Noninvasive Oxygen Strategies to Manage Confirmed COVID-19 Patients in Indian Intensive Care Units: A Survey.** Indian J. Crit. Care Med. 2020; 24:926-931 Subramaniam A, Haji JY, Kumar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281316>
24. **Early Phase Management of the SARS-CoV-2 Pandemic in the Geographic Area of the Veneto Region, in One of the World's Oldest Populations.** Int J Environ Res Public Health 2020; 17Camerotto A, Sartorio A, Mazzetto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291638>
25. **Underlying Principles of a Covid-19 Behavioral Vaccine for a Sustainable Cultural Change.** Int J Environ Res Public Health 2020; 17Couto KC, Moura Lorenzo F, Tagliabue M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291718>
26. **South Korean Nurses' Experiences with Patient Care at a COVID-19-Designated Hospital: Growth after the Frontline Battle against an Infectious Disease Pandemic.** Int J Environ Res Public Health 2020; 17Lee N, Lee HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287343>
27. **COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study.** Int J Infect Dis 2020; Alsharidah S, Ayed M, Ameen RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285283>
28. **COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation.** J Am Soc Nephrol 2020; Friedman DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288631>
29. **Taming the pandemic? The importance of homemade plant-based foods and beverages as community responses to COVID-19.** J Ethnobiol Ethnomed 2020; 16:75Pieroni A, Vandebroek I, Prakofjewa J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298108>
30. **The Use of Empathic Communication During the COVID-19 Outbreak.** J Patient Exp 2020; 7:648-652Stevens SK, Brustad R, Gilbert L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294593>
31. **Development of a Communications Program to Support Care of Critically Ill Coronavirus Disease 2019 (COVID-19) Patients.** J Patient Exp 2020; 7:673-676Wendel PK, Stack RJ, Chisholm MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294597>
32. **Anticipating the Need for Healthcare Resources Following the Escalation of the COVID-19 Outbreak in the Republic of Kazakhstan.** J Prev Med Public Health 2020; 53:387-396Semenova Y, Pivina L, Khismetova Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296578>
33. **COVID-19 and treating incarcerated populations for opioid use disorder.** J. Subst. Abuse Treat. 2020:108216Donelan CJ, Hayes E, Potee RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288348>
34. **[Endoscopy-assisted dilatational tracheostomy in patients with COVID-19].** Khirurgiia (Mosk.) 2020:16-21Starkov YG, Lukich KV, Dzhantukhanova SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301248>
35. **Patient barrier acceptance during airway management among anesthesiologists: A simulation pilot study.** Korean J Anesthesiol 2020; Querney J, Cubillos J, Ding Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285048>
36. **The flexible endoscopic nasopharyngoscopy in infectious patients.** Laryngo-Rhino- Otologie 2020; 99:770-771.

37. **Hydrothermotherapy in prevention and treatment of mild to moderate cases of COVID-19.** Med. Hypotheses 2020;110363Ramirez FE, Sanchez A, Pirskanen AT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303302>
38. **Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group.** Med. J. Aust. 2020; Brewster DJ, Groombridge CJ, Gatward JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295002>
39. **Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group.** Med. J. Aust. 2020; Triplett KE, Collett LW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295047>
40. **COVID-19: general overview, pharmacological options and ventilatory support strategies.** Multidiscip Respir Med 2020; 15:708Menzella F, Matucci A, Vultaggio A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282284>
41. **The Contributions of Immigrant Nurses in the U.S. During the COVID-19 Pandemic: A CGFNS International Study.** Nurse Lead 2020; Shaffer FA, Bakhshi M, Cook K, Álvarez TD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281507>
42. **The Benefits of Vitamin D Supplementation for Athletes: Better Performance and Reduced Risk of COVID-19.** Nutrients 2020; 12Grant WB, Lahore H, Rockwell MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291720>
43. **Engagement among physicians fighting COVID-19: the mediating role of autonomy.** Occup. Med. (Lond.) 2020; Zhang H, Zhao Y, Zou P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289031>
44. **Pain During COVID-19: A Comprehensive Review and Guide for the Interventionalist.** Pain Pract 2020; Murphy MT, Latif U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295042>
45. **Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study.** Pan Afr. Med. J. 2020; 37:9Ashinyo ME, Duti V, Dubik SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294110>
46. **COVID-19: do it like Greece. Why Greece is coping with COVID-19 better than other countries?** Pan Afr. Med. J. 2020; 35:109Damaskos C, Garmpi A, Georgakopoulou VE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282064>
47. **Preventing Acute Respiratory Distress Syndrome (ARDS) and to avoiding intubation in patients with COVID-19: an experience from a reanimation service in Morocco.** Pan Afr. Med. J. 2020; 37:6Kaissi JE, Jebbar N, Diai A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294107>
48. **Staff risks stratification in preparation for COVID-19 in a tertiary healthcare facility in Nigeria.** Pan Afr. Med. J. 2020; 35:124Obaseki DE, Akoria OA, Mokogwu N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282079>
49. **COVID-19 changing pandemic pattern: why sub-Saharan Africa should reassess the current response approach.** Pan Afr. Med. J. 2020; 35:111Ogundele OA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282066>
50. **A review of changes in COVID-19 burden in the COVID-19 treatment centres in Yaoundé (Cameroon): a call for cautious optimism.** Pan Afr. Med. J. 2020; 35:113Sobngwi E, Omgba-Moussi C, Kouanfack C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282068>
51. **COVID-19 pandemic: implementing control measures in Africa using the 'SHEF2' model.** Pan Afr. Med. J. 2020; 37:3Wirsiy FS, Nkfusai CN, Ako-Arrey DE *et*

- al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294104>
52. **Adequate anticoagulation and ECMO therapy in COVID-19 patients with severe pulmonary embolism.** Perfusion 2020;267659120979887Gaisendrees C, Walter SG, Elderia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280533>
 53. **Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19.** Pulm Circ 2020; 10:2045894020970369Franco V, Bradley EA, Badagliacca R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282201>
 54. **Improvement of COVID-19 with renal failure and paralytic ileus by using steroids.** Respirol Case Rep 2021; 9:e00689Kitamura A, So C, Jinta T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282314>
 55. **[Guide for management of patients with possible respiratory sequelae after a SARS-CoV-2 pneumonia. Support proposals developed by the French-speaking Respiratory Medicine Society. Version of 10 November 2020].** Rev. Mal. Respir. 2020; Andrejak C, Cottin V, Crestani B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280941>
 56. **Mental Health Problems in Chinese Healthcare Workers Exposed to Workplace Violence During the COVID-19 Outbreak: A Cross-Sectional Study Using Propensity Score Matching Analysis.** Risk Manag. Healthc. Policy 2020; 13:2827-2833Wang W, Lu L, Kelifa MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299370>
 57. **Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare.** Toxicol Rep 2021; 8:1-9Farsalinos K, Poulas K, Kouretas D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294384>

Mental – public health (126 articles)

1. **COVID-19 worries and mental health: the moderating effect of age.** Aging Ment. Health 2020;1-8Wilson JM, Lee J, Shook NJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291948>
2. **Longer time spent at home during COVID-19 pandemic is associated with binge drinking among US adults.** Am. J. Drug Alcohol Abuse 2020;1-9Weerakoon SM, Jetelina KK, Knell G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280423>
3. **Grief: The Epidemic Within an Epidemic.** Am. J. Hosp. Palliat. Care 2020;1049909120978796Petry SE, Hughes D, Galanos A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280398>
4. **Caring for patients in mental health services during COVID-19 outbreak in China.** Ann Gen Psychiatry 2020; 19:66Hou R, Yang L, Tang Z, Chen T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292362>
5. **The mental health of Chinese healthcare staff in non-epicenter of COVID-19: a cross-sectional study.** Ann Palliat Med 2020; 9:4127-4136Zhang L, Wang S, Shen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302673>
6. **Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis.** Arch. Gerontol. Geriatr. 2020; 93:104299Hariyanto TI, Putri C, Arisa J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285424>
7. **Effect of Covid-19 pandemic on mental health among Albanian people residing in the country and abroad - Implications for mental care.** Arch. Psychiatr. Nurs.

- 2020; 34:507-512 Kamberi F, Jaho J, Mechili EA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280673>
8. **Psychological and Livelihood Impacts of COVID-19 on Bangladeshi Lower Income People.** *Asia Pac. J. Public Health* 2020;1010539520977304 Paul A, Nath TK, Mahanta J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289393>
 9. **Australian private practice metropolitan telepsychiatry during the COVID-19 pandemic: analysis of Quarter-2, 2020 usage of new MBS-telehealth item psychiatrist services.** *Australas Psychiatry* 2020;1039856220975294 Looi JC, Allison S, Bastiampillai T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280401>
 10. **Life in 90 words: opportunities for person-centred care amidst COVID-19.** *Australas Psychiatry* 2020;1039856220975280 Theodoros T, Wyder M, Lombardo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297747>
 11. **Psychological impact in non-infectious disease specialists who had direct contact with patients with COVID-19.** *BJPsych Open* 2020; 7:e8 Liu T, Zheng Z, Sha X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283699>
 12. **Mental health and well-being of healthcare workers during the COVID-19 pandemic in the UK: contrasting guidelines with experiences in practice.** *BJPsych Open* 2020; 7:e15 Vera San Juan N, Aceituno D, Djellouli N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298229>
 13. **Burnout among Portuguese healthcare workers during the COVID-19 pandemic.** *BMC Public Health* 2020; 20:1885 Duarte I, Teixeira A, Castro L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287794>
 14. **Information uncertainty: a correlate for acute stress disorder during the COVID-19 outbreak in China.** *BMC Public Health* 2020; 20:1867 Lin D, Friedman DB, Qiao S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287780>
 15. **Mental health status during COVID-19 pandemic in Fars Province, Iran: timely measures.** *BMC Public Health* 2020; 20:1866 Mani A, Estedlal AR, Kamali M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287775>
 16. **Factors associated with the mental health status of medical students during the COVID-19 pandemic: a cross-sectional study in Japan.** *BMJ Open* 2020; 10:e043728 Arima M, Takamiya Y, Furuta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303472>
 17. **Gender differences in emotional response to the COVID-19 outbreak in Spain.** *Brain Behav* 2020:e01934 García-Fernández L, Romero-Ferreiro V, Padilla S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305891>
 18. **Health anxiety status of elite athletes in COVID-19 social isolation period.** *Bratisl. Lek. Listy* 2020; 121:888-893 Ozen G, Koc H, Aksoy C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300359>
 19. **Deviations in criminal filings of child abuse and neglect during COVID-19 from forecasted models: An analysis of the state of Oklahoma, USA.** *Child Abuse Negl.* 2020;104863 Whelan J, Hartwell M, Chesher T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298325>
 20. **Delirium: A Frequent Manifestation in COVID-19 Older Patients.** *Clin. Interv. Aging* 2020; 15:2245-2247 Mattace-Raso F, Polinder-Bos H, Oosterwijk B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293801>
 21. **The Unlikely Saviour: Portugal's National Health System and the Initial Impact of the COVID-19 Pandemic?** *Development (Rome)* 2020;1-7 Varanda J, Gonçalves L, Craveiro I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288975>

22. **Digital phenotyping and the COVID-19 pandemic: Capturing behavioral change in patients with psychiatric disorders.** Eur. Neuropsychopharmacol. 2020; Jagesar RR, Roozen MC, van der Heijden I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33298386>
23. **Face mask exemptions, psychiatric patients, and COVID-19.** Eur. Psychiatry 2020;1-4Ayuso JL, Soriano JB, Ancochea J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280621>
24. **A Polish and German Population Study of Quality of Life, Well-Being, and Life Satisfaction in Older Adults During the COVID-19 Pandemic.** Front Psychiatry 2020; 11:585813Bidzan-Bluma I, Bidzan M, Jurek P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281646>
25. **Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service.** Front Psychiatry 2020; 11:590135Janiri D, Kotzalidis GD, Giuseppin G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304286>
26. **Managing Children's Anxiety During COVID-19 Pandemic: Strategies for Providers and Caregivers.** Front Psychiatry 2020; 11:552823Kang YQ, Lim TSH, Ragen ES *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281637>
27. **The Impact of Coping Strategies and Perceived Family Support on Depressive and Anxious Symptomatology During the Coronavirus Pandemic (COVID-19) Lockdown.** Front Psychiatry 2020; 11:587724Mariani R, Renzi A, Di Trani M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281647>
28. **Behavioral Implications of the Covid-19 Process for Autism Spectrum Disorder, and Individuals' Comprehension of and Reactions to the Pandemic Conditions.** Front Psychiatry 2020; 11:561882Mutluer T, Doeniyas C, Aslan Genc H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304279>
29. **A Survey for Examining the Effects of COVID-19 and Infection Control Measures in Older Persons With Mild Cognitive Impairment and Dementia and Their Caregivers.** Front Psychiatry 2020; 11:599851Porcari DE, Palmer K, Spalletta G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304288>
30. **Antecedents of Public Mental Health During the COVID-19 Pandemic: Mediation of Pandemic-Related Knowledge and Self-Efficacy and Moderation of Risk Level.** Front Psychiatry 2020; 11:567119Wang S, Feng K, Zhang Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304280>
31. **Exploring the Motivation Behind Discrimination and Stigmatization Related to COVID-19: A Social Psychological Discussion Based on the Main Theoretical Explanations.** Front. Psychol. 2020; 11:569528Demirtaş-Madran HA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281671>
32. **Knowledge of COVID-19 and Its Influence on Mindfulness, Cognitive Emotion Regulation and Psychological Flexibility in the Indian Community.** Front. Psychol. 2020; 11:589365Dubey N, Podder P, Pandey D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281687>
33. **Poor Sleep Quality and Its Consequences on Mental Health During the COVID-19 Lockdown in Italy.** Front. Psychol. 2020; 11:574475Franceschini C, Musetti A, Zenesini C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304294>
34. **How People Evaluate Anti-Corona Measures for Their Social Spheres: Attitude, Subjective Norm, and Perceived Behavioral Control.** Front. Psychol.

- 2020; 11:567405Godbersen H, Hofmann LA, Ruiz-Fernández S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281669>
35. **What Emotion Facial Expressions Tell Us About the Health of Others.** Front. Psychol. 2020; 11:585242Hareli S, David O, Hess U.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281681>
 36. **Perceived Stress and Daily Well-Being During the COVID-19 Outbreak: The Moderating Role of Age.** Front. Psychol. 2020; 11:571873Jiang D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281675>
 37. **Choice as a Meaning-Making Device for Maximizers: Evidence From Reactance to Restrictions of Choice Freedom During Lockdown.** Front. Psychol. 2020; 11:571462Kokkoris MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281674>
 38. **Perceived Impact of Covid-19 Across Different Mental Disorders: A Study on Disorder-Specific Symptoms, Psychosocial Stress and Behavior.** Front. Psychol. 2020; 11:586246Quittkat HL, Düsing R, Holtmann FJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281685>
 39. **Analysis of COVID-19 Cases' Spatial Dependence in US Counties Reveals Health Inequalities.** Front Public Health 2020; 8:579190Saffary T, Adegboye OA, Gayawan E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282812>
 40. **Psychosocial challenges and concerns of COVID-19: A qualitative study in Iran.** Health (London) 2020;1363459320976752Alipour F, Arshi M, Ahmadi S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33287564>
 41. **Support for families of isolated or deceased COVID-19 patients in sub-Saharan Africa.** Health Psychol Open 2020; 7:2055102920975293Endomba FT, Wafeu GS, Efon-Ekangouo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282330>
 42. **Risk Perception and Worries among Health Care Workers in the COVID-19 Pandemic: Findings from an Italian Survey.** Healthcare (Basel) 2020; 8Puci MV, Nosari G, Loi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287260>
 43. **The prevalence of general anxiety disorder and its associated factors among women's attending at the perinatal service of Dilla University referral hospital, Dilla town, Ethiopia, April, 2020 in Covid pandemic.** Heliyon 2020; 6:e05593Kassaw C, Pandey D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294715>
 44. **Modeling and forecasting of COVID-19 using a hybrid dynamic model based on SEIRD with ARIMA corrections.** Infect Dis Model 2021; 6:98-111Ala'raj M, Majdalawieh M, Nizamuddin N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294749>
 45. **The perception of nurses towards their roles during the COVID-19 pandemic.** Int J Clin Pract 2020:e13919Abuhammad S, AlAzzam M, Mukattash T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296522>
 46. **Cerebrospinal fluid findings and hyponatremia in COVID-19 patients with altered mental status.** Int. J. Emerg. Med. 2020; 13:63Toklu H, Ganti L, Crimi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297938>
 47. **The Impact of the COVID-19 Pandemic on Mental Health and Psychological Well-Being of Young People Living in Austria and Turkey: A Multicenter Study.** Int J Environ Res Public Health 2020; 17Akkaya-Kalayci T, Kothgassner OD, Wenzel T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291276>
 48. **The Impact of Social Support on Public Anxiety amidst the COVID-19 Pandemic in China.** Int J Environ Res Public Health 2020; 17Ao Y, Zhu H, Meng F

et al. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291217>

49. **Investigating the Psychological Impact of COVID-19 among Healthcare Workers: A Meta-Analysis.** *Int J Environ Res Public Health* 2020; 17Batra K, Singh TP, Sharma M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291511>
50. **The Bittersweet Effects of COVID-19 on Mental Health: Results of an Online Survey among a Sample of the Dutch Population Five Weeks after Relaxation of Lockdown Restrictions.** *Int J Environ Res Public Health* 2020; 17Gijzen M, Shields-Zeeman L, Kleinjan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291765>
51. **How to Form Behavioral Intentions in the Field of Drone Food Delivery Services: The Moderating Role of the COVID-19 Outbreak.** *Int J Environ Res Public Health* 2020; 17Hwang J, Kim D, Kim JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291294>
52. **Infection and Risk Perception of SARS-CoV-2 among Airport Workers: A Mixed Methods Study.** *Int J Environ Res Public Health* 2020; 17Malagón-Rojas J, Parra BE, Mercado M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287167>
53. **Is It Possible to Find Something Positive in Being Confined Due to COVID-19? Implications for Well-Being.** *Int J Environ Res Public Health* 2020; 17Merino MD, Oliver-Hernández C, Valvellano MD, Mateo I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291398>
54. **Sleep During "Lockdown" in the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17Trakada A, Nikolaidis PT, Andrade MDS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291468>
55. **Mental Health Status of University Healthcare Workers during the COVID-19 Pandemic: A Post-Movement Lockdown Assessment.** *Int J Environ Res Public Health* 2020; 17Woon LS, Sidi H, Nik Jaafar NR, Leong Bin Abdullah MFI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302410>
56. **Impact of COVID 19 on psychosocial functioning of peripartum women: A qualitative study comprising focus group discussions and in-depth interviews.** *Int J Gynaecol Obstet* 2020; Kumari A, Ranjan P, Sharma KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305351>
57. **The Fear of COVID-19 Scale: Psychometric Properties of the Ethiopian Amharic Version.** *Int J Ment Health Addict* 2020;1-12Elemo AS, Satici SA, Griffiths MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293906>
58. **Resilience, Hope, and Subjective Happiness Among the Turkish Population: Fear of COVID-19 as a Mediator.** *Int J Ment Health Addict* 2020;1-16Satici SA, Kayis AR, Satici B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293904>
59. **Analysis of news media reports of suicides and attempted suicides during the COVID-19 lockdown in India.** *Int J Ment Health Syst* 2020; 14:88Pathare S, Vijayakumar L, Fernandes TN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292383>
60. **Predictors of stress among emergency medical personnel during the COVID-19 pandemic.** *Int. J. Occup. Med. Environ. Health* 2020; Ilczak T, Rak M, Ćwiertnia M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300503>
61. **Factors associated with mental health outcomes among health care workers in the Fangcang shelter hospital in China.** *Int J Soc Psychiatry* 2020;20764020975805Gu Y, Zhu Y, Xu G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295238>

62. **Community Supports and COVID-19: Self-Determination in a Pandemic.** Intellect Dev Disabil 2020; 58:453-457Ervin DA, Hobson-Garcia D.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33290529>
63. **Addictive behaviors and craving during the COVID-19 pandemic of people who have recovered from substance use disorder.** J. Addict. Dis. 2020:1-20Bonny-Noach H, Gold D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305702>
64. **Effect of coronaphobia on smoking habits.** J. Addict. Dis. 2020:1-9Ozcelik N, Yilmaz Kara B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283686>
65. **"Constant Stress Has Become the New Normal": Stress and Anxiety Inequalities Among U.S. College Students in the Time of COVID-19.** J. Adolesc. Health 2020; Hoyt LT, Cohen AK, Dull B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288459>
66. **"I Hate This": A Qualitative Analysis of Adolescents' Self-Reported Challenges During the COVID-19 Pandemic.** J. Adolesc. Health 2020; Scott SR, Rivera KM, Rushing E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288454>
67. **Hallucinations in a Patient with Alzheimer's Disease During the COVID-19 Crisis: A Case Study.** J Alzheimers Dis Rep 2020; 4:455-458El Haj M, Larøi F, Gallouj K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283166>
68. **Linking insomnia and OCD symptoms during the coronavirus pandemic: Examination of prospective associations.** J. Anxiety Disord. 2020; 77:102341Cox RC, Olatunji BO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285369>
69. **Impact of COVID-19 lockdown measures on a cohort of eating disorders patients.** J Eat Disord 2020; 8:57Machado PPP, Pinto-Bastos A, Ramos R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292539>
70. **Disordered eating behaviors in youths with type 1 diabetes during COVID-19 lockdown: an exploratory study.** J Eat Disord 2020; 8:76Troncone A, Chianese A, Zanfardino A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292623>
71. **Feeling Gratitude is Associated with Better Well-being across the Life Span: A Daily Diary Study during the COVID-19 Outbreak.** J. Gerontol. B Psychol. Sci. Soc. Sci. 2020; Jiang D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284976>
72. **Prevention for oneself or others? Psychological and social factors that explain social distancing during the COVID-19 pandemic.** J Health Psychol 2020:1359105320980793Christner N, Sticker RM, Söldner L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302730>
73. **Prevalence and Associated Factors of Intimate Partner Violence Among Married Women During COVID-19 Pandemic Restrictions: A Community-Based Study.** J Interpers Violence 2020:886260520976222Tadesse AW, Tarekegn SM, Wagaw GB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289437>
74. **Psychological Well-being during Covid-19 Lockdown: Insights from a Saudi State University's Academic Community.** J King Saud Univ Sci 2020; 33:101262Alfawaz HA, Wani K, Aljumah AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288977>
75. **Psychological well-being during COVID-19 lockdown: Insights from a Saudi State University's Academic Community.** J King Saud Univ Sci 2021; 33:101262Alfawaz HA, Wani K, Aljumah AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288977>
76. **Psychological Consequences of Survivors of COVID-19 Pneumonia 1 Month after Discharge.** J Korean Med Sci 2020; 35:e409Park HY, Jung J, Park HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289371>

77. **More than Just Soup: Use of a Student-Led COVID-19 Social Pediatrics Initiative to Propose the Integration of Social Medicine Electives in Undergraduate Medical Education.** J Med Educ Curric Dev 2020; 7:2382120520973210Daccache J, Khoury M, Habibi C, Bennett S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283048>
78. **Artificial Intelligence in the Fight Against COVID-19: Scoping Review.** J Med Internet Res 2020; 22:e20756Abd-Alrazaq A, Alajlani M, Alhuwail D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284779>
79. **Social Media Insights Into US Mental Health During the COVID-19 Pandemic: Longitudinal Analysis of Twitter Data.** J Med Internet Res 2020; 22:e21418Valdez D, Ten Thij M, Bathina K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284783>
80. **Obsessive compulsive symptoms severity among children and adolescents during COVID-19 first wave in Israel.** J Obsessive Compuls Relat Disord 2020:100610Schwartz-Lifshitz M, Basel D, Lang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288995>
81. **Patient Perspectives on Telepsychiatry on the Inpatient Psychiatric Unit During the COVID-19 Pandemic.** J Patient Exp 2020; 7:677-679Heyman-Kantor R, Hardy N, Corcoran AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294598>
82. **The COVID-19 Pandemic and Italian Public Mental Health Services: Experience and Future Directions.** J Patient Exp 2020; 7:642-644Pelizza L, Pupo S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294591>
83. **Development of a Communications Program to Support Care of Critically Ill Coronavirus Disease 2019 (COVID-19) Patients.** J Patient Exp 2020; 7:673-676Wendel PK, Stack RJ, Chisholm MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294597>
84. **An Unusual Case of COVID-19 Presenting as Acute Psychosis.** J. Pharm. Pract. 2020:897190020977721Lanier CG, Lewis SA, Patel PD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280502>
85. **COVID-19, Lockdowns and Well-Being: Evidence from Google Trends.** J Public Econ 2020:104346Brodeur A, Clark AE, Fleche S, Powdthavee N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281237>
86. **COVID-19, lockdowns and well-being: Evidence from Google Trends.** J Public Econ 2021; 193:104346Brodeur A, Clark AE, Fleche S, Powdthavee N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281237>
87. **Socio-demographic predictors of adherence to 2019 coronavirus prescribed recommendations and lockdown psychological impacts: Perspectives of Nigerian social media users.** J Public Health Res 2020; 9:1864Bolarinwa OA, Olagunju O, Babalola T, Saeed BQ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282791>
88. **Association of mid sleep time and social jetlag with psychosocial behaviour of Indian population during COVID-19 lockdown.** J Public Health Res 2020; 9:1870Sinha M, Pande B, Sinha R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282792>
89. **Association of Death Anxiety with Spiritual Well-Being and Religious Coping in Older Adults During the COVID-19 Pandemic.** J Relig Health 2020; Rababa M, Hayajneh AA, Bani-Iss W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284402>
90. **The use of mindfulness dialogue for life in substance use disorder treatment in the time of COVID-19.** J. Subst. Abuse Treat. 2020:108213Abatemarco DJ, Gannon M, Hand DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293178>

91. **Youth OUD treatment during and after COVID: Increasing family involvement across the services continuum.** *J. Subst. Abuse Treat.* 2021; 120:108159Hogue A, Becker SJ, Fishman M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298299>
92. **The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19.** *J. Subst. Abuse Treat.* 2021; 120:108163Hughto JMW, Peterson L, Perry NS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298301>
93. **Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.** *J. Subst. Abuse Treat.* 2020:108222Livingston NA, Ameral V, Banducci AN, Weisberg RB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303255>
94. **Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response.** *J. Subst. Abuse Treat.* 2020:108226McDonnell A, MacNeill C, Chapman B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303253>
95. **COVID-19 in Hong Kong - public health, food safety, and animal vectors perspectives.** *J. Virol. Methods* 2020:114036Hon KL, Leung KKY, Tang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285191>
96. **Psychological Impacts of COVID-19 During the First Nationwide Lockdown in Vietnam: Web-Based, Cross-Sectional Survey Study.** *JMIR Form Res* 2020; 4:e24776Ngoc Cong Duong K, Nguyen Le Bao T, Thi Lan Nguyen P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284778>
97. **[Not Available].** *MMW Fortschr Med* 2020; 162:3-9Adorjan K, Koller G, Falkai P, Pogarell O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289913>
98. **The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease.** *Neurosci Insights* 2020; 15:2633105520975743Haghighi MM, Kakhki EG, Sato C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283188>
99. **Towards universal health coverage: lessons learnt from the COVID-19 pandemic in Africa.** *Pan Afr. Med. J.* 2020; 35:128Akinleye FE, Akinbolaji GR, Olasupo JO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282083>
100. **[Psychosocial care for contacts of confirmed cases of COVID-19 in Touba, Senegal].** *Pan Afr. Med. J.* 2020; 37:5Diagne I, Dieng AB, Sougou A, Ndione AG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294106>
101. **Why policy action should focus on the vulnerable commercial sex workers in Uganda during COVID-19 fight.** *Pan Afr. Med. J.* 2020; 35:102Kawala BA, Kirui BK, Cumber SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282057>
102. **The pandemic paradox: domestic violence and happiness of women.** *PeerJ* 2020; 8:e10472Haq W, Raza SH, Mahmood T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282567>
103. **What COVID-19 tells us about the self - the deep inter-subjective and cultural layers of our brain.** *Psychiatry Clin. Neurosci.* 2020; Scalabrini A, Xu J, Northoff G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305486>
104. **Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis.** *Psychiatry Res* 2020; 295:113599Cénat JM, Blais-Rochette C, Kokou-Kpolou CK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285346>

105. **Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis.** Psychiatry Res 2020; 295:113599Cénat JM, Blais-Rochette C, Kokou-Kpolou CK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285346>
106. **State-Level Data on Suicide Mortality During COVID-19 Quarantine: Early Evidence of a Disproportionate Impact on Racial Minorities.** Psychiatry Res 2020; 295:113629Mitchell TO, Li L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290944>
107. **Trends in suicide in Japan by gender during the COVID-19 pandemic, up to September 2020.** Psychiatry Res 2020; 295:113622Nomura S, Kawashima T, Yoneoka D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290942>
108. **Psychiatric morbidity and protracted symptoms after COVID-19.** Psychiatry Res 2020; 295:113604Poyraz B, Poyraz CA, Olgun Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296818>
109. **Psychological distress in the face of a pandemic: An observational study characterizing the impact of COVID-19 on immigrant outpatient mental health.** Psychiatry Res 2020; 295:113595Serafini RA, Powell SK, Frere JJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296817>
110. **COVID-19 pandemic fear, life satisfaction and mental health at the initial stage of the pandemic in the largest cities in Poland.** Psychol Health Med 2020:1-7Gawrych M, Cichoń E, Kiejna A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300378>
111. **Resilience of nurses in isolation wards during the COVID-19 pandemic: a cross-sectional study.** Psychol Health Med 2020:1-9Ou X, Chen Y, Liang Z *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33305600>
112. **The impacts of COVID-19 outbreak on mental health in general population in different areas in China.** Psychol. Med. 2020:1-10Ran MS, Gao R, Lin JX *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33298220>
113. **Behavioral and Psychological Correlates of Well-Being during COVID-19.** Psychol. Rep. 2020:33294120978160Ryerson NC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33302799>
114. **Depression is Associated with Moderate-Intensity Physical Activity Among College Students During the COVID-19 Pandemic: Differs by Activity Level, Gender and Gender Role.** Psychol. Res. Behav. Manag. 2020; 13:1123-1134Lin J, Guo T, Becker B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299364>
115. **Adaptation of an Academic Inpatient Consultation-Liaison Psychiatry Service During the SARS-CoV-2 Pandemic: Effects on Clinical Practice and Trainee Supervision.** Psychosomatics 2020; Beran C, Sowa NA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288272>
116. **Evaluation of Emotional (Depression) and Behavioral (Nutritional, Physical Activity, Sleep) Status of Turkish Adults during the Covid-19 Pandemic Period.** Public Health Nutr. 2020:1-21Karahan Yilmaz S, Eskici G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292903>
117. **[Public healthcare expenditure and COVID-19 mortality in Spain and in Europe].** Rev Clin Esp 2020; Elola Somoza FJ, Bas Villalobos MC, Pérez Villacastín J, Macaya Miguel C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288965>
118. **Mental Health Problems in Chinese Healthcare Workers Exposed to Workplace Violence During the COVID-19 Outbreak: A Cross-Sectional Study Using**

- Propensity Score Matching Analysis.** *Risk Manag. Healthc. Policy* 2020; 13:2827-2833Wang W, Lu L, Kelifa MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299370>
119. **Health service inequalities during the COVID-19 pandemic among elderly people living in large urban and non-urban areas in Florida, USA.** *SAGE Open Med* 2020; 8:2050312120974168Yu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282304>
 120. **Evaluation of the Sexual Functioning of Individuals Living in Turkey During the COVID-19 Pandemic: An Internet-Based Nationwide Survey Study.** *Sex Med* 2020; 9:100279Karsiyakali N, Sahin Y, Ates HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291042>
 121. **Impact of home confinement during COVID-19 pandemic on sleep parameters in Parkinson's disease.** *Sleep Med.* 2020; 77:15-22Kumar N, Gupta R, Kumar H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302094>
 122. **Anxiety levels among social work students during the COVID-19 lockdown in Spain.** *Soc. Work Health Care* 2020:1-13Díaz-Jiménez RMP, Caravaca-Sánchez FP, Martín-Cano MCP, De la Fuente-Robles YMP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297878>
 123. **Sociodemographic determinants of COVID-19 incidence rates in Oman: Geospatial modelling using multiscale geographically weighted regression (MGWR).** *Sustain Cities Soc* 2021; 65:102627Mansour S, Al Kindi A, Al-Said A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288993>
 124. **Society of behavioral medicine statement on COVID-19 and rural health.** *Transl. Behav. Med.* 2020; Behrman P, Fitzgibbon ML, Dulin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289790>
 125. **Effectiveness of using a meditation app in reducing anxiety and improving well-being during the COVID-19 pandemic: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:1006O'Donnell KT, Dunbar M, Speelman DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298117>
 126. **[Research on mental health status of medical staff during COVID-19 epidemic].** *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 2020; 38:834-838Huang ZP, Zhang KT, He XY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287477>

Meta-analyses - systematic reviews (11 articles)

1. **Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis.** *Arch. Gerontol. Geriatr.* 2020; 93:104299Hariyanto TI, Putri C, Arisa J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285424>
2. **Protocol for a systematic review and meta-analysis of respiratory rehabilitation following intensive care unit discharge for COVID-19 survivors.** *BMJ Open* 2020; 10:e041184Wang D, Li J, Zhu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293395>
3. **Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications.** *Eur. J. Epidemiol.* 2020:1-16Levin AT, Hanage WP, Owusu-Boaitey N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289900>
4. **Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review.**

- [Front Med \(Lausanne\)](#) 2020; 7:572115Váncsa S, Hegyi PJ, Zádori N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282888>
5. **Random effects meta-analysis of COVID-19/S. aureus partnership in co-infection.** [GMS Hyg Infect Control](#) 2020; 15:Doc29Adeiza SS, Shuaibu AB, Shuaibu GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299742>
 6. **Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.** [Indian J. Pharmacol.](#) 2020; 52:414-421Prakash A, Singh H, Kaur H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283773>
 7. **Investigating the Psychological Impact of COVID-19 among Healthcare Workers: A Meta-Analysis.** [Int J Environ Res Public Health](#) 2020; 17Batra K, Singh TP, Sharma M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291511>
 8. **Prevalence and prognostic value of elevated troponins in patients hospitalised for coronavirus disease 2019: a systematic review and meta-analysis.** [J Intensive Care](#) 2020; 8:88Zhao BC, Liu WF, Lei SH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292649>
 9. **Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis.** [Oncoimmunology](#) 2020; 9:1824646Wang B, Huang Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294299>
 10. **Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis.** [Psychiatry Res](#) 2020; 295:113599Cénat JM, Blais-Rochette C, Kokou-Kpolou CK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285346>
 11. **Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis.** [Psychiatry Res](#) 2020; 295:113599Cénat JM, Blais-Rochette C, Kokou-Kpolou CK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285346>

Mortality (18 articles)

1. **rotracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure.** [Ann Intensive Care](#) 2020; 10:167Bitker L, Dhelft F, Chauvelot L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301059>
2. **All-cause mortality supports the COVID-19 mortality in Belgium and comparison with major fatal events of the last century.** [Arch Public Health](#) 2020; 78:117Bustos Sierra N, Bossuyt N, Braeye T *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292536>
3. **Hospice care self-efficacy among clinical medical staff working in the coronavirus disease 2019 (COVID-19) isolation wards of designated hospitals: a cross-sectional study.** [BMC Palliat. Care](#) 2020; 19:188Zheng ZH, Luo ZC, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302944>
4. **Fatal SARS-CoV-2 infection in a male patient with Good's syndrome.** [Clin Immunol](#) 2020; 223:108644Pozzi MR, Baronio M, Janetti MB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301884>

5. **Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID-19 pandemic.** ESC Heart Fail 2020; Primessnig U, Pieske BM, Sherif M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283476>
6. **Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications.** Eur. J. Epidemiol. 2020;1-16Levin AT, Hanage WP, Owusu-Boaitey N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289900>
7. **Thirty-Day Mortality in COVID-19 Positive Patients With Hip Fractures: A Case-Series and Literature Review.** Geriatr Orthop Surg Rehabil 2020; 11:2151459320972681Al Farii H, Al Rawahi S, Samaila E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282447>
8. **Pathological findings in the postmortem liver of COVID-19 patients.** Hum. Pathol. 2020; Zhao CL, Rapkiewicz A, Maghsoodi-Deerwester M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307078>
9. **The association between COVID-19 cases and deaths and web-based public inquiries.** Infect Dis (Lond) 2020;1-8Schnoell J, Besser G, Jank BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287607>
10. **A Novel Diffusion-Based Model for Estimating Cases, and Fatalities in Epidemics: The Case of COVID-19.** J Bus Res 2020; Eryarsoy E, Delen D, Davazdahemami B, Topuz K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281248>
11. **Development and Validation of a Nomogram Using on Admission Routine Laboratory Parameters to Predict In-hospital Survival of Patients With COVID-19.** J Med Virol 2020; Chen H, Chen R, Yang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289142>
12. **Demographic variables associated with Covid-19 mortality.** J Public Health Res 2020; 9:1827Madrado Cabo JM, Monter Valera NA, Hernández Sánchez EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282790>
13. **Mortality in COVID-19: Further Evidence for a Sex-Based Difference in the OpenSAFELY Study.** J Womens Health (Larchmt) 2020; Newman CB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297829>
14. **High serum nitrates levels in non-survivor COVID-19 patients.** Med. Intensiva 2020; Lorente L, Gómez-Bernal F, Martín MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293102>
15. **Investigating the factors affecting the survival rate in patients with COVID-19: A retrospective cohort study.** Med. J. Islam. Repub. Iran 2020; 34:88Eshtrati B, Baradaran HR, Erfanpoor S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306063>
16. **All-cause excess mortality and COVID-19-related deaths in Iran.** Med. J. Islam. Repub. Iran 2020; 34:80Tadbiri H, Moradi-Lakeh M, Naghavi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306040>
17. **COVID-19 autopsies: Procedure, technical aspects and cause of fatal course. Experiences from a single-center.** Pathol. Res. Pract. 2020; 217:153305Skok K, Vander K, Setaffy L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285423>
18. **Differences in RAAS/vitamin D linked to genetics and socioeconomic factors could explain the higher mortality rate in African Americans with COVID-19.** Ther. Adv. Cardiovasc. Dis. 2020; 14:1753944720977715Martín Giménez VM, Ferder L, Inserra F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283618>

1. **Availability Of Covid-19 Information From National And International Burn Society Websites.** Ann Burns Fire Disasters 2020; 33:177-181Al-Benna S, Gohritz A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304206>
2. **Australian private practice metropolitan telepsychiatry during the COVID-19 pandemic: analysis of Quarter-2, 2020 usage of new MBS-telehealth item psychiatrist services.** Australas Psychiatry 2020:1039856220975294Looi JC, Allison S, Bastiampillai T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280401>
3. **Development of a data-driven COVID-19 prognostication tool to inform triage and step-down care for hospitalised patients in Hong Kong: a population-based cohort study.** BMC Med. Inform. Decis. Mak. 2020; 20:323Tsui ELH, Lui CSM, Woo PPS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287804>
4. **High acceptability of PrEP teleconsultation and HIV self-testing among PrEP users during the COVID-19 pandemic in Brazil.** Braz. J. Infect. Dis. 2020; Hoagland B, Torres TS, Bezerra DRB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285137>
5. **Introduction to the quality of medical journalism and initial assessments of COVID-19 media coverage.** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2020; Daube D, Ruhrmann G.
6. **Challenges for science journalism in the Corona pandemic-some observations about a mediated world event.** Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2020; Stollorz V.
7. **Prediction of COVID-19 Confirmed Cases Combining Deep Learning Methods and Bayesian Optimization.** Chaos Solitons Fractals 2020:110511Abbasimehr H, Paki R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281305>
8. **Data Analysis of Covid-19 Pandemic and Short-Term Cumulative Case Forecasting Using Machine Learning Time Series Models.** Chaos Solitons Fractals 2020:110512Ballı S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281306>
9. **Data analysis of Covid-19 pandemic and short-term cumulative case forecasting using machine learning time series methods.** Chaos Solitons Fractals 2021; 142:110512Ballı S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281306>
10. **New Adopters of Telemedicine During the Coronavirus-19 Pandemic in Respondents to an Online Community Survey: The Case for Access to Remote Management Tools for Individuals with Chronic Obstructive Pulmonary Disease.** Chronic Obstr Pulm Dis 2020; Boyce DM, Thomashow BM, Sullivan J, Tal-Singer R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291190>
11. **Anomalous asthma and chronic obstructive pulmonary disease Google Trends patterns during the COVID-19 pandemic.** Clin Transl Allergy 2020; 10:47Sousa-Pinto B, Heffler E, Antó A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292529>
12. **Next-generation computational tools and resources for coronavirus research: From detection to vaccine discovery.** Comput. Biol. Med. 2020; 128:104158Kangabam R, Sahoo S, Ghosh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301953>
13. **Adoption of no-test and telehealth medication abortion care among independent abortion providers in response to COVID-19.** Contracept X 2020; 2:100049Upadhyay UD, Schroeder R, Roberts SCM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305255>

14. **The COVID-19 Infodemic: A Quantitative Analysis Through Facebook.** Cureus 2020; 12:e11346Ahmed N, Shahbaz T, Shamim A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304681>
15. **Clinical implications of telemedicine for providers and patients.** Fertil. Steril. 2020; 114:1129-1134Berg WT, Goldstein M, Melnick AP, Rosenwaks Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280717>
16. **The Effects of COVID-19 Among the Elderly Population: A Case for Closing the Digital Divide.** Front Psychiatry 2020; 11:577427Martins Van Jaarsveld G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304283>
17. **The Use of Mobile-technologies to Deliver Integrative Medicine During and Beyond the COVID-19 World Pandemic.** Glob Adv Health Med 2020; 9:2164956120977437Narayanan S, Lopez G, Liu W *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294304>
18. **Communication strategies and media discourses in the age of COVID-19: an urgent need for action.** Health Promot. Int. 2020; Génèreux M, David MD, O'Sullivan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294917>
19. **The use of Twitter by state leaders and its impact on the public during the COVID-19 pandemic.** Heliyon 2020; 6:e05540Haman M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294685>
20. **Medicine and Law in the Times of COVID-19 Pandemic: Understanding the Interphase.** Indian J. Crit. Care Med. 2020; 24:971-974Kumar A, Kapila M, Pankaj R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281324>
21. **An overview of research on air and environmental contamination with SARS-CoV-2 in healthcare settings.** Infect Control Hosp Epidemiol 2020;1-9Kanamori H.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33298221>
22. **The association between COVID-19 cases and deaths and web-based public inquiries.** Infect Dis (Lond) 2020;1-8Schnoell J, Besser G, Jank BJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33287607>
23. **Influence of Officially Ordered Restrictions During the First Wave of COVID-19 Pandemic on Physical Activity and Quality of Life in Patients after Kidney Transplantation in a Telemedicine Based Aftercare Program-A KTx360° Sub Study.** Int J Environ Res Public Health 2020; 17Hanke AA, Sundermeier T, Boeck HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297529>
24. **Tracking Websites' Digital Communication Strategies in Latin American Hospitals During the COVID-19 Pandemic.** Int J Environ Res Public Health 2020; 17Tejedor S, Pérez-Escoda A, Ventín A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297543>
25. **Phone-based outpatients' follow-up in mental health centers during the COVID-19 quarantine.** Int J Soc Psychiatry 2020;20764020979732Gentile A, Torales J, O'Higgins M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295245>
26. **Impact of 2020 SARS-CoV-2 outbreak on telemedicine management of cardiovascular disease in Italy.** Intern Emerg Med 2020;1-6Molinari G, Brunetti ND, Nodari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294959>
27. **Emerging role of artificial intelligence in therapeutics for COVID-19: a systematic review.** J Biomol Struct Dyn 2020;1-16Kaushal K, Sarma P, Rana SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300456>
28. **Transitioning to digital first line intervention - validation of a brief online screener for early identification of a suspected eating disorder: study**

- protocol.** J Eat Disord 2020; 8:60Bryant E, Miskovic-Wheatley J, Touyz S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292579>
29. **It's Corona Calling: Time for Telerehabilitation!** J Frailty Sarcopenia Falls 2020; 5:86-88Alexander M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283073>
 30. **Medical Education and E-Learning During COVID-19 Pandemic: Awareness, Attitudes, Preferences, and Barriers Among Undergraduate Medicine and Nursing Students at Makerere University, Uganda.** J Med Educ Curric Dev 2020; 7:2382120520973212Olum R, Atulinda L, Kigozi E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283049>
 31. **Artificial Intelligence in the Fight Against COVID-19: Scoping Review.** J Med Internet Res 2020; 22:e20756Abd-Alrazaq A, Alajlani M, Alhuwail D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284779>
 32. **Computing SARS-CoV-2 Infection Risk From Symptoms, Imaging, and Test Data: Diagnostic Model Development.** J Med Internet Res 2020; 22:e24478D'Ambrosia C, Christensen H, Aronoff-Spencer E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301417>
 33. **Addressing Public Health Emergencies via Facebook Surveys: Advantages, Challenges, and Practical Considerations.** J Med Internet Res 2020; 22:e20653Grow A, Perrotta D, Del Fava E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284782>
 34. **Social Media Insights Into US Mental Health During the COVID-19 Pandemic: Longitudinal Analysis of Twitter Data.** J Med Internet Res 2020; 22:e21418Valdez D, Ten Thij M, Bathina K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284783>
 35. **COVID-19 Pandemic Accelerates Need to Improve Online Patient Engagement Practices to Enhance Patient Experience.** J Patient Exp 2020; 7:657-664Meyer MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294595>
 36. **Implementation and Usefulness of Telemedicine During the COVID-19 Pandemic: A Scoping Review.** J. Prim. Care Community Health 2020; 11:2150132720980612Hincapié MA, Gallego JC, Gempeler A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33300414>
 37. **COVID-19, Lockdowns and Well-Being: Evidence from Google Trends.** J Public Econ 2020;104346Brodeur A, Clark AE, Fleche S, Powdthavee N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281237>
 38. **Teledentistry applications for mitigating risk and balancing the clinical schedule.** J. Public Health Dent. 2020; 80 Suppl 2:S126-s131Suter N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306848>
 39. **Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response.** J. Subst. Abuse Treat. 2020;108226McDonnell A, MacNeill C, Chapman B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303253>
 40. **Social Media Use and Monitoring for Adolescents With Depression and Implications for the COVID-19 Pandemic: Qualitative Study of Parent and Child Perspectives.** JMIR Pediatr Parent 2020; 3:e21644Biernesser C, Montano G, Miller E, Radovic A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289678>
 41. **Impact of Telemedicine Use by Oncology Physicians on the Patient and Informal Caregiver Experience of Receiving Care: Protocol for a Scoping Review in the Context of COVID-19.** JMIR Res Protoc 2020; 9:e25501Thiessen M, Soriano AM, Loewen HJ, Decker KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290243>

42. **Remote monitoring using donor-derived, cell-free DNA after kidney transplantation during the coronavirus disease 2019 pandemic.** Kidney Res Clin Pract 2020; Potter SR, Hinojosa R, Miles CD *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303727>
43. **COVID-AL: The diagnosis of COVID-19 with deep active learning.** Med. Image Anal. 2020; 68:101913Wu X, Chen C, Zhong M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285482>
44. **The changing trend of teleconsultations during COVID-19 era at a tertiary facility in Tanzania.** Pan Afr. Med. J. 2020; 35:125Adebayo PB, Jusabani A, Mukhtar M, Zehri AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282080>
45. **Telemedicine: an imperative concept during COVID-19 pandemic in Africa.** Pan Afr. Med. J. 2020; 35:129David KB, Solomon JK, Yunusa I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282084>
46. **The relationship between nursing students' technology addiction levels and attitudes toward e-learning during the COVID-19 pandemic: A cross-sectional study.** Perspect. Psychiatr. Care 2020; Guven Ozdemir N, Sonmez M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33305866>
47. **A data-driven approach to identify risk profiles and protective drugs in COVID-19.** Proc Natl Acad Sci U S A 2020; Cippà PE, Cugnata F, Ferrari P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303654>
48. **A data-driven approach to identify risk profiles and protective drugs in COVID-19.** Proc Natl Acad Sci U S A 2021; 118Cippà PE, Cugnata F, Ferrari P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303654>
49. **Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis.** Psychiatry Res 2020; 295:113599Cénat JM, Blais-Rochette C, Kokou-Kpolou CK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285346>
50. **Tele-rheumatology for overcoming socioeconomic barriers to healthcare in resource constrained settings: lessons from COVID-19 pandemic.** Rheumatology (Oxford) 2020; Kavadiachanda C, Shah S, Daber A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284974>
51. **Air pollution exposure and COVID-19: A look at mortality in Mexico City using individual-level data.** Sci Total Environ 2020; 756:143929López-Feldman A, Heres D, Marquez-Padilla F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302074>
52. **The new norm: Computer Science conferences respond to COVID-19.** Scientometrics 2020:1-15Mubin O, Alnajjar F, Shamil A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281245>
53. **Evaluation of the Sexual Functioning of Individuals Living in Turkey During the COVID-19 Pandemic: An Internet-Based Nationwide Survey Study.** Sex Med 2020; 9:100279Karsiyakali N, Sahin Y, Ates HA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291042>

Other – Miscellaneous (53 articles)

1. **Urgent need hybrid production - what COVID-19 can teach us about dislocated production through 3d-printing and the maker scene.** 3D Print Med 2020; 6:37Hartig S, Duda S, Hildebrandt L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284417>

2. **Association of climatic factors with COVID-19 in Pakistan.** AIMS Public Health 2020; 7:854-868Rehman Y, Rehman N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294487>
3. **Race, Power, and COVID-19: A Call for Advocacy within Bioethics.** Am. J. Bioeth. 2020:1-12Mithani Z, Cooper J, Boyd JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289442>
4. **The future of sustainability in the context of COVID-19.** Ambio 2020:1-10Cawthorn DM, Kennaugh A, Ferreira SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289053>
5. **Air pollution and critical air pollutant assessment during and after COVID-19 lockdowns: Evidence from pandemic hotspots in China, the Republic of Korea, Japan, and India.** Atmos Pollut Res 2020; Hu M, Chen Z, Cui H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281465>
6. **The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control.** Biosaf Health 2020; Souza TML, Morel CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283181>
7. **Which factors should be included in triage? An online survey of the attitudes of the UK general public to pandemic triage dilemmas.** BMJ Open 2020; 10:e045593Wilkinson D, Zohny H, Kappes A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293401>
8. **Impact of COVID-19 lockdown on air quality in Chandigarh, India: Understanding the emission sources during controlled anthropogenic activities.** Chemosphere 2021; 263:127978Mor S, Kumar S, Singh T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297028>
9. **COVID-19 and air pollution and meteorology-an intricate relationship: A review.** Chemosphere 2021; 263:128297Srivastava A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297239>
10. **Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies.** Clin Transl Allergy 2020; 10:58Bousquet J, Cristol JP, Czarlewski W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292691>
11. **COVID-19 in humanitarian settings: documenting and sharing context-specific programmatic experiences.** Confl Health 2020; 14:79Singh NS, Abraham O, Altare C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292392>
12. **The Need for Recovering the Subjugated Knowledge of Traditional Chinese Medicine.** Development (Rome) 2020:1-8Lau KC, Sit T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281422>
13. **Online alcohol delivery is associated with heavier drinking during the first New Zealand COVID-19 pandemic restrictions.** Drug Alcohol Rev 2020; Huckle T, Parker K, Romeo JS, Casswell S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283442>
14. **Cancer and COVID-19: economic impact on households in Southeast Asia.** Ecancermedicalsecience 2020; 14:1134Kong YC, Sakti VV, Sullivan R, Bhoo-Pathy N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281926>
15. **Information Search and Financial Markets under COVID-19.** Entropy (Basel) 2020; 22Ahundjanov BB, Akhundjanov SB, Okhunjanov BB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33286562>
16. **Randomness, Informational Entropy, and Volatility Interdependencies among the Major World Markets: The Role of the COVID-19 Pandemic.** Entropy (Basel)

- 2020; 22Lahmiri S, Bekiros S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33286604>
17. **On the concentration of SARS-CoV-2 in outdoor air and the interaction with pre-existing atmospheric particles.** Environ. Res. 2020;110603Belosi F, Conte M, Gianelle V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307081>
 18. **Meteorological Factors, Governmental Responses and COVID-19: Evidence from Four European countries.** Environ. Res. 2020;110596Fu S, Wang B, Zhou J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307083>
 19. **Health Benefits of Sustained Air Quality Improvements in New York City: A Simulation Based on Air Pollution Levels During the COVID-19 Shutdown.** Environ. Res. 2020;110555Perera F, Berberian A, Cooley D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285156>
 20. **Reproductive sequelae of parental severe illness before the pandemic: implications for the COVID-19 pandemic.** Fertil. Steril. 2020; 114:1242-1249Kasman AM, Bhambhani HP, Li S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280730>
 21. **Covid-19 pandemic effects on food safety - multi-country survey study.** Food Control 2020;107800Djekic I, Nikolić A, Uzunović M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281304>
 22. **Covid-19 pandemic effects on food safety - Multi-country survey study.** Food Control 2021; 122:107800Djekic I, Nikolić A, Uzunović M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281304>
 23. **The Impact of COVID-19 on Criminal Investigations and Proceedings in Sweden - A Snapshot of Practitioners' Realities.** Forensic Sci. Int. 2020; 2:325-332Lidén M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294832>
 24. **Healthy Dietary Intake Behavior Potentially Modifies the Negative Effect of COVID-19 Lockdown on Depression: A Hospital and Health Center Survey.** Front Nutr 2020; 7:581043Pham KM, Pham LV, Phan DT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304917>
 25. **Determinants of the Financial Contribution to the NHS: The Case of the COVID-19 Emergency in Italy.** Front. Psychol. 2020; 11:584473Castiglioni C, Lozza E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281680>
 26. **Getting Through COVID-19: The Pandemic's Impact on the Psychology of Sustainability, Quality of Life, and the Global Economy - A Systematic Review.** Front. Psychol. 2020; 11:585897El Keshky MES, Basyouni SS, Al Sabban AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281683>
 27. **A research blueprint for keeping our healthcare workers healthy in the age of pandemics and the crises to come.** Gen. Hosp. Psychiatry 2020; 68:35-37Chang BP, Edmondson D, Shechter A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285476>
 28. **Compound Risks of Hurricane Evacuation Amid the COVID-19 Pandemic in the United States.** Geohealth 2020; 4:e2020GH000319Pei S, Dahl KA, Yamana TK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299960>
 29. **Hospital study 2020 - Covid-19 aggravates economic situation of German hospitals.** Gesundheitsökonomie und Qualitätsmanagement 2020; 25:226.
 30. **The health and economic burden of the coronavirus in sub-Saharan Africa.** Glob Health Promot 2020;1757975920977874Bitanihirwe BKY, Ssewanyana D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302803>
 31. **Black Lives Matter in health promotion: moving from unspoken to outspoken.** Health Promot. Int. 2020; Leitch S, Corbin JH, Boston-Fisher N *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305322>
32. **From information seeking to information avoidance: Understanding the health information behavior during a global health crisis.** Inf. Process. Manag. 2021; 58:102440 Soroya SH, Farooq A, Mahmood K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281273>
 33. **Air travel in a COVID-19 world: Commercial airline passengers' health concerns and attitudes towards infection prevention and disease control measures.** Infect Dis Health 2020; Sotomayor-Castillo C, Radford K, Li C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303405>
 34. **Source Apportionment of Ambient Black Carbon During the COVID-19 Lockdown.** Int J Environ Res Public Health 2020; 17 Anil I, Alagha O.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33287365>
 35. **Association between the New COVID-19 Cases and Air Pollution with Meteorological Elements in Nine Counties of New York State.** Int J Environ Res Public Health 2020; 17 Díaz-Avalos C, Juan P, Chaudhuri S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291673>
 36. **Predicting SARS-CoV-2 Weather-Induced Seasonal Virulence from Atmospheric Air Enthalpy.** Int J Environ Res Public Health 2020; 17 Spena A, Palombi L, Corcione M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291676>
 37. **COVID-19 as Cause versus Trigger for the Collapse of Capitalism.** Int J Health Serv 2020; 20731420977711 Waitzkin H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297807>
 38. **Occurrence, fate and removal of SARS-CoV-2 in wastewater: Current knowledge and future perspectives.** J Environ Chem Eng 2020; 104870 Saawarn B, Hait S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282675>
 39. **Testing the socioeconomic determinants of COVID-19 pandemic hypothesis with aggregated Human Development Index.** J. Epidemiol. Community Health 2020; Troumbis AY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293289>
 40. **Future Perspectives of Nurses With COVID 19.** J Patient Exp 2020; 7:640-641 Abdollahimohammad A, Firouzkouhi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289000>
 41. **Is corona a feint in order to take away our freedom?** Klinikarzt 2020; 49:395-396 Leschke M.
 42. **Could changes in the airborne pollutant particulate matter acting as a viral vector have exerted selective pressure to cause COVID-19 evolution?** Med. Hypotheses 2020; 110401 Baron YM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303307>
 43. **The COVID-19 pandemic: A time for veterinary leadership in one health.** One Health 2021; 11:100193 Fathke RL, Rao S, Salman M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304981>
 44. **Financial, Food, and Housing Insecurity Due to Coronavirus Disease 2019 Among At-Risk People With Human Immunodeficiency Virus in a Nonurban Ryan White HIV/AIDS Program Clinic.** Open Forum Infect Dis 2020; 7:ofaa423 Sherbuk JE, Williams B, McManus KA, Dillingham R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33299902>
 45. **The Sustainable Development Goals and the Community of Portuguese Speaking Countries (CPLP) in the post-COVID-19 era.** Porto Biomed J 2020; 5:e102 Lapão MJC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299951>

46. **Food Worry in the Deaf and Hard-of-Hearing Population During the COVID-19 Pandemic.** Public Health Rep. 2020;33354920974666Engelman A, Paludneviene R, Wagner K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296264>
47. **Letter from Japan.** Respirology 2020; Kan OK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289211>
48. **Impact of COVID-19 on environmental noise emitted from the port.** Sci Total Environ 2020; 756:144147Čurović L, Jeram S, Murovec J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302066>
49. **Addressing dynamic uncertainty in the whale-watching industry under climate change and system shocks.** Sci Total Environ 2020; 756:143889Richards R, Meynecke JO, Sahin O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302062>
50. **Responses of decline in air pollution and recovery associated with COVID-19 lockdown in the Pearl River Delta.** Sci Total Environ 2020; 756:143868Wang S, Zhang Y, Ma J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302072>
51. **Natural and human environment interactively drive spread pattern of COVID-19: A city-level modeling study in China.** Sci Total Environ 2020; 756:143343Wu X, Yin J, Li C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302071>
52. **Geographic Disparities in COVID-19 Infections and Deaths: The Role of Transportation.** Transp Policy (Oxf) 2020; Gaskin DJ, Zare H, Delarmente B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293780>
53. **The International Virus Bioinformatics Meeting 2020.** Viruses 2020; 12Hufsky F, Beerenwinkel N, Meyer IM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291220>

Pathology (8 articles)

1. **Virtual microscopy and other technologies for teaching histology during Covid-19.** Anat Sci Educ 2020; Caruso MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283455>
2. **A comprehensive review of histopathological findings of infections induced by COVID-19.** Cell. Mol. Biol. (Noisy-le-grand) 2020; 66:143-151Balaky STJ, Zaki Abdullah SM, Alexander M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287945>
3. **Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic.** Endocrine 2020; Palladino R, Migliatino I, Sgariglia R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284396>
4. **Pathological findings in the postmortem liver of COVID-19 patients.** Hum. Pathol. 2020; Zhao CL, Rapkiewicz A, Maghsoodi-Deerwester M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307078>
5. **The Impact of COVID-19 on Women's Physical Activity Behavior and Mental Well-Being.** Int J Environ Res Public Health 2020; 17Nienhuis CP, Lesser IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291530>
6. **Biosafety Requirements for Autopsies of Patients with COVID-19: Example of a BSL-3 Autopsy Facility Designed for Highly Pathogenic Agents.** Pathobiology 2020:1-9Loibner M, Langner C, Regitnig P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296902>
7. **COVID-19 autopsies: Procedure, technical aspects and cause of fatal course. Experiences from a single-center.** Pathol. Res. Pract. 2020; 217:153305Skok K,

- Vander K, Setaffy L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285423>
8. **[Endotheliitis in COVID-19].** Pathologie 2020; Varga Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306138>

Protection (34 articles)

1. **Occupational COVID-19 risk for anaesthesia and intensive care staff - low-risk specialties in a high-risk setting.** Anaesthesia 2020; Cook TM, Lennane S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33307597>
2. **Theory-based Behavioral Predictors of Self-reported Use of Face Coverings in Public Settings during the COVID-19 Pandemic in the United States.** Ann. Behav. Med. 2020; Barile JP, Guerin RJ, Fisher KA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301024>
3. **Adherence to personal protective equipment use among healthcare workers caring for confirmed COVID-19 and alleged non-COVID-19 patients.** Antimicrob Resist Infect Control 2020; 9:199Neuwirth MM, Mattner F, Otchwemah R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33302982>
4. **SARS-Coronavirus-2 cases in healthcare workers may not regularly originate from patient care: lessons from a university hospital on the underestimated risk of healthcare worker to healthcare worker transmission.** Antimicrob Resist Infect Control 2020; 9:192Schneider S, Piening B, Nouri-Pasovsky PA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33287908>
5. **Keeping PPE barriers in COVID-19 wards while doing proper auscultation.** Antimicrob Resist Infect Control 2020; 9:196Seidel E, Luski S, Ribak Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33298120>
6. **Effects of Ozone Treatment on Personal Protective Equipment Contaminated with SARS-CoV-2.** Antioxidants (Basel) 2020; 9Clavo B, Córdoba-Lanús E, Rodríguez-Esparragón F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287249>
7. **First Line of Defense in COVID-19: Masks in Clinical Practice.** Asia Pac. J. Public Health 2020;1010539520979928Singh T, Ichhpujani P, Singh RB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291939>
8. **The impact of biosafety enhancement on stat laboratory quality metrics: lessons from the COVID-19 pandemic.** Clin Chim Acta 2020; Frater JL, Anderson J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285119>
9. **Rising to the challenge: Overcoming Shared Resource Laboratory biosafety challenges during a pandemic.** Cytometry A 2020; Aspland AM, Douagi I, Filby A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289290>
10. **Evaluation of hand hygiene and onset of hand eczema after the outbreak of SARS-CoV-2 in Munich.** Eur. J. Dermatol. 2020; Kendziora B, Guertler A, Ständer L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289485>
11. **Face masks and COVID-19: don't let perfect be the enemy of good.** Euro Surveill 2020; 25Cowling BJ, Leung GM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303063>
12. **Perception and Attitudes Toward PPE-Related Waste Disposal Amid COVID-19 in Bangladesh: An Exploratory Study.** Front Public Health 2020; 8:592345Islam SMD, Safiq MB, Bodrud-Doza M, Mamun MA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304879>

13. **Quality and Safety in Healthcare for Medical Students: Challenges and the Road Ahead.** Healthcare (Basel) 2020; 8López-Hernández LB, Díaz BG, González EOZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291837>
14. **Modified Negative Airflow Aerosol Prevention Box for COVID-19 Patients.** Indian J. Crit. Care Med. 2020; 24:981-982Kumar N, Kumar A, Kumar A, Sinha C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281326>
15. **Impact of infection prevention precautions on adenoviral infections during the COVID-19 pandemic: experience of a tertiary hospital in Singapore.** Infect Control Hosp Epidemiol 2020:1-9Wee LE, Conceicao EP, Sim JXY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298224>
16. **Contact Screening for Healthcare Workers Exposed to Patients with COVID-19.** Int J Environ Res Public Health 2020; 17Coppeta L, Somma G, Ippoliti L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291364>
17. **Aerosol Release by Healthy People during Speaking: Possible Contribution to the Transmission of SARS-CoV-2.** Int J Environ Res Public Health 2020; 17Eiche T, Kuster M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291404>
18. **Infection and Risk Perception of SARS-CoV-2 among Airport Workers: A Mixed Methods Study.** Int J Environ Res Public Health 2020; 17Malagón-Rojas J, Parra BE, Mercado M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287167>
19. **An overview of the effect of bioaerosol size in coronavirus disease 2019 transmission.** Int. J. Health Plann. Manage. 2020; Guzman MI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295073>
20. **EVALUATION OF A PERSONAL PROTECTIVE EQUIPMENT (PPE) SUPPORT PROGRAMME ('PPE HELPERS') FOR STAFF DURING THE COVID-19 PANDEMIC IN LONDON.** J Hosp Infect 2020; Castro-Sánchez E, Cm A, C A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307145>
21. **Heat Stress and PPE during COVID-19: Impact on health care workers' performance, safety and well-being in NHS settings.** J Hosp Infect 2020; Davey SL, Lee BJ, Robbins T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301841>
22. **What should we do for the safe transportation of COVID-19 patients?** J Infect Dev Ctries 2020; 14:1246-1247Akatsuka M, Shimodate Y, Inaba W, Yamakage M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296335>
23. **SARS-CoV-2 and aerosols-Arguing over the evidence.** J. Virol. Methods 2020:114033Tang JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285192>
24. **Impact of a Serious Game on the Intention to Change Infection Prevention and Control Practices in Nursing Homes During the COVID-19 Pandemic: Protocol for a Web-Based Randomized Controlled Trial.** JMIR Res Protoc 2020; 9:e25595Suppan L, Abbas M, Catho G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296329>
25. **Patient barrier acceptance during airway management among anesthesiologists: A simulation pilot study.** Korean J Anesthesiol 2020; Querney J, Cubillos J, Ding Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285048>
26. **Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols?** Med. Hypotheses 2020:110436Reis INR, do Amaral G, Mendoza AAH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288313>
27. **PPE for your mind: a peer support initiative for health care workers.** Med. J. Aust. 2020; Bridson TL, Jenkins K, Allen KG, McDermott BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294997>

28. **Three-Dimensional Analysis of Particle Distribution on Filter Layers inside N95 Respirators by Deep Learning.** Nano Lett 2020; Lee HR, Liao L, Xiao W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283521>
29. **Biosafety Requirements for Autopsies of Patients with COVID-19: Example of a BSL-3 Autopsy Facility Designed for Highly Pathogenic Agents.** Pathobiology 2020;1-9Loibner M, Langner C, Regitnig P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296902>
30. **Improved protection of filtering facepiece through inactivation of pathogens by hypertonic salt solutions - A possible COVID-19 prevention device.** Prev Med Rep 2020; 20:101270Tatzber F, Resch U, Lindschinger M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282639>
31. **Uncovering people's mask-saving intentions and behaviors in the post-COVID-19 period: Evidence from China.** Sustain Cities Soc 2021; 65:102626Si H, Shen L, Liu W, Wu G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288994>
32. **SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.** Wellcome Open Res 2020; 5:181Andersson MI, Arancibia-Carcamo CV, Auckland K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283055>
33. **Personal protective equipment in the COVID-19 pandemic and the use of cooling-wear as alleviator of thermal stress : A pilot study in plastic surgery staff members.** Wien. Klin. Wochenschr. 2020;1-9Luz H, Nischwitz SP, Kotzbeck P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301061>
34. **The Mutual Constraints of States and Global Value Chains during COVID-19: The Case of Personal Protective Equipment.** World Dev 2020;105324Dallas MP, Horner R, Li L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293754>

Pulmonary disease (18 articles)

1. **A Rapidly Deployable Test Suite for Respiratory Protective Devices in the COVID-19 Pandemic.** Appl. Biosaf. 2020; 25:161-168Blad T, Nijssen J, Broeren F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281505>
2. **New Adopters of Telemedicine During the Coronavirus-19 Pandemic in Respondents to an Online Community Survey: The Case for Access to Remote Management Tools for Individuals with Chronic Obstructive Pulmonary Disease.** Chronic Obstr Pulm Dis 2020; Boyce DM, Thomashow BM, Sullivan J, Tal-Singer R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291190>
3. **Anomalous asthma and chronic obstructive pulmonary disease Google Trends patterns during the COVID-19 pandemic.** Clin Transl Allergy 2020; 10:47Sousa-Pinto B, Heffler E, Antó A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292529>
4. **Electrical impedance tomography to titrate positive end-expiratory pressure in COVID-19 acute respiratory distress syndrome.** Crit Care 2020; 24:678Perier F, Tuffet S, Maraffi T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287864>
5. **COVID-19 Severity: Lung-Heart Interplay.** Curr. Cardiol. Rev. 2020; Puri G, Pal Singh V, Naura AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305712>
6. **What can pulmonary rehabilitation accomplish?** Deutsche Medizinische Wochenschrift 2020; 145:1782-1785Schneeberger T, Jarosch I, Koczulla AR.
7. **Mechanisms of Hypoxia in COVID-19 Patients: A Pathophysiologic Reflection.** Indian J. Crit. Care Med. 2020; 24:967-970Nitsure M, Sarangi B, Shankar GH *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281323>

8. **Validation of pneumonia prognostic scores in a statewide cohort of hospitalized patients with COVID-19.** Int J Clin Pract 2020:e13926Shi Y, Pandita A, Hardesty A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296132>
9. **Severe asthma and COVID-19: lessons from the first wave.** J. Asthma 2020:1-6Filippo P, Benfante A, Villa E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297799>
10. **Severe asthma and COVID-19: lessons from the first wave.** J. Asthma 2020:1-7Patrucco F, Benfante A, Villa E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297799>
11. **Hematological indicators for lung damage caused by COVID-19 infection.** Klin. Lab. Diagn. 2020; 65:676-682Borodulina EA, Vasneva ZP, Borodulin BE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301656>
12. **Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin.** Pan Afr. Med. J. 2020; 35:110Bouaré F, Laghmari M, Etouche FN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282065>
13. **Innovating and Adapting in Pediatric Pulmonology and Sleep Medicine During the COVID-19 Pandemic: ATS Pediatric Assembly Web Committee Consensus Statement for Initial COVID-19 Virtual Response.** Pediatr Pulmonol 2020; Taylor JB, Oermann CM, Deterding RR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300286>
14. **Gas exchange and hypertension in COVID-19.** Pneumologie 2020; 74:719Krome S.
15. **Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19.** Pulm Circ 2020; 10:2045894020970369Franco V, Bradley EA, Badagliacca R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282201>
16. **Fatal pulmonary fibrosis complicating COVID-19 infection in preexistent emphysema.** Radiol Case Rep 2021; 16:361-363Mazzolini M, Monari M, Angeletti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288987>
17. **Letter from Japan: Re-thinking our future.** Respirology 2020; Hashimoto S, Hikichi M, Maruoka S, Gon Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295008>
18. **[COVID-19 and asthma control].** Rev. Mal. Respir. 2020; Underner M, Taillé C, Peiffer G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280940>

Renal disease (12 articles)

1. **Epidemiology and Outcomes of Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome: A Multicenter Retrospective Study.** Blood Purif. 2020:1-7Wang F, Ran L, Qian C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291098>
2. **Safely reducing haemodialysis frequency during the COVID-19 pandemic.** BMC Nephrol. 2020; 21:532Lodge MDS, Abeygunaratne T, Alderson H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287730>
3. **Case Report: Renal potassium wasting in SARS-CoV-2 infection.** F1000Res 2020; 9:659Mabillard H, Tedd H, Speight A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299549>

4. **[COVID-19 emergency management at the Nephrology and Dialysis Unit in Savona, Albenga and Cairo Montenotte].** G Ital Nefrol 2020; 37Repetto M, Caputo C, Ciabattini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295705>
5. **[SARS CoV-2 related disease features in a population of chronic hemodialysis patients].** G Ital Nefrol 2020; 37Silvestri C, Di Stante S, Bertuzzi V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295704>
6. **Coronavirus Disease 2019: Virology and Drug Targets.** Infect Disord Drug Targets 2020; Krishnamurthy PT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297920>
7. **Influence of Officially Ordered Restrictions During the First Wave of COVID-19 Pandemic on Physical Activity and Quality of Life in Patients after Kidney Transplantation in a Telemedicine Based Aftercare Program-A KTx360° Sub Study.** Int J Environ Res Public Health 2020; 17Hanke AA, Sundermeier T, Boeck HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297529>
8. **Malfunctioning Temporary Hemodialysis Catheters in Patients with COVID-19.** J. Vasc. Surg. 2020; Kanitra JJ, Power AD, Hayward RD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290813>
9. **Remote monitoring using donor-derived, cell-free DNA after kidney transplantation during the coronavirus disease 2019 pandemic.** Kidney Res Clin Pract 2020; Potter SR, Hinojosa R, Miles CD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303727>
10. **Impact of COVID-19 pandemic on renal care services in Nigeria.** Pan Afr. Med. J. 2020; 35:101Adejumo OA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282056>
11. **Characteristics and outcomes of hemodialysis patients with COVID-19: a retrospective single center study.** PeerJ 2020; 8:e10459Luo Y, Li J, Liu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304660>
12. **Personal protective equipment in the COVID-19 pandemic and the use of cooling-wear as alleviator of thermal stress : A pilot study in plastic surgery staff members.** Wien. Klin. Wochenschr. 2020;1-9Luze H, Nischwitz SP, Kotzbeck P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301061>

Reviews (30 articles)

1. **Recent Insights into Emerging Coronavirus: SARS-CoV-2.** ACS Infect Dis 2020; Shang Z, Chan SY, Liu WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296169>
2. **Protective Measures For Burn Care Professionals During The Coronavirus Disease 2019 Pandemic: Systematic Review.** Ann Burns Fire Disasters 2020; 33:182-190Al-Benna S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304207>
3. **Infection-prevention measures against COVID-19 during anesthesia: a narrative review of current clinical literature.** Ann Palliat Med 2020; 9:4300-4307Chen Y, Guo X, Zhang X, Lv H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302684>
4. **Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.** Biochem. Biophys. Res. Commun. 2020; Bacca E, Digaetano M, Meschiari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303188>
5. **Autonomic balance determines the severity of COVID-19 courses.** Bioelectron Med 2020; 6:22Leitzke M, Stefanovic D, Meyer JJ *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292846>
6. **Cutaneous Manifestations in Confirmed COVID-19 Patients: A Systematic Review.** Biology (Basel) 2020; 9Conforti C, Dianzani C, Agozzino M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33291502>
 7. **The application of DNA polymerases and Cas9 as representative of DNA-modifying enzymes group in DNA sensor design (review).** Biosens. Bioelectron. 2020;112867Dronina J, Bubniene US, Ramanavicius A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33303323>
 8. **A comprehensive review of histopathological findings of infections induced by COVID-19.** Cell. Mol. Biol. (Noisy-le-grand) 2020; 66:143-151Balaky STJ, Zaki Abdullah SM, Alexander M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287945>
 9. **Acute myocardial infarction secondary to COVID-19 infection: A case report and review of the literature.** Clin Imaging 2020; 72:178-182Capaccione KM, Leb JS, D'Souza B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296828>
 10. **ACE2, a multifunctional protein - from cardiovascular regulation to COVID-19.** Clin Sci (Lond) 2020; 134:3229-3232Bader M, Turner AJ, Alenina N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33305790>
 11. **Thyrototoxic Crisis and COVID-19 Infection: An Extraordinary Case and Literature Review.** Cureus 2020; 12:e11305Pastor S, Molina Á, Sr., De Celis E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282582>
 12. **Coronavirus-Associated Coagulopathy: Lessons From SARS-CoV1 and MERS-CoV for the Current SARS-CoV2 Pandemic.** Cureus 2020; 12:e11310Singh S, Zuwasti U, Haas C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282586>
 13. **COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review.** Curr. Pharm. Des. 2020; Aziz A, Asif M, Ashraf G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280586>
 14. **An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors.** Curr. Top. Med. Chem. 2020; Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292134>
 15. **The "sex gap" in COVID-19 trials: a scoping review.** EClinicalMedicine 2020;100652Schiffer V, Janssen E, van Bussel BCT *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283178>
 16. **Coronavirus Disease 2019 and Cardiac Arrhythmias.** Eur Cardiol 2020; 15:e66Martínez-Rubio A, Ascoeta S, Taibi F, Soldevila JG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33294034>
 17. **An Update on COVID-19 Pandemic: The Epidemiology, Pathogenesis, Prevention and Treatment Strategies.** Expert Rev. Anti Infect. Ther. 2020; Tsang HF, Chan LWC, Cho WCS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306423>
 18. **Getting Through COVID-19: The Pandemic's Impact on the Psychology of Sustainability, Quality of Life, and the Global Economy - A Systematic Review.** Front. Psychol. 2020; 11:585897El Keshky MES, Basyouni SS, Al Sabban AM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281683>
 19. **Thirty-Day Mortality in COVID-19 Positive Patients With Hip Fractures: A Case-Series and Literature Review.** Geriatr Orthop Surg Rehabil 2020; 11:2151459320972681Al Farii H, Al Rawahi S, Samaila E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282447>

20. **COVID-19 infection in pregnant women: Review of maternal and fetal outcomes.** *Int J Gynaecol Obstet* 2020; Salem D, Katranji F, Bakdash T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33305352>
21. **Emerging role of artificial intelligence in therapeutics for COVID-19: a systematic review.** *J Biomol Struct Dyn* 2020:1-16Kaushal K, Sarma P, Rana SV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300456>
22. **A review of the prevalence of COVID-19 in the Arab world.** *J Infect Dev Ctries* 2020; 14:1238-1245Alwahaibi N, Al-Maskari M, Al-Dhahli B *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296334>
23. **Artificial Intelligence in the Fight Against COVID-19: Scoping Review.** *J Med Internet Res* 2020; 22:e20756Abd-Alrazaq A, Alajlani M, Alhuwail D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33284779>
24. **COVID-19 and Tuberculosis Overlapping epidemics: A holistic review from Pakistan.** *J Med Virol* 2020; Awan UA, Khattak AA, Afzal MS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33295641>
25. **Implementation and Usefulness of Telemedicine During the COVID-19 Pandemic: A Scoping Review.** *J. Prim. Care Community Health* 2020; 11:2150132720980612Hincapié MA, Gallego JC, Gempeler A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33300414>
26. **Outcomes for patients with COVID-19: known knowns, known unknowns, and unknown unknowns.** *Med. J. Aust.* 2020; Singer M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33296509>
27. **A review of changes in COVID-19 burden in the COVID-19 treatment centres in Yaoundé (Cameroon): a call for cautious optimism.** *Pan Afr. Med. J.* 2020; 35:113Sobngwi E, Omba-Moussi C, Kouanfack C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282068>
28. **[Endotheliitis in COVID-19].** *Pathologie* 2020; Varga Z.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306138>
29. **Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review.** *Trop Med Health* 2020; 48:91Girum T, Lentiro K, Geremew M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33292755>
30. **A SENSITIVE INDICATOR FOR THE SEVERITY OF COVID-19: THIOL.** *Turk J Med Sci* 2020; Erel Ö, Neşelioğlu S, Ergin Tunçay M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33306332>

Risk factors (53 articles)

1. **Correlation of Pectoralis Muscle Volume and Density with Severity of COVID-19 Pneumonia in Adults.** *Acad Radiol* 2020; Hocaoglu E, Ors S, Yildiz O, Inci E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281041>
2. **Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19.** *Am J Clin Pathol* 2020; Moosavi M, Wooten M, Goodman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300981>
3. **Inflammatory markers are poorly predictive of clinical outcomes among hospitalized patients with COVID-19.** *Am J Emerg Med* 2020; Barrett B, Pamphile S, Yang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280969>
4. **Protracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure.** *Ann Intensive Care* 2020;

- 10:167Bitker L, Dhelft F, Chauvelot L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301059>
5. **IL-6 and other biomarkers as predictors of severity in COVID-19.** *Ann. Med.* 2020;1-5Broman N, Rantasärkkä K, Feuth T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305624>
 6. **Myocardium injury biomarkers predict prognosis of critically ill coronavirus disease 2019 (COVID-19) patients.** *Ann Palliat Med* 2020; 9:4156-4165Cao L, Zhang S, Luo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302676>
 7. **COVID-19 Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs) Compared to the General Population: A US Multi-Center Comparative Cohort Study.** *Arthritis Rheumatol* 2020; D'Silva KM, Jorge A, Cohen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305544>
 8. **Elevated serum ferritin level effectively discriminates severity illness and liver injury of coronavirus disease 2019 pneumonia.** *Biomarkers* 2020:1-18Cao P, Wu Y, Wu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284041>
 9. **Serum neopterin levels in relation to mild and severe COVID-19.** *BMC Infect. Dis.* 2020; 20:942Robertson J, Gostner JM, Nilsson S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302893>
 10. **Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: a single-centre, retrospective study.** *BMC Infect. Dis.* 2020; 20:943Yi P, Yang X, Ding C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302889>
 11. **Development of a data-driven COVID-19 prognostication tool to inform triage and step-down care for hospitalised patients in Hong Kong: a population-based cohort study.** *BMC Med. Inform. Decis. Mak.* 2020; 20:323Tsui ELH, Lui CSM, Woo PPS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287804>
 12. **Biomarkers of acute respiratory distress syndrome in adults hospitalised for severe SARS-CoV-2 infection in Tenerife Island, Spain.** *BMC Res. Notes* 2020; 13:555Figueira Gonçalves JM, Hernández Pérez JM, Acosta Sorensen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298124>
 13. **Early Extrapulmonary Prognostic Features in Chest Computed tomography in COVID-19 Pneumonia: Bone Mineral Density is a Relevant Predictor for the Clinical Outcome - a Multicenter Feasibility Study.** *Bone* 2020:115790Kottlors J, Große Hokamp N, Fervers P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301962>
 14. **Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy.** *Cancer* 2020; Lara OD, Smith MJ, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294978>
 15. **Lymphocyte cell population as a potential hematological index for early diagnosis of COVID-19.** *Cell. Mol. Biol. (Noisy-le-grand)* 2020; 66:202-206Zhu Y, Cao X, Lu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287943>
 16. **Vitamin D and Covid-19: an update on evidence and potential therapeutic implications.** *Clin. Mol. Allergy* 2020; 18:23Murdaca G, Pioggia G, Negrini S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292313>
 17. **CALL Score and RAS Score as Predictive Models for Coronavirus Disease 2019.** *Cureus* 2020; 12:e11368Kamran SM, Mirza ZE, Moeed HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304701>
 18. **The role of Interleukin-6 in the pathogenesis, prognosis and treatment of severe COVID-19.** *Curr Med Chem* 2020; Giannakodimos I, Gkountana GV,

- Lykouras D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297909>
19. **Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.** Diabetes Metab Syndr 2020; 15:33-38Nafakhi H, Alareedh M, Al-Buthabhak K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296788>
 20. **The "sex gap" in COVID-19 trials: a scoping review.** EClinicalMedicine 2020:100652Schiffer V, Janssen E, van Bussel BCT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283178>
 21. **Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea.** Endocrinol Metab (Seoul) 2020; You JH, Lee SA, Chun SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297603>
 22. **Development and Validation of a Prognostic Risk Score System for COVID-19 Inpatients: A Multi-Center Retrospective Study in China.** Engineering (Beijing) 2020; Yuan Y, Sun C, Tang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282444>
 23. **Multi-dimensional COVID-19 short- and long-term outcome prediction algorithm.** Expert Rev Precis Med Drug Dev 2020; 5:239-242Deng MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283045>
 24. **Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload.** Front Med (Lausanne) 2020; 7:586307Goudot G, Chocron R, Augy JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282891>
 25. **A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level.** Front Public Health 2020; 8:584552Hambali NL, Mohd Noh M, Paramasivam S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304877>
 26. **Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study.** Gastroenterology 2020; Belli LS, Fondevila C, Cortesi PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307029>
 27. **Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort.** Gut 2020; Lee SW, Yang JM, Yoo IK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303566>
 28. **Haematological abnormalities and risk of COVID-19 infection in adult patients attending primary healthcare settings.** Hematol Rep. 2020; 12:8829Hamed E, Syed MA, Alnuaimi AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282166>
 29. **Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19.** Immunity 2020; Bacher P, Rosati E, Esser D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296686>
 30. **Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19.** Immunity 2020; Bernardes JP, Mishra N, Tran F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296687>
 31. **Validation of pneumonia prognostic scores in a statewide cohort of hospitalized patients with COVID-19.** Int J Clin Pract 2020:e13926Shi Y, Pandita A, Hardesty A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296132>
 32. **ABO Blood groups in COVID-19 patients; cross-sectional study.** Int J Clin Pract 2020:e13927Solmaz İ, Araç S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296536>

33. **Aerosol Release by Healthy People during Speaking: Possible Contribution to the Transmission of SARS-CoV-2.** Int J Environ Res Public Health 2020; 17:Eiche T, Kuster M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291404>
34. **Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection.** Int. J. Lab. Hematol. 2020; Soni M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289964>
35. **Eating to Cope With the COVID-19 Pandemic and Body Weight Change in Young Adults.** J. Adolesc. Health 2020; Mason TB, Barrington-Trimis J, Leventhal AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288456>
36. **Prognostic Factors of COVID-19 Infection in Elderly Patients: A Multicenter Study.** J Clin Med 2020; 9:Hwang J, Ryu HS, Kim HA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291617>
37. **Hyperglycemia associated with lymphopenia and disease severity of COVID-19 in type 2 diabetes mellitus.** J. Diabetes Complications 2020;107809Cheng Y, Yue L, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288414>
38. **Prevalence and prognostic value of elevated troponins in patients hospitalised for coronavirus disease 2019: a systematic review and meta-analysis.** J Intensive Care 2020; 8:88Zhao BC, Liu WF, Lei SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292649>
39. **Neutrophils mediate Th17 promotion in COVID-19 patients.** J. Leukoc. Biol. 2020; Parackova Z, Bloomfield M, Klocperk A, Sediva A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289169>
40. **Development and Validation of a Nomogram Using on Admission Routine Laboratory Parameters to Predict In-hospital Survival of Patients With COVID-19.** J Med Virol 2020; Chen H, Chen R, Yang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289142>
41. **Risk factors for severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective study.** J Transl Med 2020; 18:461Wang P, Sha J, Meng M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287826>
42. **Triage bei COVID-19: Ist Krebs ein Kriterium?** Klinikerzt 2020; 49:445Wiedemann GJ.
43. **Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.** Mech. Ageing Dev. 2020; 193:111413Sabbatinelli J, Giuliani A, Maccacchione G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307107>
44. **High serum nitrates levels in non-survivor COVID-19 patients.** Med. Intensiva 2020; Lorente L, Gómez-Bernal F, Martín MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293102>
45. **Investigating the factors affecting the survival rate in patients with COVID-19: A retrospective cohort study.** Med. J. Islam. Repub. Iran 2020; 34:88Eshtrati B, Baradaran HR, Erfanpoor S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306063>
46. **Antigenic variation of SARS-CoV-2 in response to immune pressure.** Mol. Ecol. 2020; Forni D, Cagliani R, Pontremoli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289207>
47. **The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients.** Molecules 2020; 25:Fois AG, Paliogiannis P, Scano V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291581>

48. **Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.** Mult Scler Relat Disord 2020; 46:102592Masuccio FG, Lo Re M, Bertolotto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296987>
49. **Combination of obesity and co-morbidities leads to unfavorable outcomes in COVID-19 patients.** Saudi J. Biol. Sci. 2020; Al Heialy S, Yaseen Hachim M, Yaseen Hachim I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293887>
50. **Evaluation of viral concentration methods for SARS-CoV-2 recovery from wastewaters.** Sci Total Environ 2020; 756:144105Barril PA, Pianciola LA, Mazzeo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302076>
51. **Differences in RAAS/vitamin D linked to genetics and socioeconomic factors could explain the higher mortality rate in African Americans with COVID-19.** Ther. Adv. Cardiovasc. Dis. 2020; 14:1753944720977715Martín Giménez VM, Ferder L, Inserra F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283618>
52. **The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?** Therap. Adv. Gastroenterol. 2020; 13:1756284820974914Segal JP, Mak JWY, Mullish BH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281941>
53. **[Prediction of severe outcomes of patients with COVID-19].** Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:1595-1600Peng ZH, Chen XF, Hu QY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297614>

Safety (6 articles)

1. **Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective.** Front. Neurol. 2020; 11:596528Pedrioli G, Patani R, Paganetti P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281734>
2. **Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.** J. Electrocardiol. 2020; 64:30-35Echarte-Morales J, Minguito-Carazo C, Del Castillo-García S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307378>
3. **Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.** J Infect 2020; Chen PJ, Chao CM, Lai CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301818>
4. **Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability.** J Saudi Heart Assoc 2020; 32:350-357El Ouarradi A, Abdeladim S, Oualim S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299775>
5. **Decreased serum levels of the inflammaging marker miR-146a are associated with non-clinical response to tocilizumab in COVID-19 patients.** Mech. Ageing Dev. 2020; 193:111413Sabbatinelli J, Giuliani A, Matakchione G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307107>
6. **Electrocardiogrammes d'un patient COVID-19 traité par l'association hydroxychloroquine et azithromycine.** Pan Afr. Med. J. 2020; 35:112Benouna ME, Ech-Chenbouli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282067>

Treatment options (75 articles)

1. **Effects of Inhaled Nitric Oxide in COVID-19 induced ARDS - is it worthwhile?** Acta Anaesthesiol. Scand. 2020; Lotz C, Muellenbach RM, Meybohm P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296498>

2. **A survey of US hospitals' criteria for the allocation of remdesivir to treat COVID-19.** Am. J. Health Syst. Pharm. 2020; Mun F, Hale CM, Hennrikus EF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289021>
3. **Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges.** Am. J. Respir. Cell Mol. Biol. 2020; Jia H, Neptune E, Cui H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296619>
4. **Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications.** Antioxidants (Basel) 2020; 9Rahban M, Habibi-Rezaei M, Mazaheri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291560>
5. **Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.** Biochem. Biophys. Res. Commun. 2020; Bacca E, Digaetano M, Meschiari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303188>
6. **Exploring active ingredients and function mechanisms of Ephedra-bitter almond for prevention and treatment of Corona virus disease 2019 (COVID-19) based on network pharmacology.** BioData Min. 2020; 13:19Gao K, Song YP, Song A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292385>
7. **COVID-19, microthromboses, inflammation, and platelet activating factor.** Biofactors 2020; Demopoulos C, Antonopoulou S, Theoharides TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296106>
8. **Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus.** Biomedicines 2020; 8Alavi M, Asare-Addo K, Nokhodchi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297444>
9. **An insight into the interaction between α -ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.** Biophys. Chem. 2020; 269:106510Banerjee S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285430>
10. **A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.** BMC Pulm. Med. 2020; 20:317Misset B, Hoste E, Donneau AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287790>
11. **Potential for personalised application of inhaled nitric oxide in COVID-19 pneumonia.** Br J Anaesth 2020; Garfield B, McFadyen C, Briar C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288208>
12. **Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Military Hospital Prague.** Cas. Lek. Cesk. 2020; 159:175-180Bohoněk M, Řezáč D, Holub M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297703>
13. **A case of severe course of COVID-19 treated with experimental therapy.** Cas. Lek. Cesk. 2020; 159:181-184Zlámál M, Štěchovská K, Holub M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297704>
14. **A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.** Cell Rep Med 2020; 1:100137Kost-Alimova M, Sidhom EH, Satyam A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294858>
15. **A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors.** ChemMedChem 2020; Liu W, Yang K, Ma X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283984>

16. **A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors***. ChemMedChem 2020; Yang KS, Ma XR, Ma Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33283984>
17. **Paradoxes and uncertainties of immunomodulatory treatments in the fight against COVID-19.** Clin Infect Dis 2020; Kaiser L, Vu-Cantero DL, Eberhardt CS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33285564>
18. **Corticosteroids in patients hospitalised for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data.** Clin Microbiol Infect 2020; Maulin L, Martinez S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301928>
19. **Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.** Clin Transl Immunology 2020; 9:e1218Caballero A, Filgueira LM, Betancourt J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304584>
20. **Next-generation computational tools and resources for coronavirus research: From detection to vaccine discovery.** Comput. Biol. Med. 2020; 128:104158Kangabam R, Sahoo S, Ghosh A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33301953>
21. **The role of Interleukin-6 in the pathogenesis, prognosis and treatment of severe COVID-19.** Curr Med Chem 2020; Giannakodimos I, Gkountana GV, Lykouras D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297909>
22. **COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review.** Curr. Pharm. Des. 2020; Aziz A, Asif M, Ashraf G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33280586>
23. **Natural Products Homoharringtonine and Emetine Alkaloids for SARSCoV-2 Treatment Options.** Curr. Pharm. Des. 2020; Sohrab SS, Suhail M, Kamal MA, Azhar EI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302852>
24. **An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors.** Curr. Top. Med. Chem. 2020; Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292134>
25. **Protease-activated receptor 1 as a potential therapeutic target for COVID-19.** Exp. Biol. Med. (Maywood) 2020:1535370220978372Rovai ES, Alves T, Holzhausen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302737>
26. **Repurposing drugs for the management of COVID-19.** Expert Opin. Ther. Pat. 2020; Cusinato J, Cau Y, Calvani AM, Mori M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283567>
27. **Identification of Potential Key Agents for Targeting RNA-Dependent RNA Polymerase of SARS-CoV-2 by Integrated Analysis and Virtual Drug Screening.** Front Genet 2020; 11:581668Ao S, Han D, Sun L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281876>
28. **First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.** Front Med (Lausanne) 2020; 7:596916Valenzuela O, Ibáñez S, Poli MC *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33304913>
29. **Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives.** Front Mol Biosci 2020; 7:606393Kotta S, Aldawsari HM, Badr-Eldin SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282914>
30. **Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective.** Front. Neurol. 2020; 11:596528Pedrioli G, Patani R, Paganetti P.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33281734>

31. **Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study.** Gastroenterology 2020; Belli LS, Fondevila C, Cortesi PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307029>
32. **Enhancement of the IFN- β -induced host signature informs repurposed drugs for COVID-19.** Heliyon 2020; 6:e05646Huang CT, Chao TL, Kao HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289002>
33. **An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.** Immun. Ageing 2020; 17:34Saavedra D, Añé-Kourí AL, Sánchez N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292350>
34. **Welcome to the 13th Volume of Immunotherapy.** Immunotherapy 2020; Torrington E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280421>
35. **Welcome to the 13th Volume of Immunotherapy.** Immunotherapy 2021; 13:1-3Torrington E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280421>
36. **Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.** Indian J. Pharmacol. 2020; 52:414-421Prakash A, Singh H, Kaur H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283773>
37. **Novel therapeutic approaches toward Hantaan virus and its clinical features' similarity with COVID-19.** Indian J. Pharmacol. 2020; 52:347-355Singh H, Kaur H, Medhi B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283765>
38. **FDA efficiency for approval process of COVID-19 therapeutics.** Infect. Agent. Cancer 2020; 15:73Cassidy C, Dever D, Stanbery L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33292374>
39. **Coronavirus Disease 2019: Virology and Drug Targets.** Infect Disord Drug Targets 2020; Krishnamurthy PT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297920>
40. **Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.** Int Immunopharmacol 2020; 90:107228Bolarin JA, Oluwatoyosi MA, Orege JI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302035>
41. **COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.** Int Immunopharmacol 2020; 90:107220da Costa CBP, Martins FJ, da Cunha LER *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302034>
42. **A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2.** Int Immunopharmacol 2020; 90:107232Kivrak A, Ulaş B, Kivrak H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290969>
43. **Repurposing of some anti-infective drugs for COVID-19 treatment: a surveillance study supported by an in silico investigation.** Int J Clin Pract 2020:e13877Sayed AM, Khalaf AM, Abdelrahim MEA, Elgendy MO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300221>
44. **COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study.** Int J Infect Dis 2020; Alsharidah S, Ayed M, Ameen RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285283>
45. **Biflavonoids from *Rhus succedanea* as probable natural inhibitors against SARS-CoV-2: a molecular docking and molecular dynamics approach.** J Biomol Struct Dyn 2020:1-13Lokhande K, Nawani N, S KV, Pawar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300454>

46. **Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials.** J Cardiothorac Vasc Anesth 2020; Pasin L, Navalesi P, Zangrillo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298370>
47. **Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.** J. Electrocardiol. 2020; 64:30-35 Echarte-Morales J, Minguito-Carazo C, Del Castillo-García S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307378>
48. **COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?** J Extracell Vesicles 2020; 10:e12004 Askenase PW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33304473>
49. **Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.** J Infect 2020; Chen PJ, Chao CM, Lai CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301818>
50. **Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China.** J Med Virol 2020; Dai W, Wu J, Li T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289151>
51. **SARS-CoV-2 pneumonia in a newborn treated with remdesivir and COVID-19 convalescent plasma.** J Pediatric Infect Dis Soc 2020; Hopwood AJ, Jordan-Villegas A, Gutierrez LD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306130>
52. **A Response to the Recommendations for Using Dexamethasone for the Treatment of COVID-19: The Dark Side of Dexamethasone.** J. Pharm. Pract. 2020; 897190020979608 Salem MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302762>
53. **Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability.** J Saudi Heart Assoc 2020; 32:350-357 El Ouarradi A, Abdeladim S, Oualim S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299775>
54. **Mortality in COVID-19: Further Evidence for a Sex-Based Difference in the OpenSAFELY Study.** J Womens Health (Larchmt) 2020; Newman CB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297829>
55. **Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients.** Mech. Ageing Dev. 2020; 193:111413 Sabbatinelli J, Giuliani A, Maccacchione G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307107>
56. **Decreased serum levels of the inflammaging marker miR-146a are associated with non-clinical response to tocilizumab in COVID-19 patients.** Mech. Ageing Dev. 2020; 193:111413 Sabbatinelli J, Giuliani A, Maccacchione G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307107>
57. **Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.** Mech. Ageing Dev. 2020; 193:111413 Sabbatinelli J, Giuliani A, Maccacchione G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307107>
58. **Synthetic and semi-synthetic drugs as promising therapeutic option for the treatment of COVID-19.** Mini Rev. Med. Chem. 2020; Shirbhate E, Patel P, Patel VK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33280595>

59. **Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.** Mult Scler Relat Disord 2020; 46:102592Masuccio FG, Lo Re M, Bertolotto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296987>
60. **Vitamin C-An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19.** Nutrients 2020; 12Holford P, Carr AC, Jovic TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297491>
61. **Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy.** Nutrition 2020;111055Cereda E, Bogliolo L, Lobascio F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288411>
62. **Electrocardiogrammes d'un patient COVID-19 traité par l'association hydroxychloroquine et azithromycine.** Pan Afr. Med. J. 2020; 35:112Benouna ME, Ech-Chenbouli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282067>
63. **Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin.** Pan Afr. Med. J. 2020; 35:110Bouaré F, Laghmari M, Etouche FN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282065>
64. **'Any and every cure for COVID-19': an imminent epidemic of alternative remedies amidst the pandemic?** Pan Afr. Med. J. 2020; 35:108Eboreime EA, Iwu CJ, Banke-Thomas A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282063>
65. **Treatment of COVID-19: implications for antimicrobial resistance in Africa.** Pan Afr. Med. J. 2020; 35:119Iwu CJ, Jordan P, Jaja IF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282074>
66. **FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.** Pharmaceuticals (Basel) 2020; 13Mostafa A, Kandeil A, Y AMME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291642>
67. **A data-driven approach to identify risk profiles and protective drugs in COVID-19.** Proc Natl Acad Sci U S A 2020; Cippà PE, Cugnata F, Ferrari P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303654>
68. **A data-driven approach to identify risk profiles and protective drugs in COVID-19.** Proc Natl Acad Sci U S A 2021; 118Cippà PE, Cugnata F, Ferrari P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303654>
69. **[COVID-19: Still a place for tocilizumab?].** Rev. Med. Interne 2020; Richier Q, Plaçais L, Lacombe K, Hermine O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33288230>
70. **The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp.** Saudi J. Biol. Sci. 2020; Bahadur Gurung A, Ajmal Ali M, Lee J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281478>
71. **Emergence of Ancient Convalescent plasma (CP) Therapy: to Manage COVID-19 Pandemic.** Transfus. Clin. Biol. 2020; Dassarma B, Tripathy S, Matsabisa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285298>
72. **Combining Antivirals and Immunomodulators to Fight COVID-19.** Trends Immunol. 2020; Feuillet V, Canard B, Trautmann A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33281063>
73. **Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:1014Dushianthan A, Clark H, Madsen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302976>

74. **A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.** Trials 2020; 21:1005Vanassche T, Engelen MM, Van Thillo Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298149>
75. **Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19.** Wien. Klin. Wochenschr. 2020;1-6Chiba S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296027>

Trials (8 articles)

Studien

1. **A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.** BMC Pulm. Med. 2020; 20:317Misset B, Hoste E, Donneau AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287790>
2. **Risk and mitigation actions for clinical trials during COVID-19 pandemic (RiMiCOPa).** Contemp Clin Trials Commun 2020:100682Bacchieri A, Rossi A, Morelli P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283069>
3. **Taking a stand against the politicization of medical research: How "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of science.** Expert Rev. Clin. Immunol. 2020; Bershteyn A, Schwartz MD, Thorpe LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284056>
4. **Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives.** Front Mol Biosci 2020; 7:606393Kotta S, Aldawsari HM, Badr-Eldin SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33282914>
5. **Mortality in COVID-19: Further Evidence for a Sex-Based Difference in the OpenSAFELY Study.** J Womens Health (Larchmt) 2020; Newman CB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33297829>
6. **An Educational Network for Surgical Education Supported by Gamification Elements: Protocol for a Randomized Controlled Trial.** JMIR Res Protoc 2020; 9:e21273Guérard-Poirier N, Beniey M, Meloche-Dumas L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33284780>
7. **Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:1014Dushianthan A, Clark H, Madsen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33302976>
8. **Effectiveness of using a meditation app in reducing anxiety and improving well-being during the COVID-19 pandemic: A structured summary of a study protocol for a randomized controlled trial.** Trials 2020; 21:1006O'Donnell KT, Dunbar M, Speelman DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33298117>

Vaccines (14 articles)

1. **The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.** Biochem. Biophys. Res. Commun. 2020; Santopolo S, Riccio A, Santoro MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33303190>
2. **Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future.** Br. J. Clin. Pharmacol. 2020; Calvo Fernández E, Zhu LY.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289156>
3. **Design of an epitope-based peptide vaccine against the SARS-CoV-2: a vaccine-informatics approach.** Brief. Bioinform. 2020; Alam A, Khan A, Imam N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285567>
 4. **Next-generation computational tools and resources for coronavirus research: From detection to vaccine discovery.** Comput. Biol. Med. 2020; 128:104158Kangabam R, Sahoo S, Ghosh A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33301953>
 5. **SARS-CoV-2: Targeted managements and vaccine development.** Cytokine Growth Factor Rev. 2020; Bakhiet M, Taurin S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33293238>
 6. **Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces.** Endocr. Metab. Immune Disord. Drug Targets 2020; Perosa F, Favoino E, Prete M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33290205>
 7. **Exploring the possible use of saponin adjuvants in COVID-19 vaccine.** Hum Vaccin Immunother 2020;1-10Sharma R, Palanisamy A, Dhama K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295829>
 8. **SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.** Immunity 2020; Lederer K, Castaño D, Gómez Atria D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33296685>
 9. **COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology.** Int Immunopharmacol 2020; 90:107247Han HJ, Nwagwu C, Anyim O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307513>
 10. **Hidden in plain sight: The effects of BCG vaccination in COVID-19 pandemic.** J Med Virol 2020; Toraih EA, Sedhom JA, Dokunmu TM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33289122>
 11. **Prediction of Putative Epitope-based Vaccine Against All Corona Virus strains for Chinese Population: Approach toward Development of Vaccine.** Microbiol. Immunol. 2020; Batool H, Batool S, Mahmood MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33295677>
 12. **Association between seasonal flu vaccination and COVID-19 among healthcare workers.** Occup. Med. (Lond.) 2020; Belingheri M, Paladino ME, Latocca R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300998>
 13. **BCG Vaccine does not Protect Against COVID-19.** Open Respir. Med. J. 2020; 14:45-46Allam MF, Amin GEE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33299492>
 14. **Efforts at COVID-19 Vaccine Development: Challenges and Successes.** Vaccines (Basel) 2020; 8Haque A, Pant AB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291245>

Women – pregnancy (19 articles)

1. **Prevalence and Neighborhood Geomapping of COVID-19 in an Underserved Chicago Pregnant Population.** AJP Rep 2020; 10:e413-e416Buhimschi CS, Elam GL, Locher SR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294287>
2. **Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy.** Cancer 2020; Lara OD, Smith MJ, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294978>

3. **Adoption of no-test and telehealth medication abortion care among independent abortion providers in response to COVID-19.** Contracept X 2020; 2:100049Upadhyay UD, Schroeder R, Roberts SCM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305255>
4. **Zum Beitrag „Mütter-Screening in einem COVID-19-Niedrig-Pandemiegebiet.** Deutsche Medizinische Wochenschrift 2020; 145:1580-1581Glocker MO.
5. **The "sex gap" in COVID-19 trials: a scoping review.** EClinicalMedicine 2020:100652Schiffer V, Janssen E, van Bussel BCT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33283178>
6. **Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery.** Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 256:400-404Savirón-Cornudella R, Villalba A, Zapardiel J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33285496>
7. **The prevalence of general anxiety disorder and its associated factors among women's attending at the perinatal service of Dilla University referral hospital, Dilla town, Ethiopia, April, 2020 in Covid pandemic.** Heliyon 2020; 6:e05593Kassaw C, Pandey D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294715>
8. **Examination of the effect of COVID-19 on sexual dysfunction in women.** Int J Clin Pract 2020:e13923Kaya Y, Kaya C, Tahta T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33300261>
9. **The Impact of COVID-19 on Women's Physical Activity Behavior and Mental Well-Being.** Int J Environ Res Public Health 2020; 17Nienhuis CP, Lesser IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33291530>
10. **Impact of COVID 19 on psychosocial functioning of peripartum women: A qualitative study comprising focus group discussions and in-depth interviews.** Int J Gynaecol Obstet 2020; Kumari A, Ranjan P, Sharma KA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305351>
11. **COVID-19 infection in pregnant women: Review of maternal and fetal outcomes.** Int J Gynaecol Obstet 2020; Salem D, Katranji F, Bakdash T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33305352>
12. **A neonatal cluster of novel coronavirus disease 2019: clinical management and considerations.** Ital. J. Pediatr. 2020; 46:180Olivini N, Calò Carducci FI, Santilli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33287880>
13. **"COVID-19 impact in abortions' practice, a regional French evaluation".** J Gynecol Obstet Hum Reprod 2020:102038Gibelin K, Agostini A, Marcot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33307242>
14. **Patient Experience of Obstetric Care During the COVID-19 Pandemic: Preliminary Results From a Recurring National Survey.** J Patient Exp 2020; 7:653-656Bradley D, Blaine A, Shah N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294594>
15. **Patient Perspectives on Telepsychiatry on the Inpatient Psychiatric Unit During the COVID-19 Pandemic.** J Patient Exp 2020; 7:677-679Heyman-Kantor R, Hardy N, Corcoran AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33294598>
16. **SARS-CoV-2 pneumonia in a newborn treated with remdesivir and COVID-19 convalescent plasma.** J Pediatric Infect Dis Soc 2020; Hopwood AJ, Jordan-Villegas A, Gutierrez LD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33306130>
17. **Mortality in COVID-19: Further Evidence for a Sex-Based Difference in the OpenSAFELY Study.** J Womens Health (Larchmt) 2020; Newman CB.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33297829>

18. **The pandemic paradox: domestic violence and happiness of women.** PeerJ 2020; 8:e10472 Haq W, Raza SH, Mahmood T.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33282567>

19. **Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age.** Reprod. Biomed. Online 2020; Li K, Chen G, Hou H *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33288478>

to subscribe click [here](#)
